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IN TRO DUC TION
Pso ri a sis is a chronic in flam ma tory skin dis ease
af fect ing 1-3% of gen eral pop u la tion (1). It is char -
ac ter ized by in creased pro lif er a tion and dis turbed
dif fer en ti a tion of keratinocytes, der mal/epi der mal
in flam ma tory in fil tra tions of lym pho cytes and neu -
tro phils, and en hanced angiogenesis in early pso -
riatic le sions (1,2). Etiopathogenesis of pso ri a sis
re mains un clear, al though in flu ence of some ge -
netic and en vi ron men tal fac tors has been rec og -
nized (3,4). Nu mer ous re ports in di cated a sig nif i -
cant role of cytokines ex creted by ac ti vated kerati -
no cytes and in flam ma tory infiltrate cells in the
patho genesis of psoriasis (5-7).
Trans form ing growth fac tor beta (TGF-β) may
be found in hu mans in three isoformes: TGF-β1,
TGF-β2, and TGF-β3. Al though they dem on strate
sim i lar prop er ties in vi tro, their func tions are very
dif fer ent in vivo. TGF-β1 is pro duced by dif fer ent
2
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SUM MARY Pso ri a sis is a com mon chronic cu ta ne ous dis ease
af fect ing 1-3% of gen eral pop u la tion. Its pathogenesis is not fully
un der stood, but the in volve ment of sev eral cytokines has clearly
been es tab lished. The aim of the pres ent study was to eval u ate
se rum con cen tra tions of trans form ing growth fac tor (TGF)-β1 in
pa tients with pso ri a sis vulgaris and to cor re late these con cen tra -
tions with se ver ity of pso ri a sis and sev eral other clin i cal pa ram e -
ters. Sixty pa tients with pso ri a sis and 38 healthy per sons (con trol 
group) were in cluded into the study. TGF-β1 was mea sured by
en zyme-linked immunosorbent as say (ELISA) us ing com mer -
cially avail able kits. Se rum con cen tra tions of TGF-β1 in pa tients
with pso ri a sis were sig nif i cantly in creased com pared with the
con trols (42.9±9.9 vs. 37.7±6.0 ng/mL, re spec tively, p=0.004).
Pa tients with more se vere dis ease (PASI <24 points) had sig nif i -
cantly higher se rum con cen tra tion of TGF-β1 than those with
mild pso ri a sis (PASI<24 points; p<0.001). More over, se rum
TGF-β1 con cen tra tion sig nif i cantly cor re lated with dis ease se ver -
ity (p=0.001). In pa tients with pre-ex ist ing in fec tions of the re spi -
ra tory tract, the con cen tra tions of se rum TGF-β1 were sig nif i -
cantly de creased (p=0.03). Since se rum con cen tra tions of
TGF-β1 are in creased in pa tients with pso ri a sis, TGF-β1 might
be used as a marker of pso ri a sis ac tiv ity.
KEY WORDS cytokines; pso ri a sis; trans form ing growth fac tor
beta
cells, in clud ing ac ti vated in flam ma tory in fil trate
cells and keratinocytes. TGF-β1, al though re garded
as a growth fac tor, pos sesses strong immunosup -
pressive ac tiv ity, in some ex per i ments even stron -
ger than cyclosporine. More over, TGF-β1 in hib its
keratinocytes pro lif er a tion, ac ti vates angiogenesis,
stim u lates fibroblasts pro lif er a tion, and pro duc tion
of extracellular ma trix el e ments by these cells (8,9).
The aim of our study was to eval u ate TGF-β1 ex -
pres sion in the sera of pa tients with pso ri a sis
vulgaris, and to as sess its use ful ness as a marker
of clin i cal in ten sity of pso ri a sis. An other aim was to
de fine pos si ble cor re la tion be tween the ex am ined
cytokine con cen tra tions and se lected trig ger ing
fac tors and the clin i cal course of the dis ease.
PA TIENTS AND METH ODS
Pa tients
The study was per formed among 60 pa tients
with pso ri a sis vulgaris (19 women and 41 men) di -
vided into sev eral sub groups ac cord ing to nine cri -
te ria (Ta bles 1 and 2). The mean (±SD) age of pa -
tients was 36.1±11.7 years (range, 18-61), and
mean du ra tion of the dis ease was 14.6±10.1 years,
rang ing be tween 1 month and 37 years. Skin le sion
in ten sity ranged from 7.0 to 48.4 points as mea -
sured ac cord ing to Pso ri a sis Area and Se ver ity In -
dex (PASI) (10,11). The age at on set of pso ri a sis in
our pa tients was be tween 4 and 56 years
(21.5±10.3 years). None of the pa tients had ever
been treated with any sys temic immunosup pres -
sive agent, and they had not been given any top i cal
antipsoriatic prep a ra tions for at least 1 month be -
fore the col lec tion of the blood sam ples. The con trol 
group con sisted of 38 age- and sex-matched
healthy individuals.
Mea sure ments of TGF-β1 Serum
Concentration
Eight mil li li ters of pe riph eral blood were col -
lected from all sub jects dur ing the ex ac er ba tion of
the dis ease. Af ter the 30 min utes at room tem per a -
ture, the blood was cen tri fuged for 10 min utes and
the se rum was as pi rated and frozen at –70oC.
TGF-β1 was mea sured by en zyme-linked immuno -
sorbent test (ELISA) with a com mer cially avail able
kit from R&D Sys tems (Min ne ap o lis, MN, USA), at
sen si tiv ity of <0.7 pg/mL in a sam ple vol ume of 100
µL. The as says were per formed strictly ac cord ing to 
the man u fac turer’s in struc tions. Ex tinc tion was
mea sured at 450 nm with a Microplate Reader
EL-311 au to matic an a lyzer (Boehring GmbH, Mar -
burg, Ger many). Re sults were cal cu lated from the
stan dard curve of re com bined hu man TGF-β1 and
were ex pressed as pg/mL.
Sta tis ti cal Anal y sis
Sta tis ti cal anal y sis was per formed with Stu dent
t-test, Cox-Cochran test, vari ance multifactorial
sys tem anal y sis, and Spearman rank cor re la tion
test. P-val ues less than 0.05 were con sid ered sta -
tis ti cally significant.
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Ta ble 1. The ex am ined and the con trol group di -







total number 60 38
aged <40 years 34 25
aged >40 years 26 13
men 41 26
women 19 12
Ta ble 2. Dis tri bu tion of the ex am ined (psoriatic)
group into sub groups ac cord ing to cri te ria re flect ing 
var i ous el e ments in the course of dis ease.




recurrences   1 month 23
recurrences > 1 month 37
psoriasis type I 55
psoriasis type II  5
infection influence 21
without infection influence 39
familial history - significant 18
familial history - not significant 42
full remissions 30
partial remission 30
disease duration < 20 years 40
disease duration ≥ 20 years 20
RE SULTS
Mean se rum con cen tra tion of TGF-β1 in the
group of psoriatic pa tients was sig nif i cantly higher
than that in the con trol group (42.9±9.96 ng/mL vs.
37.7±5.96 ng/mL, re spec tively, p=0.004). The sim i -
lar sig nif i cant dif fer ences in se rum con cen tra tions
of TGF-β1 were ob served be tween the sub groups
of male pa tients (44.4±10.6 ng/mL) and male con -
trols (37.4±5.72 ng/mL, p=0.003) and be tween pa -
tients (43.8±10.6 ng/mL) and healthy con trols
(37.3±6.00 ng/mL) youn ger than 40 years of age
(p=0.007; Fig. 1). No such dif fer ences were ob -
served be tween fe male pa tients and fe male con -
trols or be tween pa tients older and youn ger than 40
years of age (Fig. 1).
The se rum con cen tra tion of TGF-β1 in male sub -
jects was 44.4±10.6 ng/mL, which was sig nif i cantly
higher than in fe male sub jects (39.5±7.52 ng/mL,
p=0.019; Fig. 2). Pa tients with lower se ver ity of pso -
ri a sis, i.e. PASI <24 points, had sig nif i cantly lower
se rum con cen tra tions of TGF-β1 than the group of
pa tients with more in ten sive psoriatic le sions, i.e.
PASI <24 points (37.3±6.11 ng/mL vs. 48.8±9.86
ng/mL, re spec tively; p<0.001) (Fig. 2). More over,
se rum con cen tra tion of TGF-β1 was sig nif i cantly
lower in pa tients who ex pe ri enced up per re spi ra -
tory truck in fec tion than those with out a his tory of
such in fec tions (39.1±18.0 ng/mL vs. 44.9±10.3
ng/mL, re spec tively, p=0.03) (Fig. 2). Anal y sis of in -
flu ence of sex, PASI score, and his tory of in fec tions
on the se rum con cen tra tion of TGF-β1 by vari ance
multifactorial sys tem re vealed that the global vari -
abil ity re sulted mainly from PASI value.
More over, se rum TGF-β1 con cen tra tions sig nif i -
cantly cor re lated with se ver ity of pso ri a sis (r=0.51,
p=0.001; Fig. 3). Pa tient age, du ra tion of pso ri a sis,
du ra tion of the last out break of dis ease, fam ily his -
tory of pso ri a sis, type of pso ri a sis (type I or II), and
achieve ment of full or par tial re mis sions did not in -
flu ence TGF-β1 con cen tra tion in the sera of our pa -
tients with pso ri a sis vulgaris (data not shown).
DIS CUS SION
We found sig nif i cantly in creased con cen tra tion
of TGF-β1 in the sera of pa tients with pso ri a sis
vulgaris. More over, the se ver ity of pso ri a sis sig nif i -
cantly cor re lated with the se rum con cen tra tion of
TGF-β1. Anal y sis of vari ance showed that among
all sep a rately an a lyzed fac tors, PASI had the stron -
gest in flu ence on the con cen tra tion of TFG-β1 in
psoriatic pa tients. Pub lished data on TGF-β1 in
psoriatic in di vid u als are very lim ited. Bonifati et al
(12) showed in creased se rum con cen tra tions of
TGF-β1 in psoriatic pa tients and also dem on strated
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Fig ure 2. Se rum con cen tra tions of trans form ing growth
fac tor (TGF)-β1 in pa tients with pso ri a sis vulgaris ac cord -
ing to dif fer ent cri te ria.
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Fig ure 1. Se rum con cen tra tions of trans form ing growth
fac tor (TGF)-β1 in pa tients with pso ri a sis vulgaris and
healthy con trols di vided into sub groups ac cord ing to sex
and age.
Fig ure 3. Cor re la tion be tween se rum con cen tra tions of
trans form ing growth fac tor (TGF)-β1 and pso ri a sis ac tiv ity
(PASI), r=0.51, p<0.001.
re la tion ship be tween se rum TGF-β1 con cen tra tions 
and in ten sity of psoriatic le sions, which is in ac cor -
dance with our re sults. Al though Flisiak et al (13)
were not able to dem on strate sig nif i cant dif fer ences 
in plasma con cen tra tions of TGF-β1 be tween pa -
tients with pso ri a sis and healthy con trols, they
found sig nif i cant cor re la tion be tween the plasma
TGF-β1 and dis ease se ver ity. More over, they found
ac tiv ity of TGF-β1 in the scales, but there was no
cor re la tion be tween its con cen tra tion in the scales
and PASI. Plasma con cen tra tions of TGF-β1 were
not in creased in psoriatic pa tients and did not show
any sig nif i cant cor re la tion with se ver ity of the dis -
ease. The ob served dis crep ancy be tween stud ies
per formed by Bonifati et al (12), our study, and find -
ings by Flisiak et al (13) could be due to the fact that
Flisiak et al (13) stud ied TGF-β1 in the plasma not in 
the sera. It is well known that the main source of
TGF-β1 in blood are plate lets (9).
In the pres ent study, as well as in other stud ies,
the in creased se rum con cen tra tions of TGF-β1 in
pa tients with pso ri a sis (12) and the pos i tive cor re la -
tion be tween its con cen tra tion and PASI (12,13)
sug gested that this pa ram e ter could be used as a
marker of dis ease ac tiv ity. How ever, we must em -
pha size that se rum con cen tra tions of TGF-β1 found
by Bonifati et al (12) be fore and af ter ef fec tive
antipsoriatic treat ment were al most the same. This
find ing, in only 15 pa tients, is not sur pris ing, as sev -
eral in ves ti ga tors dem on strated in creased se rum
con cen tra tions of var i ous cytokines and ad he sion
mol e cules in ac tive pso ri a sis, but did not find their
sig nif i cant de crease af ter treat ment (7,14,15).
In creased se rum con cen tra tions of TGF-β1 were 
also found in other in flam ma tory dis eases, such as
sys temic lupus erythematosus, glomerulo nephritis,
and rheu ma toid ar thri tis. They were also in creased
in dis eases with as so ci ated scle ro sis, in clud ing
scleroderma and hepatic cir rho sis, and other dis -
eases, such as ac quired im mu no de fi ciency syn -
drome (AIDS). There fore, the in crease in se rum
TGF-β1 con cen tra tion is prob a bly not spe cific phe -
nom e non for psoriatic pro cess (8,16).
At pres ent, the role of in creased se rum con cen -
tra tion of TGF-β1 in pa tients with pso ri a sis is still un -
clear. Flisiak et al (13) stated that ob served cor re la -
tion be tween TGF-β1 con cen tra tion and PASI could
be due to vas cu lar ex pan sion with ac ti va tion of en -
do the lial cells in pso ri a sis, which are im por tant
source of TGF-β1. TGF-β1 has been shown to be a
po tent chemoattractant for neu tro phils, monocytes,
and mast cells. More over, TGF-β1 may in duce angi -
ogenesis and may in crease pro duc tion of Th1 type
cytokines (IL-2 and IFN-γ) by ac ti vated T-cells (8,9). 
Re cent stud ies con firmed pso ri a sis to be Th1-re -
lated dis ease (17) and all the above men tioned pro -
cesses could be in volved in the patho genesis of
pso ri a sis (1,2). It can not be not ex cluded that
TGF-β1 is a mol e cule reg u lat ing keratinocytes ho -
meo sta sis in pso ri a sis, in flu enc ing their pro lif er a -
tion and dif fer en ti a tion. TGF-β1 is mainly found in
the stra tum granulosum and stra tum corneum of
the epi der mis (8). Al though sig nif i cant dif fer ence in
TGF-β1 ex pres sion on mRNA level be tween pso -
riatic epi der mis and healthy skin could not be dem -
on strated (18,19), Kane et al (20) found en hanced
ex pres sion of TGF-β1 pro tein in psoriatic le sions.
In con clu sion, based on the lit er a ture data and
our own study, it seems that TGF-β1 could be in -
volved in the pathogenesis of pso ri a sis. How ever,
its ex act mech a nism is not clear. It is also dif fi cult to
clearly de ter mine the cel lu lar source of in creased
se rum con cen tra tion of TGF-β1 in pso ri a sis. There -
fore, fur ther stud ies are nec es sary to de fine the ex -
act role of this multifunctional cytokine in psoriatic
pro cess. Nev er the less, the pres ent study sug gests
use ful ness of the TGF-β1 mea sure ments in the sera 
of pa tients with pso ri a sis as a marker of the ac tiv ity
of their dis ease.
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IN TRO DUC TION
Naphthalan is a nat u ral, naph thene-based earth 
oil used for the treat ment of pso ri a sis at the Nafta -
lan Spe cial Hos pi tal in Ivaniæ Grad, Croatia. It is a
thick, dark-brown liq uid of a char ac ter is tic ar o matic
odor. In con trast to other re lated oils, Naphthalan
has a high spe cific weight (0.93-0.97) and mostly
con tains com pounds of stearic struc ture. Ther a -
peu tic prop er ties of Naphthalan have been known
since an cient times (1,2). The antipsoriatic prop er -
ties of heavy naph thene oil (Naphthalan®) make the 
ba sis of antipsoriatic treat ment reg i men that has
been suc cess fully used over the last de cade at the
re ha bil i ta tion hospital in Ivaniæ Grad.
Vul gar pso ri a sis is a chronic re laps ing skin dis -
ease af fect ing 2%-3% of the to tal pop u la tion world -
wide (3,4). The dis ease is char ac ter ized by pre cip i -
tated epidermopoiesis with con se quen tial for ma -
tion of scales on the skin and scalp, and spe cific nail 
le sions. Psoriatic ar thri tis de vel ops in 3%-5% of
pso ri a sis pa tients (2,3). In Croatia, 1%-2% of the
pop u la tion are af fected, whereas psoriatic pa tients
ac count for 6%-8% of all pa tients treated at de part -
ments of der ma tol ogy (5). The dis ease shows a fa -
mil ial clus ter ing and af fects con sec u tive gen er a -
tions. It usu ally runs a re laps ing re mit ting course,
with vary ing clin i cal be hav ior and dif fer ent age at
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SUM MARY Immunohistochemical anal y sis (cell immunopheno -
typing be fore and af ter 3 weeks of treat ment with naphthalan oil)
was per formed on bi opsy spec i mens from 10 pa tients with pso ri -
a sis vulgaris. To de ter mine the angiogenetic fac tor in psoriatic le -
sions, immunohistochemical stain ing on 3-µm par af fin block
sec tions was per formed by us ing monoclonal anti-fac tor VIII an -
ti body. There was a sig nif i cant dif fer ence in the mean num ber of
new blood ves sels be fore and af ter the ther apy (15.1 vs. 6.7). It
seems that naphthalan ther apy re duces num ber of new blood
ves sels and has ef fect on neovascularization in pa tients with
pso ri a sis.
KEY WORDS F VIII fac tor of angiogenesis; immunohisto chemi -
stry; pso ri a sis; naphthalan treat ment
dis ease on set. There is a novel con cept in the
pathogenesis of pso ri a sis, dem on strat ing the char -
ac ter is tic and well known psoriasiform epi der mal
hy per pla sia to be a sec ond ary le sion in the se -
quence of pathogenetic events in pso ri a sis caused
by migration of the inflammatory infiltrate cells from
the dermis to the epidermis (4).
In 1972, Folkman sug gested that pso ri a sis was
an angiogenesis-de pend ent dis ease and iden ti fied
vasoproliferation as a suit able tar get for the de vel -
op ment of anti-psoriatic drug. How ever, ad vance in
our un der stand ing of the angioproliferation in pso ri -
a sis has been made only re cently. The ther a peu tic
im pli ca tion of the angiogenesis in pso ri a sis has
been stud ied by many in ves ti ga tors (7-11). The fac -
tors that con trol angiogenesis in pso ri a sis are of in -
ter est not only to der ma tol o gists, but also to pa thol -
o gists. The ul ti mate aim is to re veal a crit i cal path -
way that can be modulated in the treatment of
psoriasis.
Role of Angiogenesis in Pso ri a sis
Pso ri a sis is pri mar ily a lym pho cyte-driven dis -
ease – pro nounced der mal microvascular ex pan -
sion in skin le sions sug gests that pso ri a sis is
angiogenesis-de pend ent (6). The key histopatho -
logical changes in psoriatic le sions are epi der mal
hy per pla sia, ac cu mu la tion of in flam ma tory cells
(T-lym pho cytes, monocytes, and neu tro phils), and
ex pan sion of the su per fi cial microvasculature. This
microvasculature is com posed of cap il lary loops
aris ing from ter mi nal ar te ri oles in the up per-hor i -
zon tal der mal vas cu lar plexus, pass ing up into der -
mal pa pilla, and arch ing back to con nect with
post-cap il lary ven ules in the hor i zon tal plexus.
Psoriatic skin has di lated and elon gated su per fi cial
cap il lar ies pass ing into the der mal papillae, with
mul ti ple vas cu lar seg ments in the pap il lary tip.
Immunostained microvessels in the bi opsy ma te rial 
from le sions and non-af fected skin ar eas in pso -
riatic pa tients have dem on strated a four fold in -
crease in the en do the lium of the su per fi cial micro -
vasculature in psoriatic le sions but not in the deeper 
vasculature. The changes in the microvasculature
occur early in the development of psoriatic lesions
(4).
Microvessels un der go ing angiogenesis dis play
an al tered pat tern of integrin ex pres sion, re flect ing
the key role of integrins in me di at ing cell-ma trix in -
ter ac tion and en do the lial cell ac ti va tion. Creamer et 
al (7) dem on strated a three fold in crease in the ex -
pres sion of αvβ3 integrin on the en do the lium of su -
per fi cial microvasculature in psoriatic skin, sug -
gest ing a func tional role for αvβ3 integrin in psoriatic 
angioproliferation. In creased ex pres sion in αvβ3 ex -
pres sion in microvessels of the psoriatic skin has
been con firmed by Nickoloff et al (8). Angiogenesis
is an im por tant com po nent of acute and chronic
psoriatic skin le sions, as they are erythematous and 
dis play a ten dency to bleed af ter the re moval of
scale (8). Fur ther ex per i ments have dem on strated
no up-reg u la tion of β1 integrins on psoriatic micro -
vessels, but a down-reg u la tion of β4 integrin on the
en do the lium in psoriatic le sions as com pared with
that in non-psoriatic skin (7). Sub se quent re search
has also iden ti fied microvascular pro lif er a tion in
plaque dis ease, with a monoclonal an ti body to the
proliferation marker Ki-67 revealing a 3.1%-en do -
the lial proliferation index (9).
Keratinocytes in psoriatic skin le sions are a ma -
jor source of proangiogenic cytokines (4,10). Sev -
eral angiogenic fac tors from psoriatic epi der mis
have been iden ti fied, in clud ing interleukin-8, tu mor
ne cro sis fac tor-α, trans form ing growth fac tor-α, en -
do the lial cell stim u lat ing angiogenesis fac tor, thymi -
dine phosphorylase (TP), and vas cu lar en do the lial
growth fac tor (VEGF) (4,10). Thus, psoriatic epi der -
mal hy per pla sia may in volve in creased ex pres sion
of a keratinocyte mitogen (TGF-α) rather than de fi -
cient ex pres sion of a growth in hib i tor (TGF-β) (10).
Angiopoietins have re cently been iden ti fied as
the ma jor lig ands of the en do the lial-spe cific re cep -
tor Tie 2 (11). Angiopoietin 1 in duces Tie 2 sig nal ing
as a re cep tor ac ti va tor and main tains blood ves sel
for ma tion, whereas angiopoietin 2 destabilizes ves -
sels by block ing Tie 2 sig nal ing as an an tag o nist of
angiopoietin 1 and acts with vas cu lar en do the lial
growth fac tor to ini ti ate angiogenesis (11). The
stud ies dem on strated that angiopoietins 1 and 2
and Tie 2 were up-reg u lated in psoriatic skin le sions 
com pared with non-af fected skin in psoriasis
patients (11).
Chronic in flam ma tion of the tis sue un der ly ing
the epi der mis in psoriatic skin cre ates a strong
angi ogenic sig nal. Sev eral stud ies have shown a
high de tect able blood flow in the psoriatic plaques
(9-11).
8 ACTA DERMATOVENEROLOGICA CROATICA
Vržogiæ et al:  Acta Dermatovenerol Croat
Naphthalanotherapy in Pso ri a sis Treat ment 2004;12(1):7-11
Angiogenesis Mech a nism
In ma ture (non-grow ing) cap il lar ies the ves sel
wall is com posed of an en do the lial cell lin ing, a
base ment mem brane, and a layer of cells called
pericytes, which par tially sur round the en do the lium
(Fig. 1). The pericytes are con tained within the
same base ment mem brane as the en do the lial cells
and oc ca sion ally make di rect contact with them. 
Angiogenic fac tors bind to en do the lial cell re -
cep tors and ini ti ate the se quence of angiogenesis
(12,13). When the en do the lial cells are stim u lated
to grow, they se crete pro teas es, which di gest the
base ment mem brane sur round ing the ves sel. The
junc tions be tween en do the lial cells are al tered, cell
pro jec tions pass through the space cre ated, and
the newly formed sprout grows to wards the source
of the stimulus. 
Con tin ued cap il lary sprout growth is de pend ent
upon sev eral pro cesses: the stim u lus for growth
(angiogenic fac tors or hypoxia) must be main -
tained; the en do the lial cells must se crete the pro -
teas es re quired to break down the ad ja cent tis sue;
the cells them selves must be ca pa ble of move -
ment/mi gra tion; and en do the lial cell di vi sion must
take place to pro vide the nec es sary num ber of cells
(this takes place at a site be hind the growth front of
the sprout). Neigh bor ing blind-ended sprouts then
join to gether to form a cap il lary loop, this later ma -
tures into a ves sel like the one from which it arose.
Hence, in hib it ing neovascularization would be an
in di rect means of coun ter act ing psoriatic plaque
for ma tion. This sup ports ob ser va tions that the pso -
ri a sis-ini ti at ing fac tor re sides in the keratinocytes
and that a sig nif i cant vas cu lar proliferation is re -
quired to cause hyperplasia of the epidermis.
Angiogenesis-De pend ent Dis eases
The de vel op ment of some other dermatological
and non-dermatological dis eases is also de pend -
ent on neoangiogenesis, e.g. in angiofibroma, neo -
vascular glau coma, arteriovenous mal for ma tions,
ar thri tis (in clud ing rheu ma toid ar thri tis), lupus, other 
con nec tive tis sue dis or ders, Osler-Weber syn -
drome, pyogenic granuloma, retrolental fib ro pla si -
as, scleroderma, hemangioma, and hy per tro phic
scars (12).
Anti-angiogenesis Ther a pies in the
Treat ment of Pso ri a sis
Many ef fec tive treat ments have an anti-angio -
genic ac tiv ity. Vi ta min D3 an a logue shows an anti -
proliferative ac tion on keratinocytes, thus hav ing
anti-angiogenic ac tiv ity. Top i cal calcipotriol in pso ri -
a sis acts via mod u la tion of angioproliferative path -
ways in the su per fi cial microvasculature (4). Acitre -
tin, a ma jor syn thetic retinoid, is used for top i cal
treat ment of pso ri a sis, whereas tazarotene is a
retinoid with top i cal ef fi cacy show ing anti-angioge -
nic ac tiv ity via mod u la tion of keratinocyte VEGF
pro duc tion. Hernandez et al (14) dem on strated that  
cyclosporine A (CyA) in hib its angiogenesis in duced 
by VEGF and that this ef fect is me di ated via the in -
hi bi tion of cyclo-oxygenase (Cox)-2, the tran scrip -
tion of which is ac ti vated by VEGF in en do the lial
cells. Re cently there has been a re newed in ter est in 
anti-angioge nic ef fects of razoxane, one of the most 
suc cess ful anti-psoriatic drugs, on hu man tu mors.
There is ev i dence sug gest ing a bi o log i cal sim i lar ity
in the ef fects of angiopoietin 2 and razoxane on the
vascu la ture, im ply ing that the drug may mediate the 
vessel stabilizing activity of angiopoietin 2 (4).
MA TE RIAL AND METH ODS
Study group in cluded five fe male and five male
pa tients with pso ri a sis vulgaris. Ev ery pa tient took a 
30-min ute naphthalan oil bath once a day five days
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Fig ure 1. The mech a nism of angiogenesis (ref. 12,13).
a week (ex cept week end). The clin i cal im prove -
ment at the end of the study cor re lated with the ves -
sel quan ti fi ca tion in bi opsy spec i men. Bi opsy spec i -
mens of 0.5 mm in di am e ter of the whole dermis ob -
tained from the same part of the skin le sions from
the pa tients with of pso ri a sis vulgaris were sub mit -
ted to immunohistochemical anal y sis (cell immuno -
phenotyping) be fore and af ter the 3-week treat ment 
with Naphthalan oil. Immunohistochemical stain ing
was per formed on 3-µm par af fin block sec tions by
us ing anti-fac tor VIII an ti body (Dako, Glostrup,
Den mark). Sec tions were in cu bated for 30 min utes
at room tem per a ture with pri mary an ti body at 1:100
di lu tion. Af ter wash ing, the sec tions were stained
with biotinylated multi-link (swine, anti-rab bit,
mouse, and goat im mu no glob u lin) (Dako) at a
1:1,000 di lu tion, fol lowed by stain ing with strepta -
vidin-bi o tin-peroxidase com plex (Dako) at 1:1,000
di lu tion. The re ac tion was vi su al ized by DAB stain -
ing and slides were contrast-stained with hemato -
xylin and embedded in a synthetic medium (DPX).
The ves sel quan ti fi ca tion was done for the
dermis of each skin sam ple as a to tal pos i tive cell
count per mm sample.
RE SULTS
The mean ves sels num ber in dermis of psoriatic
pa tients was 15.1 (range, 10-25) be fore the treat -
ment, and 6.7 (range, 4-12) af ter the treat ment. The 
immunohistochemical stain ing with anti-fac tor VIII
an ti body was per formed for vi su al iza tion of blood
ves sels in pa tients be fore the ther apy. The en do -
the lial cells were stained with fac tor VIII, re veal ing
many mul ti plied blood ves sels (Fig. 2A). Af ter the
ther apy, the same method showed a de crease in
the num ber of blood ves sels in the lesions (Fig. 2B).
DIS CUS SION
In psoriatic skin le sions, there is an ex panded
su per fi cial microvasculature in close prox im ity to
over ly ing epi der mis; this spa tial re la tion ship is crit i -
cal to ful fill the met a bolic needs of hyperplastic
keratinocytes and to pro vide an en larged en do the -
lial sur face area for in flam ma tory traf fick ing (4). Epi -
der mal changes in pso ri a sis in duced by an al tered
dif fer en ti a tion pro gram of the keratinocytes de velop 
along with pro found hyperproliferation, acanthosis,
parakeratosis, and the lack of gran u lar layer. Ab -
nor mal pro lif er a tion is due to an in creased num ber
of germinative keratinocytes per skin sur face area,
ac cel er ated cell cy cle (15), and in creased re cruit -
ment of ac tively cy cling lym pho cytes from a rest ing
pool and on cytokines (15-17). In hu man skin model 
of pso ri a sis, lym pho cyte-de pend ent angiogenesis
was proven, with ac tive par tic i pa tion of mul ti ple cell
types in clud ing nat u ral killer T-cells, keratinocytes,
macrophages, and microvascular en do the lial cells
(8). Our un der stand ing of the mo lec u lar and cel lu lar 
mech a nisms in volved in psoriatic angioproliferation 
has ad vanced in last thirty years. The fac tors that
con trol angiogenesis in psoriasis are of interest for
novel therapeutic strategies in the treatment of
psoriasis (4).
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  Fig ure 2. The immunohistochemical stain ing with anti-fac tor VIII in pa tients be fore (A) and af ter (B) naphthalanotherapy.
Af ter naphthalanotherapy, blood ves sels in dermis were rare in com par i son with the find ings be fore the ther apy. Con -
trast-stain ing with hematoxylin x 200.
A B
Con se quently, nor mal iza tion of these pro cesses 
may pos i tively in flu ence the course of the dis ease.
Since both mark ers are up-reg u lated by naphtha -
lan, we may as sume that this oil can in duce kera -
tinocyte dif fer en ti a tion and that it strongly in hib its
the pro lif er a tion of keratinocytes (16).
Naphthalan also in hib its the angiogenesis in
psoriatic dermis. Our re sults have shown de -
creased mean ves sel num ber af ter naphthalano -
therapy. Sweet and Smoller (18) and Creamer and
Barker (19) found sim i lar re sults.
There are many ways to treat pso ri a sis pa tient.
Rel a tively new ap proaches in pso ri a sis treat ment
are us ing anti-angiogenic agents. Angiogenic fac -
tors ini ti ate the se quence of angiogenesis and the
cells are ca pa ble of move ment/mi gra tion. The
switch to the angiogenic phe no type in volves a
change be tween pos i tive and neg a tive reg u la tors of 
the growth of microvessels. Naphthalan in duces
the de crease in the blood ves sels num ber and acts
as an anti-angiogenic agent.
CON CLU SION
Al though this pre lim i nary ap proach on pos si ble
ther a peu tic use of naphthalan as a new angiogenic
agent to treat pso ri a sis has proven its anti-angio -
genic prop er ties, fur ther stud ies are needed. The
mean num ber of new blood ves sels in dermis of our
psoriatic pa tients af ter naphthalanotherapy was de -
creased af ter 3 weeks of ther apy. It seems that
naphthalanotherapy has an ef fect on the neovascu -
larization in pa tients with psoriasis.
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At the cross roads, when texts and pic tures
came to lie athwart…
Karl Holubar
IN TRO DUC TION
In the sec ond half of the 18th cen tury, plants, an i -
mals, and dis eases (in clud ing dermatoses) were
sys tem atized, and the En light en ment pe riod brings
to mind the names of Carl von Linné, François
Boissier de Sauvages, and Jo seph von Plenck.
Linné hon ored his med i cal col leagues and con tem -
po rar ies by nam ing plants af ter them, e.g., Sauva -
gesia, a trop i cal weed, or Fothergilla, an Amer i can
shrub (af ter John Fothergill, 1712-1780, a ded i -
cated bot a nist and the most well known phy si cian in 
Lon don at the time). All this not with stand ing, it soon
be came ob vi ous that words alone would not suf fice
to de scribe phe nom ena in med i cine or be yond. As
Barbara Maria Stafford put it, and Claudia Benthien
re it er ated, the text-based cul ture be gan to change
into a vi su ally de pend ent cul ture (1,2). Der ma tol -
ogy, be cause of the ubiq ui tous vis i bil ity of symp -
toms, and oph thal mol ogy, deal ing with the op ti cal
sense per se, were in the fore front of draw ing and
paint ing in med i cine, as ev i denced by the ear li est
paint ings (wa ter col ors) from 1782 pre served in the
ar chives of the Royal Society of Medicine in London 
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SUM MARY An ac count is given of the de vel op ment of early derma -
tologic ico nog ra phy, mostly in wa ter col ors and cop per prints, as a con -
se quence of late En light en ment per spec tives and the de vel op ment of
a vi su ally-de pend ent con cept in a text-dom i nated dis ci pline of der ma -
tol ogy. The first great at lases in the field of der ma tol ogy by Rob ert
Willan (1757-1812) and Jean-Louis Alibert (1768-1837), and by M. N.
Devergie (1784-1842) in venereology, are ad dressed and Willan’s
work is elab o rated in de tail.
KEY WORDS der ma tol ogy; his tory of med i cine; ico nog ra phy
and the Institute for the History of Medicine in
Vienna.
PHY SI CIANS-PAINT ERS
The three his tor i cally most im por tant schools in
der ma tol ogy – Lon don, Paris, and Vi enna – pro -
duced a se ries of im pres sive at lases over the fol -
low ing cen tury. The unique fact that many phy si -
cians in Vi enna were paint ers made us search for
phy si cian-paint ers else where. A long list of paint ers
among der ma tol o gists in Vi enna in cluded Carl von
Rzehaczek, Lorenz Matthäus Carl Rigler, Anton
Elfinger, Carl and Jul ius Heitzmann, Salomon
Ehrmann, Carl Henning and oth ers. In oph thal mol -
ogy, there were Georg Jo seph Beer, Friedrich und
Eduard Jäger, fa ther and son; again Carl von
Rzehaczek,  and the Heitzmann broth ers (3-5). In
Alibert’s at las from 1806 (6) and Ma rie-Nicolas
Devergie’s at las from 1833 (7), no phy si cian-paint -
ers could be iden ti fied – Moreau-Valvile and Dupont 
aîné seem to have been the art ists prin ci pally em -
ployed by these au thors. In the Willan-Bate man se -
ries of edi tions from 1798 to 1817, this was dif fer ent
(8-12). Thomas Bate man con trib uted a se ries of
draw ings and paint ings for the at las. In ter est ingly,
one plate (# xxvi), pre sent ing ro se ola annulata and
ro se ola infantalis, bears the sig na ture R. W. delint in 
the left lower cor ner, prov ing that also Rob ert Willan 
(9) him self pro duced pic tures for his ep ochal book
(Fig. 1). This is ev i dent only in the 1817 edi tion (9),
but not in the ear lier one from 1808 (11). Bateman
signed his work using either his full name or initials.
ROB ERT WILLAN
Willan was the first to pro duce dermatological
pic tures in a book, which may be found in the first
fas ci cle of his draw ings of cu ta ne ous dis eases from 
1798 (10). In the in tro duc tion to that book he wrote:
“In or der to con vey dis tinct ideas on the sub ject, I
shall elu ci date ev ery ge nus by col ored en grav ings
rep re sent ing some of its most strik ing va ri et ies.
This method is new, and will be at tended with many
ad van tages…”. Alibert fol lowed Willan’s suit eight
years later, al though with few re fer rals to ear lier
texts: “Pour imprimer un plus grand sceau
d´authenticité á ce que j´ai écrit, pour ajouter á
l´énergie et á la puis sance de mes discours, pour
perpétuer et animer en quelque sorte tous mes ta -
bleaux, j´ai cru devoir recourir á l´ar ti fice ingénieux
du pinceau et du burin” (1).
For the sake of com plete ness, it shall be men -
tioned that the last and post hu mous edi tion of
Boissier de Sauvages’ Nosolgia methodica, ed ited
by C. F. Dan iel in Leip zig in 1791, did con tain one
page of small color pic tures. How ever, these il lus -
tra tions can not be com pared with Willan’s be cause
of lack of clar ity, lesser qual ity, and minute format.
Willan’s 1798 edi tion (10) car ried seven plates
(some de pict ing more than one area af fected by
dis ease). Willan’s edi tion from 1808 (11), called
“vol ume I”, ex hib ited 33 plates with one or more
sep a rate il lus tra tions. Ashby Smith’s edi tion from
1814 (12) had only two pic tures, again show ing
more than one area each (Fig. 2), whereas the cu -
mu la tive edi tion by Bate man from 1817 com prised
72 plates of which 18 were done by the hand of
Thomas Bate man him self, and one by Willan (9).
Af ter Willan’s death in April 1812, his wife Mary
(Smith)-Willan did not con fide the plates to Bate -
man but rather to Willan’s step son-in-law, Ashby
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Fig ure 1. Rob ert Willan, signed R.W.delint , J Sailliar,
sculps, plate xxvi, ro se ola, in the Bate man edi tion of 1817
(with out Willan’s ini tials in the 1808 edi tion).
Smith. It seems that Bate man made up by him self
for what he did not have, or was en trusted with by
Willan ear lier, just to equip the 1817 edi tion with suf -
fi cient pic tures. This lat ter fact proves Bate man’s
master ship on the graph i cal level as well, which
com pares well to the Vienna physician-painters
(Fig. 3).
For con trast, Alibert’s mag nif i cent at las num -
bers 55 plates, mostly done by Moreau Valvile, and
stip pled by Salvatore Tresca (6). Devergie (not Ma -
rie-Guillaume-Alphonse D., 1798-1879, but Ma -
rie-Nicolas D., 1784-1842, also re ferred to as
Devergie aîné) num bered up to 161 plates by
Dupont aîné, with some of them miss ing. His is def i -
nitely the most ex traor di nary and im pres sive at las
of ve ne real dis eases of all times (7) (Fig. 4).
So what may have made Willan to go into de pict -
ing skin le sions? Do we have any in di ca tions of his
mo tives? The an swer could be two fold. First, he
was an ex traor di nary gifted per son , a keen ob -
server, deal ing with in nu mer a ble pa tients in the
Carey Street Dis pen sary and his own of fice for
more than 20 years. Sec ond, the quag mire of
dermatologic di ag no ses and his per sonal ed u ca -
tion in the clas sic lan guages of Latin and Greek
played a de ci sive role. Munk’s Roll in the Royal Col -
lege of Phy si cians men tions Willan as ac com -
plished clas si cal scholar who even called his
horses by clas si cal names, e.g. Odys seus and
Telemachus. Where did he learn Greek and Latin?
In Sedbergh, York shire, where he was born? A
rather small place. Could there have been a gram -
mar school teaching Latin and Greek?
THE THREE YORK SHIRE MEN
Next to the Wellcome In sti tute in Lon don is the
house (and li brary) of the So ci ety of Friends (Quak -
ers). Suf fice it to men tion that Willan, as much as his 
col lab o ra tor Thomas Bate man (1778-1821), was a
Quaker, as was John Fothergill (1712-1780),
Willan’s men tor. The three York shire men. Drop ping 
into the Quaker book shop serendipitously dur ing a
re cent re search stint in Lon don yielded an un ex -
pected re sult. No bi og ra phies of the above per sons
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Fig ure 2. Ashby Smith edi tion from 1813, plate ii, porrigo
scutulata; signed: Syd Ed wards del.; Selliers fc.
Fig ure 3. Bate man edi tion from 1817, plate lxv, sycosis
menti, signed drawn by T.B., engd by J Stew art.
were on sale but a stu dent search ing other ma te rial
bus ied him self next to the coun ter, sift ing through
old pub li ca tions and, by phys i cal prox im ity, eaves -
dropped on the ques tion of such bi og ra phies be ing
avail able or not. Brows ing through such ma te rial,
he saw an ar ti cle on Fothergill and spoke up. It was
a bro chure from 1979, at sale for a few pen nies, re -
call ing the bi cen ten nial of the foun da tion by
Fothergill, of the School of Friends in Ackworth,
York shire. There it read that Fothergill him self went
to the gram mar school at Sedbergh “where he
learnt Latin and Greek” (14).
The ar chives of the Med i cal So ci ety of Lon don
trea sure let ters of Thomas Bate man to Rich ard
Willan, brother of Rob ert. In one of these let ters,
dated Au gust 19, 1812 (Rob ert died on April 7 that
year), it reads: “…he (Rob ert) re ceived his school
ed u ca tion solely at the Gram mar School at
Sedbergh un der a name sake of my own.” We may
spec u late that this fact of Mr. Bate man, (of un known 
but pos si ble re la tion to Thomas Bate man), tu tor ing
Rob ert Willan at the Sedbergh gram mar school, is
one of the roots of the close, al most fil ial re la tion -
ship Thomas had to his teacher.
Here with the rid dle is solved – Willan who at -
tended the very same school half a cen tury af ter
Fothergill, must have ac quired knowl edge of clas si -
cal lan guages in his home town. How then re late
Latin and Greek to de pict ing dermatoses?
Quite eas ily, once the au thor is fa mil iar with
Greek and Latin in gen eral and med i cal his tory in
par tic u lar. The in tro duc tion to Willan’s “Vol ume I”
from 1808 (11) suf fi ciently proves both points, and
also un der lines, what has been quoted above from
Munk’s Roll. Willan did go af ter the lit eral mean ing
of doz ens of old terms, when and where they were
ap plied, wrote that the same names were used dif -
fer ently, or dif fer ent des ig na tions given to the same
con di tion at var i ous body ar eas. Here is a quo ta tion
from the Amer i can edition of Willan’s “Volume I”
(12):
“This will ap pear from com par ing their ac counts
of Pityriasis, Ceria, Achores, Meliceris, Melitagra;
Exanthemata, Helcydria, and Psydracia capitis;
Sycose and Lychenose tu ber cles of the chin;
Madarosis, Milphosis, Ptilosis, Al o pe cia, and
Ophiasis… they [the Greek] also paid at ten tion to
the cu ta ne ous blem ishes, termed Phaci, Ephelides, 
Chalazia, Thymia, Peliomata, Celides, Rhagades,
Tyli, Myrmeciae, Acrochordones, etc.” Al most all
these terms were used with cor rect plu ral and sin -
gu lar, and only some were an gli cized. Many of
these words mean much the same. A dif fer en ti a tion
by let ters or words must ap pear in suf fi cient look ing
at this queue of terms and the urge to de pict what is
meant be comes un der stand able. Draw ing or paint -
ing was much more in fo cus in schools, as it is to -
day, as much as cal lig ra phy. Given a cer tain tal ent,
the drive to draw or paint by one’s own hand, would
be a log i cal con se quence. In Willan, we rec og nize a 
clas si cal scholar, a phy si cian de voted to the dis -
eases of the skin, and a thinker aware of the myr iad
of names and the in suf fi ciency of what these names 
mean with re spect to what they were ap plied.
Plenck’s ap proach alone looked prom is ing to him
as a writ ten con cept. And on this he built, by sim pli -
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Fig ure 4. M. N. Devergie, 1833, plate 61, végétation
(choufleur) unique, signed Th Susémihl del et sculp,
Dupont aîné typum fecit.
fi ca tion and more ex act def i ni tion of le sions, which
he then sought to pres ent to the reader’s eye graph -
i cally. The re sult was an ep ochal oeuvre, phe nom e -
nal in its clarity of description and illustration at the
same time. Why did it take so long?
From the early 1780s on wards, Willan worked in
the Carey Street Dis pen sary. In 1787, the Med i cal
So ci ety of Lon don in vited trea tises on top ics se -
lected by the so ci ety, for win ning the John Fothergill 
Medal (15,16). The first one was awarded to Dr.
John Fal coner of Bath but not handed in to the
prize-win ner on the day se lected, i.e. Fothergill’s
birth day on March 8, but later on. The medal had
not been ready in time. The sec ond medal, how -
ever, was awarded lege artis on March 8, 1790.
Rob ert Willan was awarded for an es say en ti tled
“cuticulam cu rare paratus”. This was the ba sis of
his later vol ume. In the pref ace of the first fas ci cle,
printed in 1798, Willan apol o gizes to the reader and
ex plains the lapse of al most eight years due to tech -
ni cal dif fi cul ties. Later fas ci cles fol lowed through
the years up to 1808, the year when the so-called
“Vol ume I” was ed ited, one year be fore an Amer i -
can edi tion ap peared in Phil a del phia. There af ter,
Willan’s health de te ri o rated and in 1811 he left Eng -
land for Funchal, Ma deira, where he died on April 7, 
1812. The two heirs, one by fam ily and the other by
ded i ca tion, ran into fric tions be cause Mary (Smith)
Willan handed the pa pers (and prints?) to Ashby
Smith and not to Thomas Bate man, who seemed to
have had suf fi cient ma te rial from ear lier years of co -
op er a tion with Willan to com pile post hu mous edi -
tions of the mas ter’s work. Both started to edit
Willan’s work and the re spec tive pref aces of their
vol umes, Batemans, dated May 25, 1813 (8), and
Ashby Smith’s, dated Sep tem ber 24, 1814 (13), at -
test to that suf fi ciently. Bate man fin ished the edi tion
on Oc to ber 1, 1817, em bel lish ing many cop ies by
his own hand. Ashby Smith fin ished his ver sion of
Willan’s com pi la tion in 1821, with still an other vol -
ume of lesser im por tance and a dif fer ent ti tle and
with out il lus tra tions (17). Bate man was most def i -
nitely Willan’s dermatological suc ces sor and as an
art ist ca pa ble as his teacher, as ev i denced by the
wide cir cu la tion of his edi tions, which speak in fa vor
of even greater graph i cal tal ent. His 1817 (9) pref -
ace makes that clear: “in or der, how ever, to ful fil the
wishes of the pro fes sion by the com ple tion, as far
as it was in my power, of the se ries of en grav ings
be gun by Dr. Willan, I have pur chased the copyright 
of that work together with the drawings and
engravings procured by him, and have now brought 
that series to a conclusion.”
Mod ern der ma tol ogy was built on Rob ert
Willan’s (1757-1812) work and on ac count of his
em i nent mer its for the dis ci pline, he was right fully
elected “the der ma tol o gist of the mil len nium“ at a
ses sion of the Royal So ci ety of Med i cine on Feb ru -
ary 23,1999). His life and tragic death at age 55 in
Ma deira have been the sub ject of many pa pers that
fol lowed since. In any case, he was the one who
started to equip texts de scrib ing skin dis eases with
proper color prints and thereby fore shad owed what
was to come in the 19th cen tury. Next to the two men 
men tioned, J. L. Alibert and M. N. Devergie, there
were the at lases of Eras mus Wil son (18),
Ferdinand Hebra (19), Radcliffe Crocker (20), and
many oth ers. At the end of the cen tury, pho tog ra phy 
and moulages started to re place wa ter col ors and
en grav ings or litho graphs.
POST SCRIPTUM
Ashby Smith was Willan’s step son-in-law, who
ac com pa nied Willan to Ma deira and re mained by
the mas ter’s side un til his death. He was a mem ber
of the Royal Col lege of Sur geons – aside to that
noth ing more can be said about him, not even year
of his birth. The year of his death, i.e. 1831, how -
ever, is re corded in Franz Ehring’s en cy clo pe dic
book, Skin Dis eases: Five Cen tu ries of Sci en tific Il -
lus tra tion (21) and can be ver i fied through the Royal 
Col lege of Sur geons in Lon don. Af ter all, Ashby
Smith may be a dou ble sur name, or, as some times
cus tom ary in the An glo-Saxon world, a sur name,
e.g. his mother’s maiden name used as a first name 
or mid dle name, or sim ply a first name. Some times
Ashby-Smith is hy phen ated. The ques tion re mains, 
there fore, if he should be placed un der “A” or un der
“S” in an al pha betic ref er ence list. I chose the for -
mer vari ant just be cause his name(s) ap pear al -
ways in full and not as “A. Smith”. This, on the other
hand, may be due to the way peo ple with fre quently
en coun tered fam ily names, e.g. Smith, use to write
their other names in or der to avoid be ing mis taken
for other “Smiths”. Af ter all, Moriz Kaposi men tioned 
that pos si bil ity as one of the rea sons why he wanted 
to change his name.
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IN TRO DUC TION
Pso ri a sis is a com mon in flam ma tory hyperpro -
liferative skin dis ease af fect ing 2% to 3% of the
Cau ca sian pop u la tion in North Amer ica and most of 
the Eu ro pean coun tries (1). The dis ease can be lo -
cal ized to small skin ar eas or gen er al ized. In 5-10% 
of cases, pso ri a sis is as so ci ated with seronegative,
po ten tially dis abling ar thri tis (2). How ever, as so ci a -
tion with some in tes ti nal in flam ma tory dis eases and 
ac quired im mu no de fi ciency syn drome (AIDS) has
also been re ported (3,4). Al though pso ri a sis is
rarely fa tal, it can be de bil i tat ing be cause of its un fa -
vor able effects on the quality of life and social
stigmatization (5).
Pso ri a sis is a het er o ge neous dis ease – it may
man i fest in a num ber of dis tinct clin i cal sub types.
The most com mon clin i cal sub type is pso ri a sis
vulgaris (PV), ac count ing for ap prox i mately 85% of
all cases (2). Guttate pso ri a sis (GP) is an im por tant
clin i cal vari ant that most fre quently oc curs in ad o -
les cents and young adults. It is char ac ter ized by
sud den on set of widely dis persed small red scaly
plaques, mainly over the trunk and prox i mal limbs.
GP is of ten as so ci ated with a pre ced ing strep to coc -
cal throat in fec tion (6). In most cases, the dis ease is 
self-lim it ing (acute GP), but a sig nif i cant pro por tion
of pa tients de velop PV later in life. Also, these pa -
tients of ten have a fam ily his tory of pso ri a sis (7).
Other less com mon clin i cal sub types in clude gen er -
al ized pustular pso ri a sis (GPP), palmoplantar pus -
tu lar psoriasis (PPP) and erythrodermic psoriasis
(2).
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SUM MARY There is con sid er able epidemiologic ev i dence that ge netic
com po nent plays a key role in the pathogenesis of pso ri a sis. The dis -
ease is multifactorial in or i gin and shows polygeneic in her i tance. In the
last de cade, there have been sig nif i cant ad vances in our un der stand -
ing of the ge netic ba sis of this com mon dis ease. Sus cep ti bil ity gene
char ac ter iza tion and knowl edge of the im mune ba sis of pso ri a sis have
better de fined the dis ease path ways in volved in the pathogenesis of
pso ri a sis. A num ber of ge netic loci have been iden ti fied by ge nome
wide-link age scans. In par tic u lar, the im por tance of PSORS 1 link age
char ac ter iza tion is em pha sized, as this in for ma tion will help de velop
more spe cific di ag nos tic and prog nos tic tools.
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Histologically, PV is char ac ter ized by epi der mal
hyperproliferation and al tered dif fer en ti a tion, angio -
genesis, and epi der mal and der mal leu ko cyte in fil -
tra tion (2).
Both sexes are equally af fected, and 75% of pa -
tients de velop pso ri a sis be fore age 40. Ini tial man i -
fes ta tion of PV usu ally oc curs in the third de cade of
life. Two peaks of age at on set have been de -
scribed. The first peak is be tween 20 and 30 years,
and the ma jor ity of pso ri a sis pa tients be long to this
group. The sec ond, smaller peak oc curs at 50-60
years. A hy poth e sis is that, in anal ogy to di a be tes
mellitus, there are two types of non-pustular pso ri a -
sis. Type I with early on set is hu man leu ko cyte an ti -
gen (HLA)-as so ci ated pso ri a sis with strong fam ily
his tory and more se vere clin i cal course. Type II is
spo radic and char ac ter ized by late on set (af ter age
40); it is not as so ci ated with HLA and usually
manifests in a milder form of the disease (8).
The eti ol ogy and pathogenesis of pso ri a sis re -
mains to be de fined. How ever, it is clear that pso ri a -
sis is a multifactorial dis ease in which both ge netic
and en vi ron men tal fac tors are re spon si ble for the
oc cur rence and phenotypic ex pres sion of the dis -
ease (9). En vi ron men tal fac tors in clude strep to coc -
cal in fec tions, some med i ca tions, trauma, and
stress (2). Sev eral lines of ev i dence point to a prom -
i nent role of T-cells in the pathogenesis of pso ri a sis, 
and it is now gen er ally ac cepted that pso ri a sis is the 
most prev a lent T-cell mediated inflammatory dis e -
ase in humans (10).
The ge netic ba sis of pso ri a sis has long been
rec og nized by cli ni cians be cause of fa mil ial clus ter -
ing. The mode of in her i tance does not fol low Men -
de lian pat terns. These ob ser va tions have been
sup ported by large epidemiologic stud ies. On the
ba sis of re sults of a clas sic epidemiologic study in -
clud ing more than 10,000 in di vid u als from the
Faroe Is lands (Den mark), Lomholt (11) con cluded
that pso ri a sis was ge net i cally de ter mined. The in ci -
dence of pso ri a sis on the Faroe Is lands was 2.8%,
and 91% of pso ri a sis pa tients had a pos i tive fam ily
his tory. Lomholt (11) pro posed a multifactioral
mode of in her i tance of pso ri a sis in which ge netic
com po nents end ex ter nal factors jointly influence
the onset and course of the disease.
Fur ther ev i dence for ge netic in volve ment in pso -
ri a sis came from de mo graphic, epidemiologic, se -
ro logic, fam ily, and twin stud ies, as well as from nu -
mer ous re ports on the as so ci a tion of the dis ease
with HLA Cw6 an ti gen (12). A num ber of twin stud -
ies were per formed to elu ci date the ge netic vari abil -
ity of dis sim i lar con cor dance rates in monozygotic
and dizygotic twin pairs. The con cor dance rate in di -
cates how of ten twin pairs are both af fected or both
un af fected in con trast to be ing dis cor dant when one 
is af fected and the other one is not. An a lyz ing 219
twin pairs, Farber et al (13) found that the me dian
con cor dance of pso ri a sis in monozygotic twins was
65% in con trast to 23% in dizygotic twins. The con -
clu sions were that pso ri a sis fol lowed a multifac -
tioral mode of in her i tance, and that a her i ta ble com -
po nent con trib uted to a dis tinct dis ease pat tern.
Monozygotic af fected twins more of ten show sim i lar 
age at on set as well as sim i lar dis tri bu tion pat terns,
course, and se ver ity of the disease than dizygotic
twins in whom no such trends have been observed
(13).
Be cause of the au to im mune and ge netic pre dis -
po si tion of pso ri a sis, early ge netic stud ies were fo -
cused on HLA as so ci a tion as these genes are in -
volved in an ti gen pre sen ta tion to T-cells. The HLA
genes lo cated within the ma jor histocompatibility
com plex (MHC) dis play a high de gree of poly mor -
phism (more allelic forms of the gene). As so ci a tions 
be tween pso ri a sis and HLA B13, B57, B37, B39,
Cw2, and Cw6 from HLA class I have been iden ti -
fied (14-18), with HLA-Cw6 show ing the stron gest
and most con sis tent as so ci a tion in most eth nic
groups (19). The MHC genes char ac ter is ti cally dis -
play strong link age dis equi lib rium (co-seg re ga tion
of marker and dis ease al lele, a re flec tion of phys i cal 
prox im ity and re com bi na tion frac tion, since cer tain
al leles oc cur to gether more fre quently than ex -
pected by chance) be cause of low re com bi na tion
fre quen cies be tween them, re sult ing in the pres -
ence of con served or an ces tral haplotype (20).
Later stud ies have shown strong as so ci a tion of
pso ri a sis with many ex tended haplotypes, of which
nearly all con tain Cw6.The role HLA class II DR and 
DQ an ti gens in pso ri a sis has been in ten sively in -
ves ti gated since 1981. Schmitt Egenolf et al (21)
pub lished one of the first re ports on the as so ci a tion
be tween DNA-typed HLA class II al leles and type I
pso ri a sis. They found a sig nif i cantly higher fre -
quency of HLA-DRB1*0701 (DRB1*0701 is a sub -
type of DR7) in pa tients with pso ri a sis type I than in
ACTA DERMATOVENEROLOGICA CROATICA 19
Pašiæ et al: Acta Dermatovenerol Croat
Ge net ics of Pso ri a sis 2004;12(1):18-25
con trol group. The same group of au thors also in -
tro duced an ex tended haplotype EH 57.1 (57 de -
duced from B57) – Cw6-B57-DRB1*0701- DQA1*
0201- DRB1*0303 (22). By com par ing the fre quen -
cies of the ex tended haplotype EH57.1 in 35% of
pso ri a sis type I and 2% of con trols, they cal cu lated
a 26-fold risk of pso ri a sis de vel op ment (22). An ex -
tended haplotype is a com bi na tion of sev eral dis -
tinct al leles, which is nearly al ways in her ited as a
full com plex hav ing re mained es sen tially un -
changed through out evo lu tion. Ikaheimo et al (23)
stud ied 64 Finn ish pa tients and con firmed ear lier
find ing of Cw6 as a sin gle gene, which showed a
stron ger cor re la tion with pso ri a sis than the com -
plete Cw6-DR7-DQA1*0201 haplotype. Jenisch et
al (24) showed the HLA class II DRB1*0701 and
DQB1*0303 haplotypes to increase susceptibility to 
psoriasis only in the presence to Cw6. A recent
study of 29 patients from UK revealed that all
patients with guttate psoriasis carried HLA Cw*
0602 allele (6).
As so ci a tion has been found be tween HLA and
many other dis eases, such as in su lin-de pend ent di -
a be tes mellitus, mul ti ple scle ro sis, rheu ma toid ar -
thri tis, and ce liac dis ease (25-27). All these dis -
eases are polygenic dis or ders orig i nat ing from con -
cert op er a tion of dif fer ent genes. There fore, the pat -
terns of he red ity are com plex and hard to de ci pher.
Non-HLA and HLA ge netic com po nents in ter act in
the out break of dis ease. This may also hold true for
the inheritance of nonpustular psoriasis.
Given that pso ri a sis is a com plex dis ease dis -
play ing wide vari a tion in phe no type and clin i cal re -
sponse, a num ber of sus cep ti bil ity genes are prob -
a bly re spon si ble for its ex pres sion. Since 1990, a
multilocus model of in her i tance has been ac cepted
as an ex pla na tion of pso ri a sis (12). Since that time,
sev eral ge nome-wide scans with paramateric and
nonparametric ap proaches have been per formed,
aim ing to de tect link age with any pso ri a sis sus cep ti -
bil ity loci. In eight stud ies, sig nif i cant ev i dence for
such a link age have been re ported for pso ri a sis
sus cep ti bil ity 1 (PSORS 1) re gion lo cated on the
short arm of chromosome 6 and specifically within
MHC (28-35) (Table 1).
PSORS 1 con fers a high risk for pso ri a sis. It has
been es ti mated that the HLA-as so ci ated PSORS 1
al leles ac count for 35-50% of fa mil ial clus ter ing ob -
served in pso ri a sis (28,29). Re search groups from
all over the world are fo cus ing their ef forts on de fin -
ing the ma jor sus cep ti bil ity allele within PSORS 1
(36).
SUS CEP TI BIL ITY LOCI FOR PSO RI A SIS
PSORS 1
The first com plete se quence and gene map of
hu man MHC was re ported in 1999 by the MHC Se -
quenc ing Con sor tium (37). This re gion is lo cated on 
chro mo some 6 (6p21.3), which is among the first
multi-megabase re gions of the hu man ge nome to
be com pletely se quenced. When it was dis cov ered
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Ta ble 1. Can di date loci in pso ri a sis iden ti fied by ge -
netic link age study
Locus
Chromosomal
location Authors (year) Ref. No.
PSORS1 6p21.3 Trembath et al (1997) 28
Nair et al (1997) 29
Burden et al (1998) 30
Jenisch et al (1998) 31
Capon et al (1999) 32
 Samuelsson et al (1999) 33
Enlund et al (1999) 34
Veal et al (2001) 35
PSORS 2 17q24-25 Tomfohrde et al (1994) 56
Nair et al (1997) 29
Samuelsson et al (1999) 33
Enlund et al (1999) 34
PSORS 3 4q34 Mathews et al (1996) 58
Samuelsson et al (1999) 33
PSORS 4 1q21 Capon et al (1999) 59
Bhalerao & Bowcock (1998) 1
PSORS 5 3q21 Enlund et al (1999) 60
Samuelsson et al (1999) 33
PSORS 6 19p13-p34 Lee et al (2000) 61
Veal et al (2001) 35
PSORS 7 1p35-p34 Veal et al (2001) 35
PSORS 8 16q12-13 Nair et al (1997) 29
Karason et al (2003) 62
20p Trembath et al (1997) 28
Nair et al (1997) 29
19p-13 Lee et al (2000) 61
50 years ago, the re gion was thought to spec ify
histocompatibility genes. How ever, the na ture of
these genes has only been re solved in the last two
de cades. The av er age gene den sity (in clud ing
pseudogenes) over the en tire 3.6-Mb is 1 gene per
16 kilobases (kb). Al though many of the 224 iden ti -
fied loci are still of un known func tion, the MHC Se -
quenc ing Con sor tium es ti mate that about 40% of
the ex pressed genes have an im mune sys tem func -
tion. Over 50% of MHC have been se quenced twice 
in dif fer ent haplotypes, pro vid ing an in sight into the
ex traor di nary poly mor phism end evo lu tion of this
re gion (36). The MHC genes in volved in the func -
tion ing of the im mune sys tem may be potential
candidates for psoriasis susceptibility (Fig. 1).
PSORS 1 con tains HLA Cw6. To date, no func -
tional role has been as signed to HLA-C. How ever,
HLA Cw6 may play a role in de ter min ing the age of
pso ri a sis on set. Type I pso ri a sis shows a much
stron ger HLA Cw6 as so ci a tion com pared with type
II pso ri a sis (38). Guttate pso ri a sis is also char ac ter -
ized by an early on set and strong as so ci a tion with
HLA Cw6 (6).
It has also been ob served that pa tients with pso -
ri a sis may have dif fer ent clin i cal fea tures de pend -
ing on whether they are HLA-Cw6 pos i tive or neg a -
tive. HLA Cw6-pos i tive pa tients of ten show an ear -
lier age at on set and more ex ten sive plaques on
their arms, legs and trunk, more se vere form of the
dis ease, and a higher in ci dence of Koebner’s phe -
nom e non. Dystrophic nail changes and psoriatic ar -
thri tis are more com mon in HLA Cw6 negative
patients (17,39,40).
Type I psoriatics gen er ally have a pro pen sity to
a more wide spread and re cur rent dis ease com -
pared with type II pa tients (8). Al ter na tively, HLA
Cw6 may sim ply rep re sent a ge netic marker of pso -
ri a sis sus cep ti bil ity since type I pso ri a sis is char ac -
ter ized by a strong fam ily his tory of pso ri a sis (8).
Not all pa tients with pso ri a sis carry the Cw6 al lele,
and not all HLA-Cw6-bear ing haplotypes con fer an
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Fig ure 1. PSORS 1 on chro mo some 6p21.3 with known can di date genes (mod i fied ac cord ing to ref. 9).
equal risk for pso ri a sis de vel op ment (31). The
strong HLA Cw6 as so ci a tion found in many eth nic
groups may be the re sult of link age dis equi lib rium
with a nearby gene on the same chro mo some. It is
now widely ac cepted that HLA Cw6 is prob a bly a
marker for PSORS 1 gene rather than the major
susceptibility allele itself (9,41-43).
Link age disquilibrium map ping has re fined the
PSORS 1 sus cep ti bil ity re gion to an ap prox i mately
300-kb in ter val around HLA-C (Fig. 1). This in ter val
has been se quenced and be sides HLA-C, four
other genes have been de scribed: OTF 3
(POU5F1), TCF 19 (SC1), HCR (Pg8), and corneo -
desmo sine (CDSN).
Gon za lez et al (44) have re ported on as so ci a -
tion with one al lele of OTF3 gene in a Span ish pop -
u la tion, al though they ac knowl edged that OTF3
was a some what un likely can di date for sus cep ti bil -
ity for pso ri a sis, as the gene en coded a transcriptio -
nal fac tor play ing a ma jor role in em bry onic stem
cell lineage commitments.
Teraoka et al (45) an a lyzed TCF 19 cod ing for
cell reg u la tor, ex pressed in the G1-S phase of the
cell cy cle, but failed to ob serve any as so ci a tion.
HCR and CDSN de serve spe cial men tion, as
there is a strong ge netic and func tional ev i dence for 
their role in the pathogenesis of pso ri a sis. The HCR 
gene has lately been un der in tense scru tiny (Fig. 1). 
It is lo cated 110 kb telomeric of HLA-C in the crit i cal
re gion for pso ri a sis sus cep ti bil ity. Se quenc ing anal -
y sis showed that HCR was highly poly mor phic.
HCR was first iden ti fied as a pu ta tive struc tural
com po nent of skin-re lated tis sues, as it pre sented
trichohyalin, my o sin, and laminin homologies (46).
Asumalahti et al (47) dem on strated the gene to be
ubiq ui tously ex pressed but upregulated in psoriatic
epi der mis. They also tested HCR as a PSORS 1
can di date by an a lyz ing 17 intragenic sin gle-nu cle o -
tide polymorphisms (SNPs) in a Finn ish pop u la tion
sam ple. Their study dis closed a sig nif i cant as so ci a -
tion be tween pso ri a sis and two-SNP haplotypes
bear ing two Arg›Trp sub sti tu tions (HCR*Trp-Trp al -
lele). In ad di tion, func tional stud ies sug gest that
HCR is a reg u la tor of keratinocyte dif fer en ti a tion
and pro lif er a tion, providing additional support for
HCR candidacy in psoriasis pathogenesis (47).
The CDSN gene is lo cated 160 kb telomeric of
HLA-C in class I re gion and codes for corneode -
smosin, a desmosomal pro tein in volved in keratino -
cyte co he sion and des qua ma tion (48,49) (Fig. 1). A
re cent study dem on strated CDSN over expression
and al tered dis tri bu tion in psoriatic epi der mis,
which are dis ease-spe cific changes, as they have
not been ob served in other in flam ma tory skin dis -
eases, such as atopic der ma ti tis and li chen planus
(50). The CDSN gene is highly poly mor phic and its
poly mor phism oc curs at a fre quency of 1/65 kb at
least (51).
The link age and as so ci a tion with pso ri a sis vul -
ga ris has been dem on strated for an al lele of the
CDSN gene de fined by SNPs +619 (Ser›Phe) and
+1243 (Ser›Leu) giv ing amino acid sub sti tu tion
(41,52). Given the high CDSN poly mor phism, SNP
haplotypes rather than sin gle al leles are likely to in -
flu ence pro tein struc ture. A high-risk haplotype in -
clud ing high-risk al leles +619, +1236, and +1243
has shown a sig nif i cant as so ci a tion with pso ri a sis
(53). Based on its genomic po si tion and pu ta tive bi -
o logic func tion, CDSN is an at trac tive candidate
gene for psoriasis susceptibility.
Other Can di date Loci for Pso ri a sis
Sus cep ti bil ity
It is now clear that a num ber of ge netic risk fac -
tors be sides PSORS 1 may play a role in pso ri a sis.
Bowcok et al (54,55) first dem on strated the ex is -
tence of a pre dis pos ing lo cus other than HLA in
some fam i lies. Some of the other non-MHC can di -
date loci for pso ri a sis sus cep ti bil ity are of par tic u lar
in ter est. The link age to 17q24-q25 (PSORS 2)
dem on strated by Tomfohrde et al (56) has been
rep li cated by other groups in a va ri ety of pop u la -
tions in the USA, Swe den, and Ire land (29,33). The
search for this gene is un der way (57).
The link age of pso ri a sis sus cep ti bil ity with re -
gions other than PSORS 1 and PSORS 2 has been
re ported in mul ti ply af fected fam i lies from dif fer ent
geo graphic lo ca tions: 4qter (PSORS 3) in a group
of Irish fam i lies (58), 1q21 (PSORS 4) in a fam ily
from Lazlo re gion in It aly (59), 3q21 (PSORS 5) in a
set of Swed ish fam i lies (60), 19p13 in Ger man fam i -
lies (61), and 16q in Ice lan dic fam i lies (62). The
can di date in ter val on 19p13 (PSORS 6) con tains a
gene that codes for ICAM-1, a ligand for lym pho -
cyte func tion-as so ci ated an ti gen (LFA) that acts as
a ma jor cell ad he sion mol e cule me di at ing leu ko cyte 
mi gra tion in pso ri a sis. PSORS 4 on chro mo some
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1q21 con tains the epi der mal dif fer en ti a tion com -
plex, a clus ter of genes ex pressed dur ing epi der mal 
dif fer en ti a tion. It also con tains other skin ex pressed 
genes, in clud ing loricrin, involucrin, and filagrin, a
psoriasin which is overexpressed in psoriatic skin
and acts as a po tent chemotactic in flam ma tory pro -
tein for CD4+ (63). Sev eral im mune re lated genes
have been mapped on chro mo some 1p (PSORS 7), 
in clud ing the gene en cod ing for EPS 15, a highly
spe cific intercellular sub strate for the epi der mal
growth fac tor re cep tor, which is overexpressed in
psoriatic epi der mis (35). It is in ter esting that some
pso ri a sis sus cep ti bil ity loci co in cide with the loci
iden ti fied for other in flam ma tory and au to im mune
dis eases, such as chro mo some 1q for atopic der -
ma ti tis, 3q21 and 17q24.3 for rheu ma toid ar thri tis,
and 16 p for in flam ma tory bowel dis ease (54). This
is an important finding because clinically distinct
autoimmune diseases may be controlled by a
common set of susceptibility genes. 
The iden ti fi ca tion of mul ti ple loci for pso ri a sis
sus cep ti bil ity has stressed that pso ri a sis is a het er -
o ge neous dis ease with dif fer ent ge netic causes. It
is also im por tant that epistasis (in ter ac tion) ex ists
be tween some sus cep ti bil ity loci. For ex am ple, the
penetrance of PSORS 1 is only 10%, and the pres -
ence of pso ri a sis in PSORS 1-pos i tive pa tients is
thought to be caused by epistasis with other loci
(55).
In an ef fort to con firm the pre vi ously re ported
link age to pso ri a sis, the In ter na tional Pso ri a sis
Genetics Con sor tium an a lyzed 942 af fected sib ling
pairs from 710 ped i grees for 53 microsatellites span -
ning 14 pso ri a sis can di date re gions (64). This large
col lab o ra tive study is likely to fa cil i tate fur ther re -
search ef forts to de ter mine and char ac ter ize the sus -
cep ti bil ity loci for pso ri a sis. These data pro vide un -
equiv o cal ev i dence for a ma jor role of a gene or
genes within the MHC class I re gion. Other loci are
likely to con fer a lower risk of dis ease cau sa tion (64).
Pso ri a sis is prob a bly a multigeneic dis ease, with 
mul ti ple sus cep ti bil ity genes work ing in a con cert to
pro duce the ab nor mal phenotype (65).
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IN TRO DUC TION
Pso ri a sis is a chronic hypeproliferative in flam -
ma tory skin dis ease char ac ter ized by ab nor mal
keratinocyte hyperproliferation and dif fer en ti a tion,
intra-epi der mal ac cu mu la tion of neutrophil granu lo -
cytes, and in flam ma tory vas cu lar changes (1). Im -
mu no log i cally, pso ri a sis is char ac ter ized by a
dense mononuclear in flam ma tory in fil trate, par tic u -
larly in the dermis, which mostly con sists of T-cells
(2). Pso ri a sis is now gen er ally rec og nized as a
T-cell-me di ated in flam ma tory dis ease. In fil tra tion of 
T-cells seems to be the pri mary event that pre cedes 
the keratinocyte hyperproliferation (3). The sug -
gested mech a nism is that sys temic lym pho cyte ac -
ti va tion is fol lowed by the lo cal ac cu mu la tion of
specific CD4+ T-cells and subsequent activation of
intradermal CD8+ T-cells (4).
The ev i dence ac cu mu lated in the last de cade
strongly sug gests that pso ri a sis is a T-cell-me di -
ated dis ease. The im por tant role of T-cells in pso ri a -
sis pathogenesis was first sug gested af ter ef fec -
tive ness of cyclosporine was ob served in the treat -
ment of pso ri a sis (5). Cyclosporine was found to se -
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lec tively in hibit interleukin-2 (IL-2) and in ter feron-γ
(IFN-γ) re lease from CD4+ T-cells. Fur ther ev i -
dence in cludes the suc cess ful use of diph the ria fu -
sion toxin (DAB389IL-2) in pso ri a sis treat ment (6).
DAB389IL-2 is a po tent immunotoxin only to T-cells
ex press ing IL-2 re cep tor (IL-2R). Fi nally, ex per i -
ments on a se vere com bined immunodeficient
(SCID) mouse con firmed the key role of ac ti vated
T-cells in the ini ti a tion and per sis tence of psoriatic
pro cess (7). In the SCID mouse, only in jec tion of
autologous CD4+ T-cells from the psoriatic pa tient
could in duce trans for ma tion of engrafted symptom -
less skin into a typical psoriatic lesion.
THE ROLE OF T-CELLS IN PSO RI A SIS
Sev eral stud ies have con firmed the im por tant
role of T-cells in trig ger ing the psoriatic pro cess
(8,9). So far, it seems that CD4+ T-cells cre ate an
ap pro pri ate cytokine en vi ron ment for CD8+ T-cells
ac ti va tion that even tu ally trig ger the psoriatic cas -
cade (10). Thus, in ter ac tion be tween CD4+ and
CD8+ T-cells leads to cre ation of psoriatic lesions.
The avail abil ity of nu mer ous monoclonal an ti -
bod ies has en abled the immunohistochemical cha -
r ac ter iza tion of the in flam ma tory in fil trate within the
psoriatic le sions. Immunohistochemical stud ies
show ed in creased num ber of T-cells in the epi der -
mis and dermis of psoriatic plaques (11,12). T-cells
in fil trat ing dermis are mainly of type 1 helper CD4+
T lym pho cytes (Th1) and those in fil trat ing the epi -
der mis are mostly type 1 cytotoxic CD8+ T-cells
(Tc1). Both, ac ti vated Th1 and Tc1 lym pho cytes,
are highly overrepresented in psoriatic le sions
where they ex press in creased level of HLA-DR and
IL-2R sur face mol e cules as mark ers of per sis tent
ac ti va tion (13). The Th1 and Tc1 sub sets seem to
rep re sent a ma jor effector T-cell pop u la tion within
the psoriatic le sions. In fil trat ing T-cells cre ate a type 
1 cytokine microenvironment within the psoriatic le -
sions with type 1 cytokines IFN-γ, tu mor necrotizing
fac tor-α (TNF-α) and IL-2, but not IL-4 or IL-5 (14).
Such par tic u lar cytokine pat tern is suf fi cient in in -
duc ing typ i cal psoriatic changes, mainly keratino -
cyte hyperproliferation (IL-6 and IFN-γ) and ac cu -
mu la tion of neutrophil granu lo cytes (IL-8) in the epi -
der mis (15). Ac ti vated keratinocytes also pro duce
wide range of cytokines that en hance ac ti va tion and 
chemotaxis of T-cells in the skin (IL-6 and IL-8) or
even in duce the in creased ex pres sion of par tic u lar
ad he sion mol e cules (IL-1) im por tant in T-cell traf -
fick ing (16). There fore, T-cells and keratinocytes
are equal partners in the persistent dialogue during
the creation of psoriatic lesions.
HOW T-CELLS ME DI ATE PSO RI A SIS?
The pre cise mech a nism how ac ti vated T-cells
trig ger pso ri a sis is yet un known. How ever, it seems
that the spe cific im mune re ac tion to a pu ta tive an ti -
gen me di ated by T-cells leads to cre ation of
psoriatic le sions (17). The only dif fer ence be tween
“nor mal” and “psoriatic” im mune re ac tion is in the
du ra tion of the pro cess. Nor mally, im mune re -
sponse stops af ter elim i na tion of an an ti gen. Psori -
atic im mune re ac tion con tin ues un til the for ma tion
of char ac ter is tic psoriatic plaque. Thus, it is clear
that T-cells are re spon si ble for ini ti a tion and main te -
nance of pso ri a sis (18). The real na ture of pu ta tive
psoriatic an ti gen is yet un known, but it is now rec og -
nized that bac te rial endo tox ins act ing as superanti -
gens or a par tic u lar epidermal self-antigen are
capable of triggering psoriasis (19,20).
The first step in psoriatic im mune re ac tion
seems to be the cap ture of an ti gen by epi der mal
Langerhans cells (Lc) and their sub se quent ac ti va -
tion (21). Langerhans cells are an ti gen-pre sent ing
cells that ma ture dur ing the ac ti va tion pro cess and
sub se quently ex press mark ers of ac ti va tion (CD80, 
CD86, and CD40). Ac ti vated Lc cells mi grate to the
skin-drain ing lymph nodes where T-cell ac ti va tion
oc curs. In deed, ac ti vated Lc cells are found in high
amount in the epi der mis and dermis of psoriatic le -
sions (22). An ti gens are enzimatically pro cessed
within the Lc cells and sub se quently pre sented on
their surface to activate naive T-cells.
The ac ti va tion of T-cells is a com plex pro cess of
stim u la tion the T-cell an ti gen-re cep tor (TCR) com -
plex and T-cell costimulation through par tic u lar sur -
face re cep tors (23). The rec og ni tion of an an ti gen
pep tide pre sented on the sur face of an ti gen-pre -
sent ing cells in the com plex with ei ther ma jor
histocompatibility com plex (MHC) I or MHC II is an
ini tial step in the T-cell ac ti va tion. Pep tide an ti gens
are rec og nized by T-cell an ti gen-re cep tor com plex
on the sur face of T-cells. If a match be tween a pep -
tide and par tic u lar T-cell an ti gen-re cep tor com plex
oc curs, the first ac ti va tion sig nal is send to T-cells
and IL-2 and IL-2R (CD25) are sub se quently syn -
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the sized. For the op ti mum T-cell ac ti va tion and sub -
se quent clonal ex pan sion, ac ces sory co-stim u la -
tion is re quired (24). The ac ces sory sig nals are ob -
tained through in ter ac tion be tween CD28 on T-cells 
and CD80 and CD86 on the sur face of an ti gen-pre -
sent ing cells and be tween CD40L on T-cells and
CD40 on an ti gen-pre sent ing cells. The re sult of
such co or di nated stim u la tion is in creased tran scrip -
tion of IL-2, IFN-γ, and TNFα that in duce ex pan sion
of par tic u lar T-cell clone and dif fer en ti a tion to ward
type 1 effector cells (25). The in ter ac tion be tween
CD40 and CD40L in duce tran scrip tion of IL-12, a
ma jor cytokine driv ing type-1 dif fer en ti a tion char ac -
ter ized by IL-2, IFN-γ, and TNFα re lease (26). It is
now rec og nized that pso ri a sis is a type-1 disease
mediated by type-1 cytokines (27,28). Indeed, high
concentration of type-1 cytokines is found in
psoriatic lesions.
Dur ing the mat u ra tion pro cess, T-cells ex press
par tic u lar skin hom ing re cep tor, cu ta ne ous lym pho -
cyte-as so ci ated an ti gen (CLA) that traf fics ac ti -
vated T-cells back to the skin (29). It is a glycopro -
tein that in ter acts with E-selectin or P-selectin on
en do the lial cells of cu ta ne ous microvessels, sub se -
quently slow ing down the roll ing T-cells. The en do -
the lial cells re lease wide range of chemokines
(TARC and MIG) that in duce lym pho cyte func tion
as so ci ated an ti gen-1 (LFA-1) and very late an ti -
gen-4 (VLA-4) ex pres sion on the sur face of T-cells
(30). These ad he sion mol e cules in ter act with inter -
cellular ad he sion mol e cule-1 (ICAM-1) and vas cu -
lar cell ad he sion mol e cule-1 (VCAM-1) on the en -
do the lial cells and sub se quently extravasate into
dermis. The chemotactic gra di ent of a wide range of 
chemokines (RANTES, TARC, and MIG) pro duced
by en do the lial cells, keratinocytes, monocytes and
Lc cells traf fics T-cells into epi der mis and dermis
(31). Ac tu ally, IFN-γ and TNF-α from T-cells stim u -
late the syn the sis of those chemokines that at tract
Th1 cells to dermis and Tc1 cells to ward the epi der -
mis. Wide range of chemokines and their receptors
on T- cells are highly expressed in psoriatic lesions
(32).
Fi nally, effector part of im mune re sponse oc curs
in the skin. In the dermis, af ter an ti gen stim u la tion,
Th1 cells re lease large amounts of IFN-γ that in -
duce ex pres sion of ICAM-1, CD40, and MHC-II
mol e cules on keratinocytes. In ad di tion, Th1 cells
stim u late TNF-α re lease by der mal macrophages.
LFA- 1+Tc1 cells in ter act with ICAM-1 on keratino -
cytes and mi grate to epi der mis (33,34). Intra-epi -
der mal Tc1 cells re lease IFN-γ and stim u late
keratinocyte hyperproliferation and ab nor mal dif fer -
en ti a tion, the key mark ers of psoriatic phe no type.
Fur ther more, IFN-γ and TNF-α from Tc1 cells stim u -
late IL-8 re lease from ac ti vated keratinocytes. IL-8
re lease at tracts neutrophil granu lo cytes into epi der -
mis, form ing the so-called Munro’s ab scesses (35).
Ac ti vated keratinocytes se crete wide range of
chemokines (MIG and IP-10) and cytokines (IL-6)
that ei ther am plify lym pho cyte traf fick ing and ad he -
sion to en do the lial cells or en hance fur ther kera -
tinocyte pro lif er a tion. Fi nally, keratinocytes syn the -
size par tic u lar angiogenic cytokines, such as vas -
cu lar en do the lial growth fac tor (VEGF), which in -
duce typ i cal vas cu lar changes in psoriatic le sions
(36). Hence, the vi cious cir cle is closed. The im -
mune re ac tion driven by bac te rial superantigens or
epi der mal self-an ti gens, described herein, is
constantly going on until psoriatic lesions are
created.
CON CLU SION
The psoriatic pro cess is a dy namic pro cess that
in cludes in ter ac tion be tween Th1 and Tc1 cells, as
well as be tween T-cells and keratinocytes. The
better un der stand ing of the pso ri a sis immunopa -
tho genesis would en able de vel op ment of spe cific
T-cell-tar geted and/or cytokine-tar geted new ther a -
pies.
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IN TRO DUC TION
To day, pso ri a sis is a well-known skin dis ease, in
whose etiopathogenesis take part ge netic fac tors,
en vi ron men tal fac tors, and im mu no logic mech a -
nisms. It is hard to un der stand the im pos si bil ity to
find de scrip tion of pso ri a sis in the works of great
phy si cians of the passed cen tu ries in spite of the
fre quency of dis ease, its long last ing course, and
typ i cal le sions and lo cal iza tion. Prob a bly in the
elapsed age the de scrip tion of skin dis eases, con -
sid ered morbi in pulchredine, was not pre cise, the
ter mi nol ogy not stan dard ized, the trans la tion from
one lan guage to oth ers was dif fi cult, and dif fer ent
au thors called the same dis ease differently, while
different diseases bore the same name.
In the Egyp tian Ebers pa py rus that had been
writ ten at the time of the 18th Dy nasty (15th cen tury
BC), one may find de scrip tions of many skin dis -
eases, such as šuf. t for scale, but it is im pos si ble to
rec og nize pso ri a sis (1). Some be lieve that the dis -
ease called zaraath (trans lated in Greek as lepra) in 
the Bi ble was ei ther lep rosy or pso ri a sis (2). The
con found ing of these two dis eases cre ated great
prob lems to psoriatics for a long time. Hip poc ra tes
used the word psora that meant scale and itch for
itchy le sions on the eye lids and gen i tals, so this
surely was not pso ri a sis al though he used tars and
cli mate to treat skin dis eases (3). It seems that in
the books of A. Cornelius Cel sius, who lived dur ing
the Ro man Em pire in the 1st cen tury AD, there is the 
first de scrip tion of pso ri a sis, but un der the name of
im pe tigo; the dis ease was treated with me di ca -
ments con tain ing pitch and sul fur (4). The word
psora was also men tioned in the books of the other
encyclopedist Pliny, but he did not de scribe the dis -
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ease (5). Galen from Pergamo was the first one
who used the term pso ri a sis, but only for an itchy
erup tion of the scro tum (6). Re cently, Holubar wrote 
about the se man tic as pects of the word psoriasis
(7).
Dur ing the dark Mid dle Ages, the med i cine was
full of su per sti tion, ig no rance, and mys ti cism and
gave lit tle at ten tion to skin dis eases. Per haps the
Ara bian phy si cians first dis tin guished pso ri a sis
from other skin dis eases, what hap pened in the 8th
cen tury AD. They also used a kind of psy cho ther -
apy to treat the disease (8).
In the 18th cen tury, the great Swed ish nat u ral ist
and phy si cian Carl Linnaeus in tro duced the bi no -
mial ter mi nol ogy and first clas si fied the plants in a
com pre hen si ble man ner. Later on, he pro posed to
clas sify the dis eases in his Gen era Morborum (9).
Short af ter, Jo seph Plenck in Vi enna, also a great
ex pert in bot any who com piled a list of about 800
me dic i nal plants, com piled the book Doctrina de
Morbis Cutaneis in 1776, in which he clas si fied
about 120 skin dis eases into 14 classes af ter the el -
e men tary le sions, which he only mar gin ally de fined. 
He also paid lit tle at ten tion to pso ri a sis and its ther -
apy, and used the old term im pe tigo for that dis ease
(10). It was the Eng lish phy si cian Rob ert Willan
who, in his work On Cu ta ne ous Dis ease from 1798,
de vel oped a sim pler and better clas si fi ca tion of skin 
dis eases af ter the el e men tary le sions (11). He used 
the term pso ri a sis for the papulosquamous dis ease
and partly dif fer en ti ated pso ri a sis from leprosy. His
work was continued and completed by his disciple
Thomas Bateman.
At the be gin ning of the 19th cen tury, the great
French phy si cian Jean Louis Alibert worked and
taught at the Hos pi tal of St. Louis in Paris. He also
tried to sys tem atize skin dis eases and pro posed a
“tree of skin dis eases”, which made only greater
con fu sion. Pso ri a sis was clas si fied in the group of
dartrous dermatoses to gether with leprosy (12).
It was Ferdinand von Hebra who, around 1850,
work ing in Vi enna at the Allgemeine Krankenhaus
fi nally sep a rated pso ri a sis from lep rosy and also
clas si fied skin dis eases not only on the ba sis of
gross anat omy, but also, af ter Karl Rokitansky,
used the mi cro scopic cri te ria in the clas si fi ca tion of
diseases (13).
THE LAST TWO CEN TU RIES
Af ter these pre lim i nary re marks, it be comes
clear that we can speak about the treat ment of pso -
ri a sis from the be gin ning of the 19th cen tury. The
treat ment was top i cal and/or sys temic. Ar senic was
among the first drugs that were used sys tem i cally.
In 1806, Thomas Girdlestone was the first who
used po tas sium ar se nate as solutio Fowleri, usu ally 
6 drops 3 times a day (14). This so lu tion was in tro -
duced into med i cine in 1780 by the Eng lish phy si -
cian and phar ma cist Fowler (15). The drug is eas ily
ab sorbed from the gas tro in tes ti nal tract and de pos -
ited in var i ous or gans, es pe cially in the skin and
hair. It acts through inhibiting some enzymes.
Hebra and Kaposi also pro posed solutio Fowleri
and pilulae asiaticae in the treat ment of pso ri a sis
(13). It seems that ar senic com pounds mostly im -
proved pso ri a sis guttata, but some times also other
forms of the dis ease. In 1869, ar senic acid was also 
in jected sub cu ta ne ously. Be cause pso ri a sis is a
chronic dis ease, with time this ther apy led to ac cu -
mu la tion of arsine and tox ic ity, with pa tients de vel -
op ing pig men ta tions, keratoses, and can cers of the
skin, liver, blad der, and lar ynx. In spite of these ad -
verse re ac tions, arsine had re mained in use un til
the mid dle of the 20th cen tury and the in tro duc tion of 
corticosteroids in the therapy of psoriasis.
Mer cury was used for cen tu ries in the treat ment
of syph i lis and skin dis eases. In 18th cen tury, Turner 
cured pso ri a sis with in junc tions of an oint ment con -
tain ing am mo ni ated mer cury (hydrargiri amidochlo -
rati) (16). Mer cury oint ment was also used by Bate -
man and other phy si cians dur ing the 19th cen tury. In 
1895, Brault (17) used or ganic mer cury com pound
in jec tions in the treat ment of ar thri tis psoriatica.
Even in 1972 Jadassohn and Kogoj (18) rec om -
mended a mer cury ointment for psoriasis capillitii.
The lo cal or in ter nal (in tra mus cu lar) use of sul fur 
and sal i cylic acid in treat ment of skin dis ease has
been known for a long time. Hebra and Kaposi used 
it in var i ous oint ments. Later, many dis eases as well 
as pso ri a sis were con sid ered in fec tious and an an -
ti bac te rial treat ment was in tro duced (io dine, phe -
nol, or acetic acid).
In the mid dle of the 19th cen tury in In dia, Chrysa -
robin was used in the treat ment of dermato mycoses 
and pso ri a sis, i.e. long be fore the Eng lish phy si cian
Balmanno Squire (19) in 1876 wrote about its use
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for pso ri a sis. The drug was pres ent in the Goa (or
Bahia) pow der, ob tained from the cen ter of the
trunk of the tree Andira Araroba (vata ireopis
araroba), which grows in some parts of Brasil. To -
day this plant is hard to find and also only few bot a -
nists know of it (20). Chrysarobin is an antranone
that eas ily ox i dizes; its con cen tra tion in the pow der
was very vari able. This drug was used in the form of 
1-5% oint ment and when ap plied, it caused ir ri ta -
tion, itch ing, and col ored the skin and linen.
Chrysarobin was not to be used on the face be -
cause it pro voked keratitis. The drug was ef fec tive,
but also ex pen sive and toxic. So, at tempts were
made to syn the size a sim i lar sub stance with lit tle
side ef fects. At the end of 19th cen tury, the de vel op -
ment of chem is try and tech nol ogy es pe cially in Ger -
many and Eng land fa vored these at tempts: first
antrarobine ob tained had no ef fect on pso ri a sis;
later in 1916, the syn the sis of dithranol (cignolin or
antralin) per mit ted treat ing pso ri a sis in a better way
(21). It was ap plied as ointment or paste (0.1%) or,
as today, in a stick for short contact therapy.
Yet, Hip poc ra tes used tars in the treat ment of
skin dis ease (pine tar), and tars were also used dur -
ing the last two cen tu ries. Lit tle im prove ment was
ob tained with wood tars (pine, birch, ju ni per, or pix
betulina) con tain ing ace tic acid and phenolcarbonic 
acid. Be cause of their acidic re ac tion, they ir ri tated
the skin. They were in cor po rated in oint ments,
paste, and oils and ap plied di rectly on the skin or
used for baths (22).
Bi tu mi nous tars, such as ich thy ol, were also
used. Like wood tars, they are not pho to sen si tiz ing.
A greater im prove ment was the in tro duc tion of coal
tar ob tained from dis til la tion of coal in the man u fac -
ture of il lu mi nat ing gas. This sub stance is photo -
toxic (un der UVA and vis i ble rays). In 1925,
Goeckerman (23) used coal tar in con junc tion with
ul tra vi o let light ir ra di a tion. This method is to day one 
of the most efficient treatments for psoriasis.
The ben e fi cial ef fect of sun on skin dis eases had 
al ready been known among the old civ i li za tions,
who left us the knowl edge of heliomarinotherapy,
which is still used in the treat ment of pso ri a sis (24).
Finsen in tro duced ar ti fi cial ul tra vi o let ra di a tion in
med i cine at the be gin ning of 20th cen tury. Alderson,
in the twen ties of the last cen tury, re ported an im -
prove ment with UV in pso ri a sis (24). In the last de -
cade, lamps were de vel oped with wavebands be -
tween 300 and 320 nm and nar row spec trum
around 311 nm, to gether with PUVA ther apy. In
1973, Tronnier and Schule (25) first ob served a
good im prove ment of pso ri a sis af ter the top i cal use
of psoralen and UVA. Soon af ter Par ish et al (26)
used oral psoralens and UVA ir ra di a tion. This treat -
ment is highly effective and produces long lasting
remissions.
At the mid dle of the 20th cen tury, corticosteroids
were in tro duced into med i cine. The lo cal ap pli ca -
tion of cor ti sone and hy dro cor ti sone was with out
any ef fect on pso ri a sis. Chang ing the ste roid mol e -
cule per mit ted ob tain ing more po tent ste roids, like
fluocinolone acetonide, betamethasone valerate,
and clobetasol pro pi o nate, which were ef fec tive in
clear ing most cases of pso ri a sis. Their ef fi cacy can
be en hanced with oc clu sive dress ing or use in com -
bi na tion with sal i cylic acid, tars, and other. The
draw backs of this ther apy are at ro phy of the skin,
sup pres sion of the hy po thal a mus-pi tu itary-ad re nal
axis, and tachyphylaxis. In ter nal use of corticoste -
roids is recommended only in problematic cases.
Among other drugs em ployed in the treat ment of 
pso ri a sis there are cytostatics and antimetabolits.
Par tic u lar men tion de serves methotrexate, which
can give sat is fac tory re sponse in se vere cases, but
– it is hepatotoxic (27). There were also at tempts to
treat pso ri a sis with di ets low in fat, veg e tar ian, or
with low or high con tains of potassium (28,29).
In re cent years, the in ter nal use of cyclosporine,
an immunosuppressive drug, has shown good re -
sults in the treat ment of the dis ease, but a prob lem
has been its nephrotoxicity (30). Analogs of vi ta min
D slow ing epidermopoiesis can be used top i cally to
im prove pso ri a sis. In the erythrodermic and pustu -
lar form of pso ri a sis a great step was the in tro duc -
tion of sys temic retinoids etretinate and acitretin
(31). They act through the nu clear re cep tors RAR
and RXR and on the ex pres sion of genes im por tant
for the pro lif er a tion and dif fer en ti a tion of keratino -
cytes. Retinoids can be used in combination with
PUVA.
So, to avoid the ad verse ef fects of all these po -
tent drugs, we use com bined or ro ta tional ther apy,
i.e. we change the treat ment af ter a course. The
suc cess of immunotherapy or pso ri a sis in the last
years and ad vances in the elu ci dat ing the patho -
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genesis of the dis ease (32) have per mit ted us to be -
lieve in the fu ture use of drugs that act on spe cific
re cep tors, such as IL-2, cytokines, chemo kines, or
on some mol e cules on the sur face of lym pho cytes
(33). These new drugs de rived from liv ing or gan -
isms, so-called the bi o logic agents, such as hu man -
ized or re com bi nant monoclonal an ti bod ies and fu -
sion pro teins, will find more em ploy ment in the fu -
ture. They can act on mol e cules such CD4, CD2,
mol e cules of the an ti gen-pre sent ing cells, or on en -
do the lial cells. Other may block some of the pro -
inflam matory cytokines, like tu mor ne cro sis fac tor
α, or per haps interleukins that change the TH1 to
TH2 im mune re sponse (34-37). Some of these
“biologics” have been shown ef fec tive and safe in
the treat ment of other au to im mune dis eases and
thus in pso ri a sis as well, with the pos si bil ity to ob -
tain long last ing re mis sions. The prog ress in pso ri a -
sis ge net ics and in pharmacogenetics will per mit a
better and in di vid u al ized treat ment of the dis ease
(38).
Ref er ences
1 Ebbel B. The papirus Ebers. Co pen ha gen 1937.
2 Goldman L, Moraites RS, Kitzmiller K. White spots in
Bib li cal times. Arch Dermatol 1966;93:748-53.
3 Hippocrate. Ouvres com pletes. Littre E, transl. and ed i -
tor. Paris: Bailliere et fils; 1839-1861.
4 Celsus CA. De medicina, Spencer WG, transl. Book V,
17. Cam bridge: Har vard Uni ver sity Press; 1989. p.
168-73.
5 Plinius C. Naturalis historia. Cam bridge: Har vard Uni -
ver sity Press; 1969. .p. XXIII.3.
6 Galenus C. Op era om nia. Kuhn C, ed i tor. Lipsia:
Cnobloch; 1830. p. 449.
7 Holubar K. Pso ri a sis 100 years ago. Dermatologica
1990;180:1-4.
8 Shafii M, Shafii SL. Ex plor atory psy cho ther apy in the
treat ment of pso ri a sis twelve hun dred years ago. Arch
Gen Psy chi a try 1979;36:1242-5.
9 Carl Linnaeus. Gen era morborum. Uppsala; 1763.
10 Plenck JJ. Doctrina de morbis cutaneis, Wien; 1776.
11 Willan R. On cu ta ne ous dis eases. Lon don: John son St.
Paul’s Church Yard; 1809.
12 Alibert JL. Monographie des dermatoses. Pre cis theo -
rique et pra tique des mal a dies de la peau. Paris:
Daynac; 1832.
13 Hebra F. At las der Hautkrankheiten. Vol I-X , Wien;
1856-1876.
14 Girdlestone T. Ob ser va tion on the ef fect of dr Fowler’s
min eral so lu tion in lep rosy and other dis eases. Med
Phys J 1806;15:297.
15 Fowler T. Med i cal re ports of the ef fects of ar senic in the 
cure of agues, re mit ting fe vers and pe ri od i cal head -
aches. Lon don Med J 1786;7:192-205.
16 Turner D. Dis ease in ci dent to the skin. 3rd ed. Lon don:
Bonurike; 1726. p. 45.
17 Brault J. Deux cas de pso ri a sis traite par les in jec tions
mercurielles. Bull Soc Franc Dermatol 1895:332.
18 Jadassohn W, Kogoj F. Bemerkungen zur psoriasis -
therapie. Zbornik radova sa VII kongresa dermato -
venerologa Jugoslavije. Opatija–Rijeka, Yu go sla via,
1972; p. 65.
19 Squire B. On the treat ment of pso ri a sis by an oint ment
of chrysophanic acid. Lon don: Chur chill; 1878. p. 8.
20 Swanbeck G. Der Baum, aus welchem Chrysarobin
gewonnen wurde. Haut-arzt 1992;43:388-9.
21 Galewsky E. Ûber Cignolin, ein Ersatzpräparat des
Chrysarobins. Derm Wschr 1916;62:113-5.
22 Leigheb V. Il valore pratico attuale della terapia esterna 
medicamentosa delle malattie cutanee. Mi nerva
Dermatol 1958; 33 Suppl 1:81-2.
23 Goeckerman WH. Treat ment of pso ri a sis. North west
Med 1925;24:229.
24 Alderson HE. Heliotherapy for pso ri a sis. Arch Derma -
tol 1923;8:79-80.
25 Tronnier H, Schule N. Zur dermatologischen Therapie
von Dermatosen mit Langwelligen UV nach Photo -
sensibilisirung der Haut mit Methoxsalen, erste
Ergebnisse bei Pso ri a sis vulgaris. Zeitschr Haut
Geschlkr 1973;48:385-93.
26 Parrish JA, Fitzpatrick TB, Tannenbaum L, Pathak MA.
Photochemotherapy of pso ri a sis with oral methoxalen
and long wave ul tra vi o let light. N Engl J Med 1974;
291:1207-11.
27 Edmundson WF, Guy BW. Treat ment of pso ri a sis with
fo lic acid an tag o nists. Arch Dermatol 1958;78 :200-3.
28 Nobl G. Pso ri a sis. In: Jadassohn J. Handbuch der Haut
und Geschlechts-krankheiten. Vol. VII. Berlin: Springer;
1928. p. 180-288.
29 Nardelli L. La psoriasi nella storia della medicina. G Ital 
Dermat 1959;100:363-88.
30 Mueller W, Herrmann B. Ciclosporin A for pso ri a sis. N
Engl J Med 1979;30:555.
31 KingstonT, MattL, Lowe N. Etretin ther apy for se vere
pso ri a sis. Arch Dermatol 1987;123:55-8.
32 Nickoloff BJ, Wrone-Smith I. In jec tion of pre-psoriatic
skin with CD4+ T cells in duces pso ri a sis. Am J Pathol
1999;155:145-58.
ACTA DERMATOVENEROLOGICA CROATICA 33
Gruber et al: Acta Dermatovenerol Croat
Treat ment of Pso ri a sis 2004;12(1):30-34
33 Kirby B, Griffiths CE. Pso ri a sis: the fu ture. Br J Dermatol 
2001;144 Suppl 58:37-43.
34 Tutrone WD, Saini R, Wein berg JM. Bi o log i cal ther apy
for pso ri a sis: An over view of infliximab, etanercept,
efalizumab and alefacept. Drugs 2004;7:45-9.
35 Mrowietz U. Therapie der Pso ri a sis mit Bi o log i cals.
Hautarzt 2003;54:224-9.
36 Sobell JM, Hallas SJ. Sys temic ther a pies for pso ri a sis:
un der stand ing cur rent and newly emerg ing ther a pies.
Sem Cutan Med Surg 2003;22:187-95.
37 Boehncke WH. Immunomodulatory drugs for pso ri a sis.
New “biologics” of fer prom ise. BMJ 2003;327:634-5.
38 Bowcock AM, Barker JN. Ge net ics of pso ri a sis: the po -
ten tial im pact on new ther a pies. J Am Acad Dermatol
2003;49 Suppl 2:51-6.
34 ACTA DERMATOVENEROLOGICA CROATICA
Gruber et al: Acta Dermatovenerol Croat
Treat ment of Pso ri a sis 2004;12(1):30-34
Up date on the Pso ri a sis Ther a pies
Jasna Lipozenèiæ, Aida Pašiæ, Ronni Wolf1
De part ment of Der ma tol ogy and Venerology, Zagreb Uni ver sity Hos pi tal Cen ter, Zagreb
Croatia; and 1Der ma tol ogy Unit, Kaplan Med i cal Cen ter, Rechovot, Israel
Cor re spond ing au thor:
Prof. Jasna Lipozenèiæ, MD, PhD
De part ment of Der ma tol ogy and Venerology




Re ceived: 19. 12. 2003
Ac cepted: 27. 02. 2004
IN TRO DUC TION
Pso ri a sis is a chronic life long skin dis ease af -
fect ing 2% of the pop u la tion world wide (1). Pso ri a -
sis has been tra di tion ally di vided into mild, mod er -
ate, and se vere form, based on the per cent age of
body sur face area in volve ment. Un der stand ing the
pa tho physiology of pso ri a sis, cou pled with ad -
vances in mo lec u lar re search, has led to the de vel -
op ment of tar geted bi o logic treat ments for pa tients
with pso ri a sis, es pe cially plaque pso ri a sis. T lym -
pho cytes play an im por tant role in ini ti at ing the re -
ac tion of im mune sys tem and the in flam ma tory re -
sponses that re sult in de vel op ment of psoriatic
plaque. The hall mark fea ture of pso ri a sis is thick -
ened, erythemato us, scaly plaques, most com -
monly on pre di lec tion sites (el bows, knees, scalp,
and sa crum). There is a ge netic ba sis to the dis -
ease, with mul ti ple loci of nu mer ous chro mo somes
be ing iden ti fied and their role fur ther elu ci dated (2).
The de ter mined immu no genic in flam ma tory dis or -
der is based on on go ing autoreactive Th-1 re -
sponse (2). Pso ri a sis is now con sid ered to be a
T-cell-me di ated (auto) im mune dis ease, in which
cytokines and chemokines play an es sen tial role,
with lym pho cyte ac ti va tion as a key step in the pro -
cess. It is dem on strated that pso ri a sis is a granu -
locyte-me di ated dis ease; the pres ence of large
granulocyte in fil tra tions and hyperex pression of
interleukin-8 (IL-8) sug gest that IL-8 plays a sig nif i -
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SUM MARY New pso ri a sis ther a pies of fer a great hope for the
peo ple who suf fer from chronic in flam ma tory skin dis eases. Pso -
ri a sis and psoriatic ar thri tis are the dis eases that can be treated
with bi o log i cal ther apy, which tar gets ei ther the in ter ac tion be -
tween an an ti gen-pre sent ing cell and the T-cell, or cytokines,
such as tu mor ne cro sis fac tor al pha (TNF-α), that are pre sumed
to be in volved in the pathogenesis of pso ri a sis vulgaris and
psoriatic ar thri tis. Cur rent bi o logic ther a pies now seem to hold
prom ise of po ten tially ex cel lent ef fect, with the tox ic i ties as so ci -
ated with ex ist ing ther a pies: phototherapy (PUVA or UVB), reti -
noids, cyclosporin, methotrexate (MTX). Top i cal ther apy will
con tinue to be used in com bi na tion with new bi o log i cal ther a pies
for re sid ual psoriatic plaques. In this pa per, we high light the cur -
rent pso ri a sis treat ments, new bi o logic ther a pies, and their use
in prac tice.
KEY WORDS pso ri a sis vulgaris; ther apy; novel immuno the -
rapies for pso ri a sis; bi o logic ther a pies for pso ri a sis
cant role in pso ri a sis. Var i ous fac tors in duce re -
lapse or ex ac er ba tion of pso ri a sis, in clud ing psy -
cho log i cal stress, skin trauma, med i ca tions, and in -
fec tion (2). Pso ri a sis can have sig nif i cant ad verse
ef fect on pa tient’s phys i cal, psy cho log i cal, and so -
cial life. A wide spec trum of clin i cal pre sen ta tions of
pso ri a sis in cludes plaque pso ri a sis, pso ri a sis
inversa, erup tive pso ri a sis, erythtodermic pso ri a sis, 
gen er al ized form of pso ri a sis, pso ri a sis pustu losa,
and pso ri a sis arthropatica (3). Pso ri a sis pla qu es
show epi der mal hyperproliferation, epi der mal and
der mal in flam ma tion, and en hanced angio genesis
in early le sions (1). A sig nif i cant pro por tion (≤30%)
of pa tients suf fers from joint man i fes ta tions of the
dis ease, which has gen er ally a neg a tive im pact on
the qual ity of their life (4). Treat ment of pso ri a sis is
aimed at symp tom atic re lief and im proved qual ity of
life. The cur rent man age ment of pso ri a sis de pends
on the se ver ity of dis ease, qual ity of life, risk ver sus
ben e fit as sess ment of var i ous treat ment strat e gies, 
and a pa tient’s re s ponse to prior treat ment (5). Con -
sen sus state ment for pso ri a sis treat ment is in the fi -
nal stages of de vel op ment by the Amer i can Acad -
emy of Der ma tol ogy (6).
PRAC TI CAL CON SID ER ATIONS IN THE
TREAT MENT OF PSO RI A SIS
The man age ment of pso ri a sis is a com plex is -
sue for both pa tients and phy si cians. Pa tients with
pso ri a sis rep re sent a large pop u la tion in Eu ro pean
coun tries, and ap prox i mately 2 mil lion Amer i cans
are af flicted with mod er ate to se vere plaque pso ri a -
sis (4). These pa tients are faced with sig nif i cant lim -
i ta tions of tra di tional pso ri a sis ther a pies. While
some sys temic treat ments have good short-term ef -
fects, their side ef fect pro files pro hibit their long-
 term use in the treat ment of this chronic dis ease.
Cur rent stan dard ther a pies, such as phototherapy,
methotrexate, and cyclosporine, are as so ci ated
with long-term safety con cerns, risk of birth defects, 
organ toxicity, and carcinogenicity.
Pa tients with mild, lo cal ized form of the dis ease
nor mally re ceive top i cal ther apy with calcipotriene,
tazarotene, coal tar, anthralin or top i cal corticoste -
roids. Pa tients with mod er ate, re sis tant form of dis -
ease are can di dates for phototherapy, broad band
or nar row-band ul tra vi o let (UVB), or psoralen plus
UVA (PUVA) phototherapy, which may be ap plied
sep a rately or in com bi na tion with top i cal therapy or
systemic retinoids.
Pa tients with mod er ate-to-se vere dis ease and
with or with out con com i tant psoriatic joint dis ease,
or those in whom phototherapy/PUVA ther apy is
pre cluded, are can di dates for sys temic ther apy with 
retinoids, methotrexate, or cyclosporine. Pa tients
un re spon sive to tra di tional top i cal ther apy and
phototherapy, those with good qual ity of life, and
those with lo cal ized dis ease pose a chal lenge to cli -
ni cians (3,4,6). Ro ta tional ther apy is lim ited by the
du ra tion of safe treat ment with conventional ther a -
pies.
Con ven tional pso ri a sis ther a pies (top i cal treat -
ments, phototherapy, and sys temic agents such as
methotrexate, cyclosporine, and acitretin) leave
many needs un met. Com mon pso ri a sis treat ment
de pends on pa tient’s age, type of pso ri a sis, con -
com i tant dis eases, and triggering factors.
Lo cal Ther apy for Pso ri a sis
Lo cal ther apy is very use ful and in cludes
keratolitics, tars oint ment, anthralin (dithranol), top i -
cal corticosteroids (class II-IV), analognes of D3 vi -
ta min (calcipotriol and tacalcitol), top i cal retinoids
(tazarotene gel 0.1%), phototherapy (UVB; nar -
row/band; or broad/band), naphthalanotherapy, he -
lio marinotherapy, spa ther apy, PUVA-bath, and
PUVA-cream. If cur rent top i cal treat ments are in ef -
fec tive, the com bi na tion with sys temic ther apy is
nec es sary.
Sys temic Ther apy for Pso ri a sis
Sys temic pso ri a sis ther apy en sured long-term
ther apy safety and in cludes photochemotherapy
(PUVA-oral); retinoids (acitretin); retinoids + PUVA
(RE-PUVA), methotrexate, cyclosporine, mycophe -
no late mofetil, and fumar acid es ter (leflunomide).
How ever, thick psoriatic plaques are still par tic u larly 
prob lem atic to treat. Sys temic agents are ex pected
to pro vide im proved long-term ther apy, ef fi cacy,
and pro longed re mis sion. Be cause pso ri a sis is a
chronic immunoinflammatory skin dis or der, op tions
for clin i cal ther apy are lim ited when con ven tional
ther a pies cease to be safe due to long du ra tion.
Since treat ment dis con tinu a tion re sults in even tual
re lapse, the need for long-term efficacy and safety
of the therapy is evident.
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Psychosocial ther apy (re lax ing group ther apy or
self-train ing) is nec es sary to pro long re mis sion of
pso ri a sis (4).
IMMUNOSUPPRESSIVE THER APY FOR
PSO RI A SIS
Ac cord ing to pathobiological find ings in pso ri a -
sis, the ther a peu tic use of immunosuppressant
agents, such as methotrexate, cyclosporine A, my -
co phe no late mofetil, fumar acid es ter, tacrolimus,
and pimecrolimus, in pso ri a sis has been ef fec tive
de spite the side effects.
Methotrexate
Methotrexate is not a new immunosuppressive
agent. It has been used for de cades in the treat -
ment of re sis tant chronic plaque pso ri a sis, erup tive
pso ri a sis, erythroderma, and es pe cially psoriatic
ar thri tis. Ap plied in to tal weekly doses of 7.5-20 mg
ei ther orally, in tra ve nously, or intra mus cu larly, me -
tho trexate is an ef fec tive immunosuppressant with -
out immunoproliferative ac tion (7). Be fore and ev -
ery 4-8 weeks dur ing the ther apy with methotre -
xate, liver and re nal func tion must be checked.
Mycophenolate Mofetil
Mycophenolate mofetil has been used as an ef -
fec tive immunosuppressive in the treat ment of pso -
ri a sis for 25 years. To day, this drug is ex pe ri enc ing
a sort of re nais sance as an agent for the treat ment
of au to im mune dis eases. Al though there are no
large ran dom ized, pla cebo con trolled stud ies of
mycophenolate mofetil among pa tients with pso ri a -
sis, smaller stud ies have found good ef fect in 11 pa -
tients with daily doses of 2 g mycophenolate mofetil
dur ing 3 weeks, with the re duc tion of Pso ri a sis Area 
and Se ver ity In dex (PASI) score by 40-70% (8). The 
lower dose is not rec om mended.
Leflunomide
Fumar acid es ter, or leflunomide, is use ful
through many years. Leflunomide, a new immuno -
sup pressive agent, has shown good ef fect in the
treat ment psoriatic ar thritic and psoriatic pa tients
(7). The phar ma co log i cal ac tion of newly de vel oped 
immunosuppressive agents is based on ac tion on
calmodulin-de pend ent calcineurin serin phos pha -
tase, reg u la tion of tran scrip tion fac tors genes (es -
pe cially for IL-2, IL-4, GM-CSF, and IL-3), pro duc -
tion of cytokines, and psoriatic in flam ma tion cas -
cade. Cyclosporin A and FK 506 have sup pres sive
ac tion on IL-1 and IL-8 ex pres sion in psoriatic epi -
der mis and on ex pres sion of IL-8 re cep tor on
keratinocytes (7).
Cyclosporine A
Cyclosporine A is ef fec tive immunosuppressive
agent for twenty years in trans plan ta tion med i cine
and es pe cially in atopic der ma ti tis ther apy. In pa -
tients with se vere and re sis tant pso ri a sis cyclospo -
rine A is use ful in spite of nephrotoxicity and hepato -
toxicity. Cyclosporine A in the treat ment of pso ri a sis
in dose of 3-4 mg/kg/day for 8 weeks, or 5
mg/kg/day af ter 4-8 weeks, as well as in dose 1-14
mg/kg/day/ for a week is ef fec tive, al though it is also 
as so ci ated with well-known tox ic i ties, in clud ing
dose-de pend ent re nal im pair ment and hy per ten -
sion (7). The dose can be re duced ac cord ing to the
ef fect af ter 4-week in ter val from 0.5-1 mg/kg/day to
the main te nance dose. How ever, re lapse of pso ri a -
sis is pos si ble af ter ces sa tion of the cyclosporine A
ther apy. In pa tients with hy per ten sion, cyclosporine
A ther apy can be con tin ued with si mul ta neous ad -
min is tra tion of cal cium an tag o nists (nifedipine or
isradipine).
Immunosuppressive Macrolactams
Tacrolimus and ascomycin macrolactam deri -
vate pimecrolimus (ASM 981) are chemicaly very
sim i lar. Tacrolimus (FK 506) has an “allyl”-group at
po si tion 21, whereas ascomycin has an “ethyl”-
 group, which are bounded on cytoplasmatic pro -
tein12 (FKBP12), al ter na tively named macrophylin12.
Like cyclosporine A, they both in hibit phosphatase
calcineurin. Tacrolimus has in hib i tory ef fects on ex -
pres sion of IL-8 re cep tor on psoriatic keratinocytes
and in atopic skin, where it in hib its the ex pres sion of 
high af fin ity IgE re cep tors (FcεRI) on den dritic epi -
der mal cells. Sys tem i cally ad min is tered tacrolimus
has been proven ef fec tive in trans planted pa tients
with pso ri a sis (7). In the larg est con trol study
among 50 pa tients, tacrolimus was ad min is tered in
daily doses of 0.05 mg/kg/bw, and in creased af ter
3-6 weeks to 0.10 (0.15) mg/kg/bw for 6 weeks if the 
pre vi ous dose had not been ef fec tive enough (7).
How ever, in 19 out of 50 pa tients the ther apy had to
be stopped be cause of side ef fects. Af ter 9 weeks
of tacrolimus ther apy, the re duc tion of PASI score
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was ob served in 83% of pa tients and 47% of par tic i -
pants in pla cebo group (7). Ef fi cacy of lo cal use of
tacrolimus has been proven not only in pso ri a sis
ther apy, but also in the ther apy of in flam ma tory
dermatoses.
Pimecrolimus in hib its the re lease of mast cell
proinflammatory me di a tors and TNF-α with in flu -
ence on lym pho cytes. Pimecrolimus has been used 
for the treat ment of pso ri a sis since 1996, and has
proven ef fi cacy and ad van tage in com par i son with
corticosteroids. Orally ad min is tered at doses of 5
mg-20 mg, or 40 mg (20 mg twice a day, or 30
mg/twice a day), pimecrolimus is use ful in the treat -
ment of se vere psoriatic plaques, where it re duces
PASI score by 60% (40 mg) or even 75% (60 mg).
For sys temic immunosuppression, it is nec es sary
to ad min is ter high doses of pimecrolimus (7).
A new macrolide, rapamycin (sirolimus), has
been re cently in tro duced as an immunosup pres -
sant af ter trans plan ta tion. How ever, lit tle in for ma -
tion is avail able on the use of sirolimus in the treat -
ment of pso ri a sis. Sirolimus in hib its T lym pho cyte
ac ti va tion and pro lif er a tion, which oc curs in re -
sponse to an ti genic and cytokine stim u la tion.
Reitamo et al (9) found syn er gis tic ther a peu tic ef -
fect (70.5% re duc tion of PASI score) of sirolimus
with cyclosporine A in pa tients with se vere plaque
pso ri a sis. Monotherapy of sirolimus with daily dose
of 0.5 mg, 1.5 mg, or 3.0 mg/mm2 body sur face has
no sig nif i cant ad van tage (9).
THE ERA OF NEW THER A PEU TICS
Based on the im mu no log i cal ba sis of pso ri a sis,
se lec tive T-cell tar get ing in pso ri a sis gives a novel
ap proach to im prove clin i cal out comes. The ef fi -
cacy of ther a peu tic agents that tar get T-cells, such
as anti-CD4 monoclonal an ti bod ies, cyclosporin,
and interleukin-2 fu sion toxin has pro vided fur ther
ev i dence that pso ri a sis is a T-cell me di ated dis -
ease. Sup pres sive treat ment in hib its the pro duc tion 
of cytokines, re duc tion of in flam ma tion and hyper -
pro liferation of keratinocytes, apoptosis and tar get -
ing T-cells in blood and skin.
The ma jor ity of T-cells in psoriatic plaques are
CD45RO+ mem ory-effector T-cells that mi grate
into the skin (6,10,11). Novel immunotherapies for
pso ri a sis are based on tar get ing an ti gen pre sen ta -
tion and costimulation, T-cell ac ti va tion and leu ko -
cyte ad he sion, ac ti va tion of proinflammatory me di -
a tors, and ad min is tra tion of anti-inflammatory cyto -
kines.
In psoriatic plaques, there is pre dom i nance of
Th1 cytokines, namely in ter feron gamma (IFN-γ)
and IL-2. For T-cells to gain ac cess to skin, they
must bind to en do the lial cells and move out to pe -
riph eral cir cu la tion and into the dermis where they
can bind to keratinocytes. This pro cess is me di ated
by the up-reg u la tion of ad he sion mol e cules on the
sur face of en do the lial cells, in clud ing E-selectin,
intercellular ad he sion mol e cule 1 (ICAM-1), and
vas cu lar-cell ad he sion mol e cule 1 (VCAM-1). E-se -
lectin is the en do the lial ligand for cu ta ne ous lym -
pho cyte an ti gen (CLA) on mem ory T-cells. In pso ri -
a sis, there is a fo cal ex pres sion of ICAM-1 on kera -
tinocytes, al low ing T-cells to bind and sub se quently
induce the psoriatic process (12).
Tar get ing cells with in tra ve nous in fu sions anti-
CD4+ monoclonal an ti bod ies has led to sig nif i cant
im prove ments in the treat ment of pa tients with
psoriasis.
Nu mer ous dis cov er ies have sup ported the con -
cept that pso ri a sis is an im mune T-cell-me di ated
dis ease, in clud ing the ef fect of cyclosporin, the ef -
fects of var i ous immunosuppressive ther a pies on
T-cells, the ef fi cacy of a T-cell toxin, anti-CD4 and
–CD3 an ti bod ies for pso ri a sis, and the re cent de vel -
op ment on an an i mal model (6). Cur rently, there are 
over 40 bi o logic agents un der eval u a tion (and at dif -
fer ent stages of de vel op ment) tar get ing dif fer ent
mo lec u lar en ti ties. These agents are those that ef -
fect T lym pho cyte-me di ated pro cesses on those
that al ter cytokine ac tiv ity (10-12). Some tar gets of
bi o logic agents for T-cells are LFA-1/ICAM-1
(CD11a sub unit): efalizumab; LFA-3: CD2-alefa -
cept; Anti-CD2: MEDI-507: Siplizumab; Anti-CD25:
dalizumab, basiliximab; IL-2-cou pled diph the ria to -
x in DAB398 IL-2. Tar gets of anticytokine are TNF-α:
etanercept, infliximab; INF-γ (Pro tein de sign lab, in
tri als) (6). Alefacept is the first bi o logic agent
approved in 2003 for the treatment of mod er ate-
 to-se vere psoriasis.
New Ap proaches in Pso ri a sis
Treat ment
By se lec tively tar get ing a spe cific por tion of the
im mune sys tem, the new gen er a tion of bi o logic
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prod ucts can pro vide re mit ting or sup press ing ef -
fect. A greater un der stand ing of the im mu no logic
ba sis of pso ri a sis has en abled de vel op ment of new
treat ments that se lec tively tar get a spe cific po si tion
in the im mune sys tem (12,13). Sev eral ba sic strat e -
gies have emerged, each with the com mon goal of
re duc ing or elim i nat ing the patho genic ef fects of
T-cells (13). These in ves ti ga tion strat e gies have led 
to the de vel op ment of a new gen er a tion of bi o logic
prod ucts that can provide either a disease remitting
or disease suppressing effect.
STRAT E GIES FOR BI O LOGIC
TREAT MENT
Tar get ing Patho genic T-Cells
Tar get ing patho genic T-cells is based on the se -
lec tive block ing of the CD2 re cep tor on CD45RO+
T-cells. Po ten tial ther a pies can lead to se lec tive
apoptosis of patho genic T-cells while spar ing
CD45RA+ naïve T-cells. Hu man LFA-3-IgG1 fu sion
pro tein is a bi o logic agent (ge net i cally en gi neered),
which binds to CD2 on the sur face of T-cells and
thereby blocks the in ter ac tion of CD2 with nat u ral
LFA-3 and pre vents T-cell ac ti va tion (sub se quently
re duc ing patho genic CD45RO+ T-cells over ex -
press ing CD2 mol e cules) (12,14). Tar get ing T-cells
with anti-CD4 monoclonal an ti bod ies (MoA) and se -
lec tive block ade of ac ti vated T-cells in duces im -
prove ment in pso ri a sis. MoAs are pro duced by fus -
ing a nor mal, ac ti vated an ti body-pro duc ing B-cell
with a myeloma cell. The re sult of this cell fu sion is a 
hy brid cell, which has the im mor tal-growth prop er -
ties. The clones of B-cell hybridomas are a source
of large quan ti ties of MoA used for therapeutic,
diagnostic, and research purpose (12,13).
Hu man Interleukin-2 (IL-2) ef fects are based on
se lec tive block ade of ac ti vated T-cells. The se lec -
tive blocker of ac ti vated T-cells, but not keratino -
cytes, is a fu sion pro tein com posed of hu man inter -
leukin-2 and frag ments of diph the ria toxin (DAB398
IL-2, or IL-2 diph the ria toxin) (14,15). Re duc tion in
tis sue-in fil trat ing T-cells, keratinocyte pro lif er a tion,
and epi der mal thick ness cor re lates with ad min is tra -
tion of IL-2 diph the ria toxin and im prove ment of
pso ri a sis.
Interleukin 2 fu sion toxin (DAB398 IL-2, a re cep -
tor-tar geted cytotoxin), is a re com bi nant fu sion pro -
tein proved to be ef fec tive in the se lec tive de struc -
tion of cells ex press ing high-af fin ity IL-2 re cep tors.
In se vere cases of pso ri a sis, it is ad min is tered in tra -
ve nously at doses of 100 kU/kg or 200 kU/kg, 5
times daily for a week, fol lowed by a 23-day as sess -
ment pe riod. The treat ment cy cle is re peated once
for a to tal of 10 doses over the 56-day (12). Clin i cal
and histological im prove ments in duced by the IL-2
toxin show that pso ri a sis is linked to skin in fil trates.
In duc ing Im mune De vi a tion
T-cells in pso ri a sis pri mar ily re lease Th1 cyto -
kines (IL-2, INT-γ), which lead to the re lease of in -
flam ma tory cytokines, such as TNF-α and IL-1. Ad -
min is tra tion of Th2 cytokines to re duce Th1 re -
sponse is a po ten tial ther apy for pso ri a sis. Re com -
bi nant hu man IL-10 (Th2 cytokine) is ef fec tive at
sup press ing le sions (13,14).
In hib it ing T-Cell Ac ti va tion
The pri mary or costimulatory sig nals for ac ti va -
tion are blocked by re duc ing im mune re sponse in
pso ri a sis. Dis ease-sup press ing agent would likely
re quire a chronic ad min is tra tion with out in ter rup -
tion. CTL A 4-Ig is a fu sion pro tein that se lec tively
in hib its T-cell ac ti va tion by block ing CD28; CD80 is
a costimulatory sig nal re quired for T-cell ac ti va tion
(13,14).
In hib it ing Cytokines
In flam ma tory cytokines re leased by cells in
psoriatic le sions per pet u ate the in flam ma tory pro -
cess. Bind ing and elim i nat ing this cytokines could
al ter the course of pso ri a sis. Ther a pies that bind
and block the ac tiv ity of the cytokine TNF-α are re -
com bi nant TNF-re cep tor fu sion pro teins (13).
Bi o log i cal Ther apy Agents for the
Treat ment of Pso ri a sis
Bi o log i cal ther apy agent for the treat ment of
psoriasis is etanercept (fu sion pro tein com posed of
hu man TNF type II re cep tor [TNF-RII] and hu man
IgG1 Fc re gion), which spe cif i cally binds TNF-α,
blocks in ter ac tion with cell-sur face TNF re cep tors,
and in hib its TNF-α-me di ated in flam ma tion, cell in fil -
tra tion, and keratinocyte pro lif er a tion. It can be ad -
min is tered as at-home sub cu ta ne ous in jec tion
twice a week (15).
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Efalizumab (hu man ized monoclonal an ti body to
the CD11a chain of LFA-1) blocks T-cell ac ti va tion
and re ac ti va tion; bind ing and traf fic into dermis and
epi der mis. Efalizumab is cur rently as sessed by
Food and Drug Ad min is tra tion (FDA) USA for its
pos si ble ap pli ca tion in the treat ment of pso ri a sis
(16). Efalizumab (anti-CD11a, Raptiva, Genen -
tech) is a hu man ized monoclonal IgG1 an ti body that 
binds to CD11a (the α-sub unit of LFA-1) and pre -
vents LFA-1 from in ter act ing with ICAM-1. A sin gle
in fu sion of efalizumab in doses 0.03-10.0 mg/kg
dem on strated sig nif i cant clin i cal im prove ment and
led to an im prove ment in PASI scores dur ing 2-10
weeks, de creased T-cell mi gra tion into pso ri a sis
plaques, and de creased ICAM-1 ex pres sion, which
sug gested a de crease in the se cre tion of pro-in -
flam ma tory cytokine. Sub cu ta ne ous home ad min is -
tra tion of efalizumab of fers an in ter est ing new ther -
a peu tic op tion for the treat ment of pso ri a sis and a
po ten tially safer long-term ther apy (16).
Infliximab is a chi me ric monoclonal an ti body to
TNF-α com posed of murine-vari able re gions and
hu man IgG Fc re gion, which spe cif i cally binds
TNF-α, in hib its TNF-α-me di ated in flam ma tion, and
in duces apoptosis in monocytes (15,17).
A year ago, FDA ap proved the use of alefacept
(fu sion pro tein com posed of the ex ter nal do main
LFA-3 and a hu man IgG1 Fc-re gion), which elim i -
nates patho genic T-cells by bind ing to nat u ral killer
(NK) cells and blocks T ac ti va tion, for the treat ment
of pso ri a sis. It is ad min is tered as in-of fice in tra ve -
nous push or in tra mus cu lar injection once weekly
(16,17).
Etanercept and infliximab are in phase III tri als
for the treat ment of pso ri a sis.
Ac cord ing Asadullah et al (18), new immuno -
modulatory ther a pies for the treat ment of pso ri a sis
in clin i cal de vel op ment (Phases I-III) are as fol lows:
ac tion of the func tion of an ti gen-pre sent ing cells:
CTLA-4 (BMS 188667), LFA-3TIP (amivene/ale -
facept), Anti-CD80 an ti bod ies (IDEC 114), Calci -
triols (rocaltrol), Fumaric acid es ters (fumaderm);
T-cell in hib i tors: Macrolides [FK506 (tacrolimus),
SDZASM981 (pimecrolimus) and sirolimus (rapa -
mycin)], Anti-CD2 an ti bod ies [MEDI507 (siplizu -
mab)], Anti-CD3 an ti bod ies (OKT3,HuM291), Anti-
 CD4 an ti bod ies (BB14), Mycophenolate mofetil
(cellcept), IL-2-cou pled diph the ria toxin (DAB3 98IL-
 2), Anti-CD25 an ti bod ies (basiliximab, dalizu mab);
In hib i tors of ad he sion: Anti-CD11a an ti bod ies
[hu1124 (efalizumab)], Anti CD6 an ti bod ies (bor-
 t1); In hib i tors of proinflammatory cytokine/me di a tor
ac tion: Anti-IL-8 an ti bod ies (ABX-IL8), Anti- TNF-α
re cep tors [etanercept (enbrel)], LTB4-re cep tor an -
tag o nist (VLM 295), Anti-IFN-γ an ti bod ies.
Ad min is tra tion of Anti-in flam ma tory
Cytokines IL-4, IL-10, and IL-11
Lo cal immunosuppressive macrolides, such as
tacrolimus (FK 506) and ascomycin deri vate (ASM
981) pimecrolimus, have been very use ful es pe -
cially for the treat ment of fa cial skin le sions in atopic 
der ma ti tis and pso ri a sis. How ever, ac cord ing clin i -
cal tri als tacrolimus has not been an ideal ther a peu -
tic agent in case of psoriasis (7,18).
Ac cord ing to the Con sen sus State ment on new
immunomodulatory ther apy in pso ri a sis, there are
many ways to help our pa tients with pso ri a sis. We
must take into ac count that all mo dal i ties in pso ri a -
sis treat ment are good, from lo cal ther apy, sys temic 
ther apy, photother apy, heliomarinototherapy, com -
bined ther apy with lo cal agents, sequentional ther -
apy with good immunosuppressants like MTX/fu -
maric acid; cyclosporin/UV-ther apy; fumaric acid/
UV- ther apy; and MTX/UV-therapy (7,17,18).
CON CLU SION
Con ven tional pso ri a sis ther a pies leave many
needs un met. Sys temic agents need to have im -
proved long-term safety, whereas long-term ef fi -
cacy and con ve nience should be im proved in top i -
cal agents. Bi o logic ther a pies are tar geted treat -
ments that have been shown ef fi ca cious in man ag -
ing mod er ate-to-se vere plaque pso ri a sis. They are
gen er ally safe and well-tol er ated, with lit tle like li -
hood for ma jor or gan tox ic ity, bone mar row tox ic ity,
teratogenecity, or drug in ter ac tion. The new bi o -
logic agents may well trans form the way that mod -
er ate to se vere pso ri a sis is treated.
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IN TRO DUC TION
The ben e fi cial in flu ence of sun light on a broad
va ri ety of dis eases has been rec og nized since an -
cient times, and a va ri ety of ther a pies have been
de vel oped based on these ob ser va tions. Niels
Finsen used the first ar ti fi cial light source, in the
form of a car bon arc, for the treat ment of lupus
vulgaris in 1893. He won the No bel Prize in 1903 for 
this pi o neer ing ap pli ca tion of UV light in med i cal
treat ment. Phototherapy of pso ri a sis with ar ti fi cial
light sources has a his tory of al most 80 years, ever
since Goeckerman, in 1925, in tro duced a com bi na -
tion of top i cal crude coal tar and sub se quent UV ir -
ra di a tion (1). To day, phototherapy rep re sents one
of the three ther a peu tic op tions for managing
psoriasis, along with topical and systemic therapy.
UVB PHOTOTHERAPY
Phototherapy is the use of ar ti fi cial UVB de liv -
ered by flu o res cent lamps with out the ad di tion of
ex og e nous photosensitizers. The UVB ra di a tion is
ab sorbed by en dog e nous chormophores. The
best- char ac ter ized chromo phore for UVB is nu clear 
DNA. Ab sorp tion of UV by nu cleo tides leads to DNA 
photoproduct for ma tion, mainly py rim i dine dimers
(2). De spite the quan ti ta tive pre dom i nance of the
dimers, the py rim i dine pyrimidone photoproduct is
prob a bly bi o log i cally more sig nif i cant (3).
UVB ex po sure is known to cause a re duc tion of
DNA syn the sis (4,5). It can be used to sup press the
ac cel er ated DNA syn the sis in psoriatic epi der mal
cells. Be sides the ef fect on cell cy cle, UV in duces
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pros ta glan din re lease and al ters cytokine ex pres -
sion and se cre tion (6). One im por tant as pect of
phototherapy is its ef fect on the cu ta ne ous im mune
re sponse. UV-in duced sys temic im mune sup pres -
sion has also been linked to the for ma tion of py rim i -
dine dimers (7). UV light is known to have di rect
immu nosuppressive ef fects on de creas ing Langer -
hans cells as well as in di rect ef fects on spe cific
cytokines and ad he sion mol e cules. What is also
clear is that UV pho tons in duce an over all se lec tive
re duc tion in T-cells within psoriatic skin through
apoptosis (8).
The use of UVB con tin ues to be one of the most
im por tant ther a peu tic in ter ven tions for mild to mod -
er ate pso ri a sis. Since UVB is eas ier to ad min is ter
and does not in volve ad min is tra tion of oral pho to -
sen si tiz ing med i ca tion, this form of phototherapy is
of ten cho sen be fore PUVA. In ad di tion, fac tors that
sug gest use of UVB ther apy in com par i son with
PUVA ther apy are brief his tory of pso ri a sis, as it is
pos si ble that main te nance treat ment will be un nec -
es sary (acute guttate pso ri a sis); less then 30% of
the body sur face in volved by dis ease be fore treat -
ment; thin, macular psoriasis; young age; and skin
type I or II (9).
Con ven tional UVB lamps de liver ra di a tion over
en tire UVB spec trum (280-320 nm). Ad vance ment
in UVB-based phototherapy was the in tro duc tion of
flu o res cent light bulbs (TL-01) that de liver mono -
chro matic light at 311 nm UVB. The pri mary im pe -
tus for de vel op ing narrowband UVB (NB UVB) were 
the de tailed pso ri a sis ac tion spec trum stud ies. In
1976, Fisher (10) in di cated that the wave length of
313 nm was the most ef fec tive in treat ing the dis -
ease. In 1981, Parrish and Jaenicke (11) ex panded
this line of in ves ti ga tion. They de ter mined that UV
wave lengths lon ger than 313 nm were not as ef fec -
tive in re solv ing pso ri a sis, whereas wave lengths
shorter than 300 nm only pro duced UV burns with -
out clear ing pso ri a sis. Pa tients treated with the nar -
row-band UVB lamps (311 nm) showed faster clear -
ing of psoriatic le sions, fewer ep i sodes of ex ces sive 
er y thema, and a lon ger pe riod of re mis sion when
com pared with broad band sources (12-17). When
TL-01 phototherapy and oral PUVA were com -
pared, nar row-band UVB was al most as ef fec tive
as PUVA (18-20). How ever, pa tients with higher
base line PASI scores responded significantly better 
to PUVA than to narrow-band UVB (18).
The ad van tages of nar row-band UVB over oral
PUVA ther apy are as fol lows: shorter treat ment
time; no sys temic ef fects since oral drugs are not
re quired; less burn ing in ci dents; no need for post-
 treat ment eye photoprotection; al lowed use in chil -
dren and preg nant and lac tat ing women (21,22).
A re cent study has shown that TL-01 UVB is
more ef fi cient than trimethoxypsoralen (TMP) bath-
 PUVA (23).
In Eu rope, nar row-band UVB has com pletely
sup planted broad band UVB, whereas in North
Amer ica it has not been adopted as quickly, pri mar -
ily be cause the lamps had not been avail able in the
US un til 1998.
It is stan dard in nar row-band UVB ther apy to first 
ob tain a min i mal er y thema dose (MED) and to ini ti -
ate treat ment at 70% of the MED (8,21). Sub se -
quent dose in cre ments can be 10-20% over the
pre vi ous nar row-band UVB dose (21,24). An other
ap proach is to use skin type-de pend ent start ing
doses and fixed in cre ments de pend ing upon the
pa tient’s er y thema re sponse. The min i mal fre -
quency of treat ment is 3 times a week, al though 4 or 
5 treat ments each week are pref er a ble. Upon clear -
ing the treat ment is ei ther dis con tin ued or the main -
te nance ther apy is in tro duced (one or two treat -
ments weekly for one or two months). It is gen er ally
felt that main te nance ther apy keeps pa tients clear
of dis ease. On the other hand, the ef fi cacy and re -
quire ments of main te nance are con tro ver sial be -
cause of the ad di tional ra di a tion load de liv ered to
the pa tient skin (6). More multicentric tri als are nec -
es sary to quantify the long-term risks and assess
the role of maintenance therapy.
UVB can be ad min is tered in com bi na tion with a
va ri ety of top i cal and sys temic treat ments to
achieve more ef fec tive re sults more quickly.
Top i cal corticosteroids are fre quently used to -
gether with UVB phototherapy, but there is no con -
sen sus as to whether they en hance the ther a peu tic
re sponse to UVB (25). When UVB is ad min is tered
with top i cal corticosteroids, the du ra tion of re mis -
sion is shortened (26).
Top i cal sal i cylic acid, which is of ten used in the
treat ment of pso ri a sis, can de crease the ef fec tive -
ness of phototherapy by pro vid ing photoprotection
(24,27).
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The com bi na tion of calcipotriol and UVB (ei ther
broad band or nar row-band) leads to a better clear -
ing of psoriatic le sions than UVB monotherapy, es -
pe cially in the terms of ra pid ity of ac tion and UVB-
 spar ing ef fect (lower cu mu la tive dose) (28- 32). It is
im por tant to in struct pa tients to ap ply calcipotriol
after phototherapy.
De Rie et al (33) found that calcipotriol oint ment
and cream blocked UVB trans mis sion when ap plied 
im me di ately be fore UVB ra di a tion.
Sev eral stud ies have shown that the ad di tion of
tazarotene to UVB phototherapy pro motes more ef -
fec tive and faster clear ing of pso ri a sis than does
UVB monotherapy (34-36).
The Ingram method uses UVB light and top i cal
anthralin. The heal ing is more rapid and the cu mu -
la tive UVB dose lower than with monotherapy (37,
38).
The Goeckerman reg i men (UVB + tar) is not
clearly su pe rior to UVB monotherapy and has
ceased to be ac cept able in re cent years (25,39).
The treat ment of pso ri a sis with acitretin com -
bined with UVB is emerg ing as a vi a ble clin i cal
strat egy. The com bi na tion of this retinoid with UVB
en hances the ef fi cacy of phototherapy while
sharply re duc ing the cu mu la tive UV dose as well as
the to tal num ber, fre quency, and du ra tion of ther -
apy. More over, pa tients whose pso ri a sis does not
clear with monotherapy will of ten achieve sig nif i -
cant clear ing with the com bi na tion of acitretin and
phototherapy (40-44). When retinoids and UVB
phototherapy are com bined, the doses of retinoids
nec es sary for clear ing can be dra mat i cally re duced. 
Doses of 10-30 mg may be suf fi cient to com pletely
clear pa tients on a reg i men of UVB phototherapy,
but at low doses, side effects are significantly less
common.
Reg i men com bin ing methotrexate and UVB
may po ten tially re duce the to tal dose of metho -
trexate re quired to achieve con trol over the dis -
ease, which pre sum ably low ers the risk of hepato -
toxicity (45). How ever, this reg i men is rarely used,
since methotrexate en hances the prob a bil ity of
UV- in duced skin tumors (39).
The main short-term side ef fects of UVB are er y -
thema (sun burn re ac tion) and dry skin with pru ri tus. 
Slightly erythematogenic UVB doses are con sid -
ered nec es sary to clear pso ri a sis ef fec tively, but se -
vere sun burn re ac tions should be avoided. Well-
 known oc u lar side ef fects of UVB in clude con junc ti -
vi tis and keratitis, and there fore both the pa tient and 
the phototherapy tech ni cian should al ways wear
eye protective glasses.
The most im por tant po ten tial long-term tox ic i ties 
of UVB phototherapy are photoaging and an in -
creased risk of cu ta ne ous can cer. Al though UVB is
a known car cin o gen, re search does not in di cate
that broad band UVB treat ment for pso ri a sis has
been as so ci ated with an in crease in the risk of skin
can cer (44,46). The ex cep tion is high-ex po sure
broad band UVB (>300 treat ments) that may be as -
so ci ated with an in creased risk of gen i tal tu mors in
men treated with out shield ing (47). The ac tual risk
of can cer due to narrowband UVB is un known at
the mo ment and will await long-term fol low-up stud -
ies for the re sults to be seen due to the long latent
period for human UV carcinogenesis.
PUVA PHOTOCHEMOTHERAPY
Photochemotherapy (PUVA) is a ther a peu tic
method that uses psoralen and ex po sure to long-
 wave ul tra vi o let A ra di a tion (320-400 nm).
Psoralens are tricyclic furocoumarins nat u rally
oc cur ring in cer tain plants, most of them be ing also
syn thet i cally pro duced. Psoralens can be used sys -
tem i cally, top i cally, or as bath ther apy. Cur rently, the 
most com monly pre scribed psoralen is methoxsa -
len (8-MOP). The use of bergapten (5-MOP) in Eu -
rope has been in creas ing be cause 5-MOP is less
phototoxic agent. The in ci dence and se ver ity of ad -
verse events, such as nau sea, vom it ing, pru ri tus,
and er y thema, is 2-11 times more fre quent with 8-
 MOP than with 5-MOP (48). The syn thetic furocou -
marin, trimethylpsoralen (TMP), is used for bath -
water-de liv ered PUVA mainly in Scan di na via. 8-
 MOP and 5-MOP are avail able as oral prep a ra -
tions, which con tain ei ther crys tals, or micronized
crys tals, or solubilized psoralens in a gel ma trix.
The liq uid prep a ra tion in duces ear lier, higher, and
more re pro duc ible peak plasma concentrations
than the crystalline preparation (6).
PUVA mech a nism of ac tion in cludes pro duc tion
of ox y gen-de pend ent and ox y gen-in de pend ent
pho to chem i cal re ac tions. Type I re ac tions are ox y -
gen-in de pend ent and ex em pli fied by the for ma tion
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of DNA cross-links and de vel op ment of cyclobutane 
rings. A DNA cross-link is a co va lent bond that re -
mains as a de fect in the DNA. DNA-psoralen
cross- links in hibit DNA rep li ca tion and cause cell
cy cle ar rest. The type II re ac tion is de pend ent upon
the gen er a tion of re ac tive ox y gen spe cies, which
pri mar ily re sults in dam age of cell and mi to chon -
drial mem branes (49). Psoralen pho to sen si ti za tion
leads to an al ter ation of cytokine and cytokine re -
cep tor ex pres sion, as well as cytokine se cre tion
(50). In fil trat ing lym pho cytes are strongly sup pres -
sed by PUVA, with variable effects on different
T-cells subsets (51).
PUVA is very ef fec tive ther apy and is still the
most ef fec tive form of phototherapy for se vere ex -
ten sive dis ease PUVA ther apy should be given ad -
van tage over UVB ther apy in case of long his tory of
pso ri a sis; more than 30% of the body sur face in -
volved by the dis ease be fore treat ment; thick
plaques; in volve ment of the palms and soles; nail
dis ease; fail ure to re spond to UVB phototherapy;
very ac tive, ag gres sive dis ease with marked in flam -
ma tory com po nent; and skin type III or IV (9).
Oral PUVA tim ing for UVA ex po sure de pends on
the drug for mu la tion used. With 8-MOP-liq uid (0.6
mg/kg) and 5-MOP-liq uid (1.2 mg/kg), it is 1 h and 2
h be fore ex po sure, re spec tively, whereas with crys -
tal line tab lets it is 2 h for 8-MOP and 2.5 h for
5-MOP, re spec tively (6). The choice of ini tial UVA
dose is of par a mount im por tance. There are very
big inter-in di vid ual dif fer ences in the phototoxic re -
sponse. In di vid ual phototoxic re sponse is as sessed 
by de ter min ing minimal phototoxic dose (MPD).
Two ther a peu tic pro to cols of PUVA-treat ment
for pso ri a sis were de vel oped si mul ta neously. The
Eu ro pean PUVA Study (EPS) pro to col in cludes
MPD as ini tial dose, fol lowed by four ex po sures per
week (52). The weekly UVA dose in crease is 0.5 to
2.0 J/cm2, de pend ing on the pa tient’s phototoxic
and pig ment re sponse. Der ma tol o gists from the
USA mostly use the United States Co op er a tive
Clin i cal Trial (USCCT) pro to col (53). The ini tial UVA
dose is de ter mined ac cord ing to the pa tient’s skin
type. PUVA ther apy is per formed 2-3 times per
week, with a 0.5-1.5 J/cm2 in crease in the UVA ra di -
a tion dose. Ac cord ing to the pro to col for PUVA ther -
apy adopted by the Brit ish Photodermatology
Group (BPG), the ini tial dose is 50% of MPD, fol -
lowed by only two weekly ex po sures with a con sid -
er able in crease in the weekly dose and re duced risk 
of cu mu la tive phototoxicity (54). The re spec tive
suc cess rates re ported by the USCCT and EPS are
es sen tially sim i lar: 88.0% vs. 88.8% treat ment re -
sponse better than marked im prove ment. How ever, 
in the for mer trial, the me dian num ber of ex po sures
un til clear ing was higher (25 vs. 20) and there fore
the du ra tion of the clear ing phase was twice (12.7
vs. 5.3 weeks) as long as in the lat ter (53,54). When 
pa tients reach a pla teau in their re sponse, a ta per -
ing main te nance ther apy can be per formed, en -
abling them to grad u ally de crease the fre quency of
treat ments be fore dis con tinu ing phototherapy. Still,
it is well known that pa tients, al lowed to con tinue
with long-term main te nance PUVA ther apy with re -
sul tant high cu mu la tive num bers of treat ment, were
the ones who had the high est risk of squamous cell
car ci no mas (55,56).
PUVA bath ther apy has been pop u lar in Scan di -
na via for many years, and has re cently at tracted in -
ter est world wide. Pa tients spend 15 to 20 min utes
in 150 L of wa ter con tain ing 0.5-5 mg/L of 8-MOP or
0.2-0.5 mg/L TMP at 30-37°C (57). TMP is tra di tion -
ally used in Scan di na vian coun tries and the United
King dom, whereas 8-MOP is used in most other
coun tries. The tem per a ture of the wa ter should be
at least 30°C be cause it has been shown that the
pho to sen si tiz ing ca pac ity of 8-MOP de creases at
wa ter tem per a ture be low 30°C (58). UVA ra di a tion
is given im me di ately af ter the bath, as the de sired
phototoxic ef fect van ishes rap idly af ter 20-30 min -
utes (59,60). Ad van tages of PUVA-bath are the lack 
of gas tro in tes ti nal (nau sea and vom it ing) and
hepatic (in creased liver transaminases) side ef fects 
and no need for post-treat ment eye photoprotection 
be cause there is no sys temic pho to sen si ti za tion.
Dis ad van tages are in creased com plex ity and as so -
ci ated costs (in creased nurs ing time and greater
costs of top i cal prep a ra tions). Sev eral stud ies have
shown that PUVA-bath is as ef fec tive as, or even
more effective than, oral-PUVA. The total UVA dose 
was 2-6 times lower with PUVA-bath (61-65).
As with phototherapy, PUVA can be com bined
with other treat ments to im prove ef fi cacy and re -
duce pos si ble side ef fects.
The com bi na tion of PUVA with top i cal cortico -
ste roids has pro duced con tro ver sial re sults, with
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some au thors claim ing that the com bi na tion re sults
in faster clear ing with out short en ing the du ra tion of
re mis sion, whereas other au thors claim that the ad -
di tion of top i cal corticosteroids to a reg i men of
PUVA ther apy re sults in shorter remissions (66,67).
Two stud ies have shown that calcipotriol im -
proves the re sponse of pso ri a sis to PUVA (68,69).
How ever, there have been no clin i cal tri als of taza -
rotene or tacalcitol in com bi na tion with PUVA pub -
lished, and the re sponse to PUVA en hanced with
tazarotene or tacalcitol has been re ported only
anecdotally (70,71).
The com bi na tion of PUVA with oral retinoids
(acitretin only) may be ideal be cause the treat ments 
also re duce one an other’s side ef fects. The num ber 
of treat ments re quired for clear ing is dra mat i cally
re duced when an oral retinoid is added to the PUVA
reg i men. The to tal amount of UVA ex po sure re -
quired is also pro nouncedly re duced (42,44,72,73).
The doses of oral retinoids re quired are much
lower. Be cause the car ci no ge nic ity of PUVA seems
to be re lated to the to tal dose ad min is tered, reti -
noids can be viewed as a PUVA-spar ing ther apy.
Retinoids should be ap plied first for 2 weeks. This
flat tens le sions and re duces scales, facilitating
PUVA therapy.
In view of the pos si ble long-term side ef fects
(immunosuppression and skin carcinogenesis), the 
com bi na tion of PUVA and cyclosporin A, or PUVA
and methotrexate can not be rec om mended (49,74,
75).
Er y thema is the most com mon acute side ef fect
of PUVA ther apy. It is well known that er y thema
from PUVA is de layed by 48-72 hours or lon ger in
case of se vere re ac tion com pared with that from
UVB, which usu ally peaks within 24 hours. Pa tients
fre quently com plain of gen er al ized pru ri tus, which
is mostly caused by dry ness of the skin. PUVA ther -
apy can cause an other type of pru ri tus, com monly
called “PUVA itch” – a deep, burn ing sen sa tion. It is
a symp tom of phototoxicity. Oral ad min is tra tion of
psoralens can in duce sys temic side ef fects in the
ab sence of light. Ther apy with 8-MOP is not in fre -
quently dis rupted by acute gas tro in tes ti nal ad verse
re ac tions, mostly nau sea and vom it ing. Hepatic ad -
verse ef fects of psoralens are un com mon, ex cept in 
case of a pre-ex ist ing liver dys func tion (76,77).
Care ful ophthalmologic eval u a tion be fore the treat -
ment and eye pro tec tion dur ing and af ter UVA ex po -
sure are both nec es sary to avoid acute in flam ma -
tion of the con junc tiva and cor nea. Al though ex per i -
men tal data in di cated a risk of pre ma ture cat a ract
for ma tion, pro spec tive stud ies did not find an
increased frequency of cataracts in patients treated
with oral PUVA therapy (78-80).
The ma jor con cern with pro longed and re peated 
phototherapeutic reg i mens is the in duc tion of pro -
mo tion or skin can cers. High-dose ex po sure to oral
PUVA is as so ci ated with a per sis tent dose-re lated
in crease in the risk of squamous cell can cer, even
among pa tients lack ing sub stan tial ex po sure to
other car cin o gens (55,81,82). A meta-anal y sis of
the PUVA Fol low-up Study and other tri als showed
a 14-fold in ci dence of squamous cell can cer in pa -
tients who re ceived high-dose PUVA (>200 treat -
ments or >2,000 J/cm2) com pared with those ho re -
ceived low-dose PUVA (<100 treat ments or <1,000
J/cm2) (83). Since male gen i ta lia are par tic u larly
sen si tive to the de vel op ment of squamos cell can -
cer, it has been ad vo cated that male gen i tals must
be shielded dur ing all of the PUVA ex po sures (84).
Un like the case with squamous cell car ci noma, the
risk of basal cell car ci noma did not sig nif i cantly in -
crease with the de gree of long-term PUVA ex po -
sure (46,47,55).
It is not clear whether ex po sure to PUVA in -
creases the risk of ma lig nant mel a noma. Ex cept for
an ec dotal re ports, ma lig nant mel a noma has not
been ob served in PUVA-treated pa tients un til re -
cently, and no in crease in mel a noma in ci dence has
been found in a large num ber of stud ies per formed
so far. How ever, in 1997 Stern et al (85) re ported an
in creased risk of ma lig nant mel a noma de vel op ing
15 years af ter first treat ments and most no ta ble
among pa tients who had re ceived 250 or more
treat ments. In their PUVA Fol low-Up Study in 2001,
Stern et al (55) de tected seven ad di tional in va sive
mel a no mas and the risk seemed to be in creas ing
with time. Al though their find ings have not been
con firmed by other multicentric tri als, they are
alarm ing since the as so ci a tion be tween ex po sure
to ul tra vi o let light and de vel op ment of mel a noma
has been well es tab lished in both hu mans and ex -
per i men tal an i mals (25).
While an in creased fre quency of skin can cer
was ob served in pa tients treated with oral PUVA
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ther apy, it was not ob served in pa tients treated with
PUVA bath ther apy. Trioxsalen bath PUVA did not
in crease the risk of squamous cell skin car ci noma
and cu ta ne ous ma lig nant mel a noma in a joint anal -
y sis of 944 Swed ish and Finn ish pa tients with pso ri -
a sis (86). In ad di tion, no as so ci a tion be tween cu ta -
ne ous can cer and 8-MOP bath PUVA was found in
158 Finn ish psoriatic pa tients (87). These data on
the long-term safety of PUVA bath are en cour ag ing
but no pre ma ture conclusions should be drawn (6).
EXCIMER LA SER TREAT MENT OF
PSO RI A SIS
A new al ter na tive for treat ing pso ri a sis by
phototherapy is the 308-nm xe non chlo ride excimer 
la ser. Bonis et al (88) com pared 311-nm nar row-
 band UVB phototherapy ith the 308-nm excimer la -
ser. The 308-nm excimer la ser re quired 6.47-fold
less ir ra di a tion and 3.6-fold fewer treat ments than
311-nm UVB phototherapy to achieve com plete
clear ance of psoriatic changes. Two stud ies have
shown that a sin gle high-dose (8-16 MED) excimer
la ser treat ment can be ef fec tive for lo cal ized
plaque-type pso ri a sis (89,90). The higher fluences,
how ever, were as so ci ated with pain ful blis ter ing
erup tions. In a multicenter study, 84% of pa tients
reached im prove ment of 75% or more af ter 10 or
fewer treat ments (91). In the most re cent study,
66% of pa tients were at least 90% clear af ter a max -
i mum of 10 treat ments, with MED starter dose (92).
Excimer la ser has sev eral ad van tages over UVB 
phototherapy. This de vice al lows spe cific tar get ing
of af fected sites with out need less ex po sure of un af -
fected skin. The excimer la ser can ef fec tively clear
psoriatic plaques in fewer treat ments with lower cu -
mu la tive dose than the stan dard phototherapy. Po -
ten tial lim i ta tions of la ser ther apy for pso ri a sis in -
clude rel a tive cost of treat ment, time con straints
when treat ing a large sur face area (the spot size is
less than 2 cm2), and the un known risk of car ci no -
ge nic ity. The 308-nm excimer la ser holds prom ise
for be com ing a use ful tool in the treat ment of sta ble, 
lo cal ized pso ri a sis (93).
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IN TRO DUC TION
Pso ri a sis is a rel a tively fre quent au to im mune in -
flam ma tory skin dis ease pres ent in 1-3% of the
pop u la tion, some times af fect ing the joints (1).
One- third of the cases are pa tients be low twenty
years of age (type I psoriasis).
It is well known that pso ri a sis is a re sult of pro -
nounced hyperproliferation of keratinocytes (2).
Re cent in ves ti ga tion has dem on strated the im por -
tance of en vi ron men tal as well as ge netic and im -
mu no log i cal fac tors in the or i gin of pso ri a sis. Pso ri -
a sis, as an au to im mune dis ease, is caused by an
au to im mune re ac tion to an epi der mal and/or der -
mal autoantigene (3). The vis i ble changes of the
skin, scal ing of the scalp, and the chronic course of
the ill ness in flu ence the psy cho log i cal state of these 
pa tients and re duce their qual ity of life (4). Helio -
marinotherapy is one of the old est treat ment mo dal -
i ties for pso ri a sis. Since an tiq uity, the ef fects of cli -
ma tic fac tors have been known to have pos i tive in -
flu ence on the health and skin dis eases. The Egyp -
tians and other peo ple of the an cient world wor -
shipped the sun as their god and were aware of
what an enor mous in flu ence this star had on life on
earth. The Greek phy si cians un der stood what
mean ing the light, wa ter, and air had for life, and
Hip poc ra tes de scribed the in flu ence of di verse cli -
ma tic fac tors and sea water on health and disease,
and considered natural factors to cause illnesses
(5).
The im por tance and ben e fits of cli ma tic fac tors
and their in flu ence on hu man health are well
known, but in case of ir ra tio nal ex po sure, they can
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pro voke dif fer ent patho log i cal states. In ad di tion to
var i ous ex ter nal fac tors, ge netic fac tors also play a
sig nif i cant role (6). Sun rays, wind, air tem per a ture,
air pres sure, and hu mid ity may have ben e fi cial ef -
fects on psoriatic skin le sions, which de pend on the
in ten sity of these fac tors and vary ac cord ing to geo -
graph ical lat i tudes, dis tance from the sea, altitude,
season, time of day, and weather.
Long time ago, der ma tol o gists in ves ti gated the
ef fect of cli ma tic fac tors on the struc ture and func -
tion of the skin, e.g. on the cap il lar ies and cir cu la -
tion in them, the amount of ox y gen they con tain, on
sweat ing and func tion ing of se ba ceous glands, on
the state of the hair, the senses, in ten sity of itch ing,
on pro duc tion of D3 vi ta min from cho les terol, which
can all pro voke the man i fes ta tion and/or de te ri o ra -
tion of numerous skin diseases in psoriasis (6).
The ap pli ca tion of sun light in the treat ment of
skin dis ease is called heliotherapy; the use of sun -
light and baths in sea wa ter is called heliomarino -
therapy; and the use of aero sol with sea wa ter is
called heliomarinothalassotherapy.
The treat ment of var i ous dis eases with sea wa ter 
– thalassotherapy – is very old. Pliny wrote that Ro -
man and Ara bian phy si cians know about hydro -
therapy. In the New Age, the first es tab lish ments for 
hydrotherapy were founded in Eng land and It aly
(Viareggio) at the be gin ning of the 19th cen tury (7).
Stüttgen et al (8) di vided cli ma tic fac tors in sev eral
groups as fol lows: photoactinic com plex, which in -
cludes di verse types of rays (vis i ble light, ul tra vi o let
rays, in fra red rays, cos mic rays); hygrothermic
com plex, which com prises air tem per a ture, air hu -
mid ity, and rain fall; phys i cal com plex, which in -
cludes air pres sure and wind; elec tric ity, which is
pres ent in the at mo sphere; and chem i cal com plex,
which in cludes the amount of ox y gen in the air, car -
bon di ox ide, dust, smoke and waste gases from
engines and industrial plants.
HELIOMARINOTHERAPY
Long ago it was noted that heliomarinotherapy,
i.e. treat ment with sea wa ter and sun, has a ben e fi -
cial ef fect on skin dis eases, es pe cially on pso ri a sis.
Ap pli ca tion of this phys i cal nat u ral fac tor is based
on the fact that sun rays com bined with sea wa ter
have a stron ger ef fect, for which ul tra vi o let rays are
mostly re spon si ble (UVA and UVB). Coblentz
(1934) grouped them on the ba sis of their bi o log i cal
ef fects into long-wave, mid dle-wave, and short-
 wave UV rays (9). To day, we are aware of the im -
por tance of UV in dex for our skin dur ing the year
and in the dif fer ent geo graphic re gions. Ul tra vi o let
rays make up ap prox i mately 1% of all rays com ing
from the sun to the earth; nev er the less, they have a
large amount of en ergy and can con sid er ably af fect
the skin. UVA rays, or long-wave rays of 320-400
nm, make up 95% of UV rays reach ing the earth’s
sur face. Their en ergy is rel a tively small, but they
pen e trate into the dermis, en abling a quick brown -
ing of the skin. The long ex po si tion to UVA has sig -
nif i cant ef fects on photoaging of the skin. In derma -
totherapy, UVA is usu ally used with photo sensi -
tizers as they act antiproliferatively on kerati nocytes 
and pro duce de ple tion of lym pho cytes from the epi -
der mis and dermis. UVB rays, mid dle-wave rays of
290-320 nm, pro duce er y thema and skin in flam ma -
tion prob a bly due to the re lease of me di a tors, such
as prostaglandins (E2 and F2), his ta mine, and
cytokines (IL-1, IL-6, and IL-8). The most ef fec tive
UV rays are those of 311 nm. Ther a peu ti cally, they
act through in hi bi tion of DNA syn the sis by in duc ing
apoptosis of lym pho cytes in the epi der mis. UVC
rays or short UV rays (wave length of 200-290 nm)
are ger mi cidal. They are not to be found on the
earth’s sur face since they are prac ti cally com pletely 
ab sorbed by the ozone in the strato sphere. Vis i ble
light can produce photo der ma toses, whereas in fra -
red rays can contribute to chronic skin damage, e.g. 
aging from UVA rays.
Based on ben e fi cial ef fects of UV rays in pso ri a -
sis, a spe cial ap pa ra tus has been de vel oped that
en ables ap pli ca tion of UVA rays in the treat ment of
psoriatic pa tients the whole year round. It should be
em pha sized that Prof A. Vukas es tab lished the
Cen ter for UVB and PUVA ther apy in Rijeka,
Croatia, the first one in this re gion of Eu rope, in
1974 (10). The Cen ter was sit u ated at the Rijeka
Hos pi tal De part ment of Der ma tol ogy and Venero -
logy, site Sušak (10). At the De part ment of Der ma -
tol ogy and Venerology, Zagreb Uni ver sity Hos pi tal
Cen ter, the same type of Cen ter for UVA and PUVA
ther apy was established in 1978 by Vera Pasini-
 Omeljèenko.
The Dead Sea (Is rael) is well known for suc -
cess ful treat ment of pso ri a sis by means of helio -
marinotherapy, with out harm ful top i cal or in ter nal
52 ACTA DERMATOVENEROLOGICA CROATICA
Stašiæ et al: Acta Dermatovenerol Croat
Heliomarinotherapy in Pso ri a sis 2004;12(1):51-54
ther apy. The Dead Sea (390 m un der sea level) has 
an enor mous salt con tent (33%). Mostly, pa tients
from north ern Eu rope are treated there. Re sults are 
ex cel lent con sid er ing that im prove ment has been
ob served in 88% of the treated (11). Ther apy usu -
ally lasts 4 weeks and dur ing this in ter val, pa tients
with skin type 4 re ceive about 3.11 J/cm2 of the skin, 
or 148 er y thema doses (MED), which is less than
what pa tients re ceive with phototherapy in con ti -
nen tal Cen ters (12). With re spect to the de vel op -
ment of skin can cer, this ther apy is less dan ger ous
than UV ther apy, es pe cially that per formed in
hospitals, where large doses are applied.
The most fre quent side ef fects ob served dur ing
heliomarinotherapy are slight so lar der ma ti tis
(8.22%), edema of the legs (2%), and her pes sim -
plex (12). Re cently, Shani et al (13) have de scribed
even better re sults, ob tain ing re mis sions in their pa -
tients up to 7 months, which are the lon gest re mis -
sions achieved in the treat ment of pso ri a sis with
any method ap plied so far. More over, the costs of
this long treat ment for psoriatic pa tients from the
Scan di na vian Pen in sula as well of those from It aly,
Aus tria, Ger many, and France is cov ered by their
health in sur ance (14). Of in ter est are also com par a -
tive stud ies of pso ri a sis treat ments at the Dead
Sea. In cases where only sea wa ter from the Dead
Sea was ap plied, im prove ment was ob served in
28% of pa tients, whereas treat ment con sist ing of
mere sun bath ing led to im prove ment in 73% of pa -
tients (15). The re search in the treat ment of pso ri a -
sis with heliomarinotherapy car ried out on the
Canarian Is lands has also shown great ef fi cacy of
this kind of ther apy, with an im prove ment in 86.3%
of pa tients (16) and a positive influence on the
patient’s quality of life (17).
Heliomarinotherapy in Veli Lošinj
In Croatia, heliomarinotherapy has been de vel -
oped in the Hos pi tal of Veli Lošinj, lo cated on the
south east part of the is land of Lošinj, Croatia. In
1880, Professor A. Haraèiæ be gun mea sur ing the
cli ma tic fac tors in Veli Lošinj, and pub lished his re -
sults in Vi enna. Soon af ter, Aus trian phy si cians
Clar, Schrotter (pulmologist), Lang (der ma tol o gist),
and oth ers vis ited the is land and re ported to the
Aus trian gov ern ment that the cli mate was ben e fi -
cial, so that in 1892 Veli Lošinj be came a “Kurort”.
Chil dren were cured there as well as adults with
lung al ler gies and skin dis eases. Živkoviæ (18) stud -
ied the ef fi cacy with heliomarinotherapy in 1,450
psoriatic pa tients and es tab lished that in 32%
psoriatic skin le sions dis ap peared com pletely,
whereas 55% of pa tients showed con sid er able im -
prove ment. Such good re sults achieved in 87% of
pa tients cer tainly pro vide proof of the ef fi cacy of this 
kind of ther apy, which is also fol lowed by long re -
mis sions last ing 5.5 months on av er age (18).
Rožmaniæ et al (19) ob tained sim i lar re sults some
years later: of 312 psoriatic pa tients, 31% had a
com plete re gres sion of the le sions, whereas 58%
had a good re gres sion af ter hav ing re ceived a to tal
of 2,581 sun hours/year. Apart from the ef fi cacy of
the sun rays and the sea wa ter, this method also has
cer tain sig nif i cance with re spect to psy cho log i cal
re lax ation due to lovely sur round ings, free of pol lu -
tion. Our sea con tains el e ments such as salt, Mg,
Ca, J, P, and many oligoelements. It con tains ten
times less salt (3.7%) than the Dead Sea, but re cent 
re search per formed in 2001 by Ger man au thors
has in di cated that balneophototherapy gives the
same re sults ir re spec tive of whether sea or fresh
wa ter are used (20). The mech a nisms through
which heliomarinotherapy acts have not been
completely elucidated, but probably include ther -
mal, chemical, and immunomodulatory effects.
To day, we must pro tect these re gions from hasty 
de vel op ment of in dus tries and con tam i na tion,
which have un for tu nately al ready reached a crit i cal
point in many seas. Our mis sion to help the 2% of
psoriatic pa tients in Croatia in volves help ing the re -
newal of the Hos pi tal for Heliomarinotherapy in Veli
Lošinj. Dur ing the win ter months, ap pli ca tion of ul -
tra vi o let rays is pos si ble with the use of var i ous de -
vices and according to diverse schemes.
CON CLU SION
Heliomarinotherapy is a use ful method for
psoriatic pa tients. We had good re sults with this
treat ment ap plied in the treat ment of pso ri a sis in
Veli Lošinj, where the clear sea and clean air are
plea sur able for the pa tients. Un der the con trol of
dermatovenerologists (to pre vent side ef fects), this
method of fers long last ing re mis sion of pso ri a sis
and spares pa tients from chronic ad min is tra tion of
top i cal corticosteroids, which is very im por tant in
pa tients with chronic relapsing diseases.
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Vjesnik, Zagreb, 4 Jan u ary 2004. “As we were
close to erad i cat ing mea sles from the list of in fec -
tious dis eases in Croatia, epidemi ologists – to put it
mildly – are not happy about the ep i dem ics that has
re cently bro ken out in our coun try,” says Dr Ira
Gjenero-Margan, Head of the In fec tious Dis eases
Ep i de mi ol ogy Di vi sion of the Cro atian In sti tute of
Pub lic Health in Zagreb. Con sid er ing the sat is fac -
tory level of pub lic health mea sures, mea sles were
ex pected to ap pear only in part of the pop u la tion
with de creased im mu nity, i.e. in those who were not
vac ci nated and were in con tact with in fected per -
sons.
Al though six to eight in fected per sons is the
usual an nual toll from mea sles in Croatia, at pres -
ent this num ber ex ceeds 20 pa tients, with all ac -
com pa ny ing symp toms (Fig. 1). This num ber gives
ba sis for call ing it an ep i demic, and there are some
in di ca tions that the num ber of peo ple in fected with
mea sles will in crease. All we know is that the mea -
sles has been brought from France (by an adult car -
rier), where, like in other west Eu ro pean coun tries,
sys tem atic vac ci na tion of the pop u la tion is not car -
ried out, whereas in Croatia vac ci na tion has been
oblig a tory since 1968. The source of dis ease was a
sin gle adult, at the Stanèiæ Cen ter for Oc cu pa tional
Ther apy and Re ha bil i ta tion of Phys i cally and Men -
tally Chal lenged Per sons in Dugo Selo, near
Zagreb. The mea sles was clin i cally pres ent in five
in mates, and 19 in mates who were in close con tact
with the in fected per sons have been un der sus pi -
cion of hav ing been in fected. Most of them have
never been vac ci nated against mea sles.
Mea sles is a pri mar ily chil dren’s acute dis ease
caused by the Morbillivirus, which be longs to a ge -
nus of vi ruses of the Paramyxoviridae subfamily. In
the ini tial phase, mea sles can be sim i lar to a cold
with some times very high fe ver, con junc ti vi tis, and
cough, but with a char ac ter is tic maculo-papulous
rash, enanthem on the buccal mu cosa, and the
so-called Koplik’s spots, for ma tions of small
punctate blue-white le sions on the bright red back -
ground, pres ent in 80% of the pa tients. The symp -
toms dis ap pear within 4-7 days af ter the ap pear -
ance of the rash and the dis ease grad u ally sub -
sides with rest, high fe ver de creases and cough dis -
ap pears. In case when the weak ened or gan ism is
at tacked by bac te ria, the most fre quent com pli ca -
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tions are otitis me dia, pneu mo nia, and, most se ri -
ously, en ceph a li tis (1). The pa tient is con ta gious
one day be fore the ap pear ance of the symp toms
and four days af ter. There is no spe cific drug for
treat ment, but the ex po si tion to in fec tion does not
ex clude vac ci na tion. Pres ently, all the per sons un -
der the age of 25 years have been vac ci nated. The
dis ease can be pre vented, or its ap pear ance can be 
sig nif i cantly re duced, if ac tive im mu ni za tion is re -
ceived within three days of the con tact with the
mea sles vi rus, and pas sive im mu ni za tion within six
days.
In the last five years, smaller or large-scale mea -
sles ep i dem ics have been de scribed among chil -
dren <1 year of age with no his tory of vac ci na tion
and once vac ci nated 15-year-old chil dren in Po land 
(2,255 cases of mea sles were re ported in chil dren
in 1997-1998) (2). In Ja pan, 69 cases were re -
ported dur ing 1998 and 1999 (3), 111 cases were
re ported in Ire land in the pe riod from 1999 to 2000
(4), and 55,000 mea sles cases were re ported in Ko -
rea in the 2000-2001 period (5).
Ac cord ing to the data of the World Health Or ga -
ni za tion (WHO), al most 40 mil lion peo ple were re -
ported to have con tracted mea sles world wide dur -
ing 2000, with a to tal of 770,000 mea sles-as so ci -
ated deaths, and 28 mil lion cases re ported to have
had sec ond ary com pli ca tions af ter be ing in fected
with the Morbillivirus (6). It has been es ti mated that
the num ber of fa tal i ties among chil dren of the un -
der de vel oped coun tries of Af rica and South East
Asia amounted to 1.7 mil lion in 2000, with 46% of
measles-related deaths (7).
Ep i de mi o log i cal stud ies have shown that a vac -
ci na tion level ex ceed ing 90%, with bi va lent vac cine
and by in ten sive vac ci na tion mea sures, can ef fec -
tively erad i cate mea sles. Dur ing re cent mea sles
ep i dem ics in Croatia, the Ep i de mi ol ogy Di vi sion of
the Cro atian In sti tute of Pub lic Health in Zagreb has 
in formed all health in sti tu tions on anti-mea sles pro -
ce dures and pro to cols, such as re port ing sus pi -
cious dis ease signs, oblig a tory iso la tion of pa tients,
and serological test ing for prov ing the dis ease
(RT-PCR test). All the health in sti tu tions in Croatia
were or dered to re view the mea sles vac ci na tion
sta tus in per sons <35 years of age. Per sons pre vi -
ously not vaccinated should be vaccinated against
measles with a mono-component vaccine.
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Fig ure 1. Char ac ter is tic maculo-papulous rash in a mea -
sles pa tient.
UPCOMING MEDICAL MEETINGS
Continuing Medical Education Course
UP DATE ON PSO RI A SIS
Zagreb, Croatia
Oc to ber 15-16, 2004
The Con tin u ing Med i cal Ed u ca tion Course is or ga nized by the Chair of Dermatovenerology, Zagreb Uni -
ver sity School of Med i cine, un der the aus pices of Acad emy of Med i cal Sci ences of Croatia.
Known ex perts in the field of pso ri a sis will also par tic i pate in the Course.
Con tact:
Prof. Jasna Lipozenèiæ
De part ment of Der ma tol ogy and Venerology
Zagreb Uni ver sity Hospital Cen ter
Šalata 4, 10000 Zagreb, Croatia
Tel./Fax: +385-1-4920-014
jasna.lipozencic@zg.tel.hr
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Re port From the An nual Meet ing of the Aus trian
Dermatovenerological So ci ety
Graz, Aus tria, No vem ber 21-23, 2003
This year’s Meet ing of the “Österreichische
Gesellschaft für Dermatologie und Venerologie
(ÖGDV), or ga nized by Pro fes sor Werner Aberer,
cur rently Pres i dent of the So ci ety, was as suc cess -
ful as al ways. The In ter na tional Meet ing held in
Graz, Aus tria, No vem ber 21-23, 2003, was at -
tended by ap prox i mately 400 par tic i pants not only
from Aus tria, but also from Swit zer land, Ger many,
Slovenia, Hun gary, It aly, United King dom, and
Croatia. About 50 firms were pres ent at the phar -
ma ceu ti cal ex hi bi tion that was part of the whole
event.
On Sat ur day, No vem ber 22, 2003, Al bert Finlay
(Car diff), as a guest of the ÖGDV, gave a lec ture on
“Qual ity of life in dex in der ma tol ogy” within the
“Ferdinand von Hebra Me mo rial Lec ture.” Dr Finlay, 
as an ex pert in this field, has a large ex pe ri ence in
con firm ing the der ma tol ogy qual ity of life in dex
(DQLI) for many dermatological dis eases like pso ri -
a sis, atopic der ma ti tis, and many oth ers. The DQLI
is very im por tant mea sure of pso ri a sis pa tient’s
qual ity of life and even better than PASI score or
SCORAD in dex for as sess ment of qual ity of life in
atopic dermatitis patients.
Very in ter est ing was a lec ture given by Prof.
Diepgen, who pre sented fun da men tals of mod ern
med i cine and talked about the Cochrane li brary and 
ev i dence-based med i cine. Prof. Sterry held a very
in struc tive lec ture about ISO certification.
There were 11 in ter est ing clin i cal cases pre -
sented, fol lowed by rich dis cus sions. A poster pre -
sen ta tion of fered about 27 post ers, and ev ery day,
there were lec tures given by in vited speak ers from
abroad.
On Sunday, No vem ber 23, 2003, pres i dent of
the Collegium Internationale Allergologicum, and
elected pres i dent of the Eu ro pean Acad emy for
Der ma tol ogy and Venerology, Pro fes sor Johannes
Ring de liv ered a very com pe tent “Jo seph von
Plenck me mo rial lec ture” en ti tled “Skin, Al lergy and
En vi ron men tal prob lems”, fo cused on mod ern der -
ma tol ogy in 21st cen tury, es pe cially on allergies and 
atopy.
Con grat u la tions to Prof. Aberer for ex cel lent or -
ga ni za tion.
Prof. Jasna Lipozenèiæ, MD, PhD
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Marko Polo´s Di ary
Stella Fatoviæ-Ferenèiæ, ESHDV rep re sen ta tive of Croatia
12th EADV Con gress, Bar ce lona,
Spain, Oc to ber 15-18, 2003
The city of Gaudi, tow ered by the im pres sive
spikes of the Sa grada Fa milia, hosted a huge crow
of 8,000 par tic i pants of the Eu ro pean Acad emy of
Dermatovenerology (EADV) Con gress dur ing sev -
eral rainy days in Oc to ber last year. The warmth of
our hosts and their hos pi tal ity made us noth ing but
en chanted in this puls ing cen ter of com mer cial and
ad min is tra tive power, the city where Joan Miró, Sal -
va dor Dalí, and Pablo Pi casso moved the bor ders
of art and sen si tiv ity. The His tory day started as
usual with a guided tour to the Hos pi tal de la Santa
Creu i Saint Pau. The long pe riod de voted to the
con struc tion of the hos pi tal is a dem on stra tion of its
com plex ity, size, and cre ative ar chi tec ture. We
were fas ci nated with the sen si tiv ity of the ar chi tects
who cre ated a place were pa tients would feel sur -
rounded with dig nity, with col or ful stained-glass
win dows, and beau ti ful gar dens they could wan der
through all day long. I could n’t re sist but think how
col ors and gar dens are usu ally ne glected de tails in
hos pi tal ar chi tec ture of our time. Af ter the tour, we
were brought to a room where the Alibert Lecture
was given, entitled The honor of living, by Professor 
Mascaró.
The His tory sym po sium Mas ters in Dermato -
vene rology, which took place the next af ter noon,
ac quainted us with the lives and leg acy of Jo seph
Plenck (1735-1807), Ferdinand-Jean Darier (1856- 
1936), José E. Olavide (1836-1901), Jaume Peyri
(1877-1950), Luca Stulli (1772-1828), Franziszek
Krysztalowicz (1869-1931), and Al fred Blascho
(1858-1922).
The fol low ing day, an ed i to rial board meet ing of
the Jour nal of the Eu ro pean Acad emy of Dermato -
venerology took place at the Ho tel Catalonia Plaza.
In tro duc tion of the elec tronic sub mis sion of manu -
scripts and web-based peer re view sys tem was dis -
cussed, and we were all pleased to hear that the Im -
pact Fac tor of the Jour nal has risen in 2003. The
mar ket ing ob jec tives for the forth com ing year would 
have to re flect the growth of the jour nal in both its
print and electronic forms.
Sat ur day, an other rainy and gray day, en -
chanted us by a visit to the Cusi Mu seum of Phar -
macy at El Masnou, in the re gion known as El
Maresme, north of Bar ce lona. The Cusi mu seum of
Phar macy houses ob jects and an tiques of phar -
macy ac quired, pre served, stud ied, and ex hib ited
by a phar ma cist Joaquim Cusi i Furtunet. Al though
ex hib it ing mostly the prep a ra tion of oph thal mic
prod ucts, the Mu seum also con tains col lec tions of
di verse phar ma ceu ti cal and med i cal ac ces so ries,
ce ram ics and glass, mor tars, and col lec tion of il lus -
tra tions and paint ings of med i cal in stru ments, as
well as an out stand ing library of 6,000 volumes of
old books and writings.
Visit of Coleman Ja cob son to
Zagreb’s Der ma tol ogy Clinic,
No vem ber 7, 2003
Dr. Ja cob son has held all ac a demic ranks from
Clin i cal In struc tor to Clin i cal Pro fes sor at the South -
west ern Med i cal School of the Uni ver sity of Texas
and has been Chief of the Di vi sion of Der ma tol ogy
at Baylor Uni ver sity Med i cal Cen ter and the Der ma -
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tol ogy Ser vice at the Chil dren’s Med i cal Cen ter,
Dal las, Texas. He is for mer Pres i dent and Chair -
man of the Board of Trust ees of the Der ma tol ogy
Foun da tion, and he also served as Ex ec u tive Vice
Pres i dent of the In ter na tional So ci ety of Der ma tol -
ogy (ISD). As a true Texan, he charmed ev ery one
with his open ness in com mu ni ca tion and a typ i cal
sense of hu mor. I took him to the Der ma tol ogy
Clinic at Zagreb School of Med i cine, where Pro fes -
sor Ivan Dobriæ, Head of the Clinic, and his staff or -
ga nized a warm wel come. While lis ten ing to case
re ports and dis cus sions and dur ing a visit tour
around the pre mises, I felt proud and as sured that
the attempts our dermatologists make in the field
are ambitious and promising.
Hydrotherapy: Ap proaches and
Par a doxes – Sym po sium, Cro atian
Acad emy of Sci ences and Arts,
No vem ber 25, 2003
The year of 2003 was pro claimed the Year of
Fresh Wa ter and the sym po sium en ti tled Hydro -
therapy: Ap proaches and Par a doxes held in the
build ing of the Cro atian Acad emy of Sci ences and
Arts was our con tri bu tion to this oc ca sion. Wa ter
has a deep sym bol i cal mean ing in all cul tures and
re li gions and since an cient times, it has been linked
to the cre ation, birth and life, de struc tion and death.
The use of wa ter in heal ing has been known since
the dawn of civ i li za tion. Hydrotherapy gained in
pop u lar ity dur ing the 18th and 19th cen tury and still
pre serves its place within med i cine. The ex perts
from dif fer ent dis ci plines (med i cine, his tory, re li -
gion, ge ol ogy, and bi ol ogy) who par tic i pated at the
sym po sium brought dif fer ent view points into the
dis cus sion. The event was per vaded by the cross-
 cul tural, sym bolic, and re li gious mean ing of wa ter,
its sig nif i cance in early med i cal con cep tions, ther a -
peu tic ap pli ca tions, and place in pub lic health ac tiv i -
ties through out his tory. Two pre sen ta tions were
given by der ma tol o gists: Andrija Stanimiroviæ
spoke about climatotherapy at the Dead Sea in the
treat ment of pso ri a sis, whereas Jasna Lipozenèiæ
and Marija Kanižaj-Vlahovski de liv ered a talk on the 
use of water in maintaining the physiological status
of skin and in the treatment of dermatoses.
Good for the itch, Marko Polo was taught when
he reached a hot spring in south ern Iran more then
700 years ago. He took a bath in a big hot spring at
Cheshmeh Genu, where lo cals still bathe in min -
eral-rich wa ter. Peo ple travel, times change, cul -
tures mix, yet the hu man link to wa ter in all seg -
ments of life re mains equally strong.
*********************************
The world is wait ing, sretan vam put ! 
stella@hazu.hr
*********************************
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ER RA TUM:
In my pa per on Jo seph Planck (1735-1807), Acta Dermatovenerologica Croatica 2003;11:207-11, the
He brew cap tion was spelled wrongly. It should read:
I ask the reader’s apol ogy.
Karl Holubar, Vienna
Book Re view
Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldshmith LA, Katz SI, ed i tors.
Fitzpatrick’s Der ma tol ogy in Gen eral Med i cine, 6th edi tion. New York:
McGraw-Hill, Med i cal Pub lish ing Di vi sion; 2003. Set: ISBN 0-07-138076-0.
For mat: hard cover, two vol umes, 2,850 pages,
280 chap ters, 37 sec tions. Vol ume 1: ISBN 0-07-
 138066-3, Vol ume 2: ISBN 0-07-138067-1.
This is a new, sixth edi tion of Fitzpatrick’s Der -
ma tol ogy in Gen eral Med i cine (DIGM), re mind ing
us of the first edi tion of this clas sic and def i nitely
best known text book in der ma tol ogy, which was
pub lished by the same pub lisher in 1971. The pre -
ced ing, fifth, edi tion was is sued in 1999. Ev ery new
edi tion of Fitzpatrick’s DIGM has shed new light and 
brought novel con cepts to the dermatologic pro fes -
sion and sci ence. It is a clas sic med i cal book in the
field of der ma tol ogy use ful to phy si cians, sci en tists,
and stu dents all over the world. How ever, it is pri -
mar ily in tended for der ma tol o gists and residents in
dermatology.
The first, in tro duc tory part and chap ter 1, re fer -
ring to the his tory of der ma tol ogy and pro vid ing a
con cise his tor i cal sur vey of the pro fes sion, were
writ ten by Prof Karl Holubar from Vi enna and As sist. 
Prof. Stella Fatoviæ-Ferenèiæ from Zagreb. Other
seg ments of the first part are ded i cated to derma -
tologic prope de utics. The ma te rial is pre sented in a
mod ern and con ve nient style, ad di tion ally elu ci -
dated by all kinds of il lus tra tions, thus bring ing it
closer pri mar ily to the young gen er a tions of der ma -
tol o gists. The more so, all chap ters of the book are
ac com pa nied by a large body of references, most of 
them very recent.
The sec ond part of the book is ded i cated to the
bi ol ogy and de vel op ment of the skin. There are 34
chap ters, which deal with the ge net ics, struc ture,
and de vel op ment of skin; epi der mal ki net ics; dif fer -
en ti a tion and keratinization; skin as a pro tec tive or -
gan; and bi ol ogy of melanocytes, hair fol li cles,
nails, extracellular ma trix, blood ves sels, and basal
mem brane. A spe cial chap ter is ded i cated to the
en do the lium, neurobiology, and wound heal ing.
The sixth sec tion of the sec ond part of the book
deals with im mu nity and skin as an im mune bar rier,
whereas the ef fect of HLA sys tem on dis ease sus -
cep ti bil ity and role of cytokines and chemokines are 
dealt with in spe cial chap ters. The same holds for
lym pho cytes, reg u la tion of the pro duc tion and ac ti -
va tion of neu tro phils, eosinophils, and basophils,
mo lec u lar and cel lu lar bi ol ogy of mastocytes, com -
ple ment sys tem, and eicosanoids. Three chap ters
re fer to carcinogenesis, i.e. chem i cal and vi ral
carcinogenesis, photocarcinogenesis, and onco -
genes. The last chap ter in the sec ond part of the
book is the chap ter on photoimmunology. The en -
tire sec ond part of the book is richly il lus trated, with
ex cel lent sche matic pre sen ta tions and mi cro pho to -
graphs, ren der ing this highly complex material very
reader-friendly, which especially holds for the
chapter on melanocyte biology.
The third part of Fitzpatrick’s DIGM is ded i cated
to the dis eases man i fest ing on the skin and mu -
cosa. This huge ma te rial is di vided into 12 sec tions
and as many as 101 chap ters. The sec tion on
non-cu ta ne ous man i fes ta tions of skin dis eases
elab o rates psy cho log i cal as pects of skin dis eases
and pathophysiology and clin i cal as pects of pru ri -
tus, with spe cial ref er ence to the di ag no sis and
man age ment of these dis or ders. Sec tion 8 deals
with the epi der mis and dis eases as so ci ated with in -
flam ma tory le sions of the epi der mis, and ki net ics
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and dif fer en ti a tion im pair ments. De scrip tion is pro -
vided of pso ri a sis and psoriatic ar thri tis, with the lat -
est con cepts on their pathogenesis and treat ment.
Clin i cal pic ture, nov el ties in the pathogenesis and
man age ment of other dis eases as so ci ated with
keratinization dis or der, e.g., parapsoriasis, pityria -
sis rosea, and pityriasis rubra pilaris, are thor oughly 
and con ve niently pre sented. Spe cial at ten tion is
paid to the as so ci a tion of parapsoriasis with skin
lym phoma. A rel a tively new term of clonal der ma ti -
tis is men tioned. Also, it is em pha sized that the
so-called parapsoriasis group of dis eases is char -
ac ter ized by the po ten tial trans for ma tion to cu ta ne -
ous lymphoproliferative dis eases, which is ac com -
pa nied by clone pro gres sion of cer tain T-cells pro -
duced by mutation. Clonal dermatitis has been
postulated to represent a stage in the progression
of precursor diseases to skin lymphomas.
Along with a de tailed de scrip tion of par tic u lar
en ti ties, the chap ter ded i cated to ichthyosiform der -
ma toses pro vides a sur vey of clin i cal fea tures and
as so ci ated symp toms, eti ol o gies (gene, pro tein,
and func tion) and histologic char ac ter is tics of this
group of dis eases. The chap ter is en riched by ex -
cel lent clinical photos.
Sec tion 9 de scribes a group of bullous derma -
toses as epi der mal co he sion dis or ders, pre sent ing
a num ber of new con cepts on er y thema multiforme, 
pemphigus, bullous pemphigoid, and cicatricial
pemphigoid. Spe cial chap ters deal with paraneo -
plastic pemphigus, lin ear IgA dermatosis and
chronic bullous dis eases of child hood, her pes ges -
tationis, im pe tigo herpetiformis, and Hailey-Hailey
dis ease. The chap ter on he red i tary bullous epider -
mo lyses is pro vided by ex cel lent clin i cal and micro -
mor phological pic tures and sche matic pre sen ta -
tions that make this com plex dermatologic is sue
eas ier and con ve nient to com pre hend. Con sid er -
able at ten tion is also ded i cated to the dis eases as -
so ci ated with se ba ceous gland dis or ders, es pe -
cially acne. The chap ter on acne pro vides a thor -
ough sur vey of ther a peu tic options for this common
cutaneous disease of the young.
Dermatologic on col ogy be gins with sec tion 11
on ep i the lial pre can cer ous le sions. Con sis tently
with the ma jor ity of cur rent dermatologic text books,
Bowen’s dis ease, erythroplasia of Queyrat, and
erythroplasia are de scribed among pre can cer ous
le sions. Spe cial chap ters are ded i cated to plano -
cellular and basal cell car ci noma. In the chap ter on
planocellular car ci noma, verrucous car ci no mas are 
de scribed as a group of planocellular, exophytic,
slowly grow ing car ci no mas at the sites ex posed to
chronic ir ri ta tion. Ac cord ing to the site of de vel op -
ment, there are four types of this tu mor: oral florid
papillomatosis, anogenital type de scribed by
Buschke and Loewenstein, epithelioma cunicu -
latum, and type IV that may de velop in other re gions 
of the trunk and ex trem i ties. De tec tion of type 6, 11,
16, and 18 HPV in the epithelioma cuniculatum
points to the possible evolution of this tumor from
vulgar verruca.
Sec tion 12 re fers to melanocyte dis or ders. Al bi -
nism, vitiligo, and many other pig men ta tion dis or -
ders as so ci ated with var i ous dis eases and syn -
dromes as well as phys i cal im pacts are thor oughly
de scribed. Spe cial chap ter deals with be nign mela -
nocyte hy per plas ias and neoplasms, atyp i cal nevi,
and mel a noma. The chap ter on mel a noma brings a
sur vey of ther a peu tic op tions, some of them per -
haps find ing wide ap pli ca tion in the near fu ture,
e.g., vaccination and monoclonal antibodies.
Spe cial sec tion pro vides a de tailed sur vey of in -
flam ma tory and non-neo plas tic dis eases of the
dermis. Spe cial chap ter is ded i cated to vas cu lar
anom a lies and tu mors of the skin and sub cu ta ne -
ous tis sue, il lus trated with im pres sive clin i cal pic -
tures. The chap ter on Kaposi’s sar coma brings a lot
of new data on the disease pathogenesis.
The sec tion on cu ta ne ous changes in dis or ders
of al tered re ac tiv ity de scribes var i ous forms of im -
mu no de fi ciency. Spe cial chap ters are ded i cated to
ur ti caria and angioedema, con tact al ler gic der ma ti -
tis, and graft-ver sus-host dis ease (GvHD). Atopic
der ma ti tis and seborrheic der ma ti tis are described
in detail.
Sec tion 17, which deals with skin changes due
to me chan i cal and phys i cal fac tors, de scribes skin
le sions caused by ex po sure to heat and cold. Spe -
cial chap ters are ded i cated to radiobiology and ra -
dio ther apy of skin dis eases. This text is very con -
cise, ev i dently writ ten by ex perts, and cer tainly use -
ful to ev ery der ma tol o gist, par tic u larly those en -
gaged in dermatologic ra dio ther apy. Men tion
should be made of the chap ters on skin prob lems in
pa tients hav ing un der gone ex trem ity am pu ta tion or
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with stoma. A chap ter on sports der ma tol ogy is for
the first time found in a dermatologic textbook.
The sec tion on skin dis eases caused by drugs
and chem i cal agents gives an ac count of oc cu pa -
tional skin dis eases, mucocutaneous com pli ca tions 
of antineoplastic ther apy, and skin changes as so ci -
ated with cytokine (es pe cially in ter feron) and
growth fac tor ther apy, and drug abuse.
The fourth part of Fitzpatrick’s DIGM is en ti tled
Der ma tol ogy and Med i cine, and con tains eight sec -
tions and 50 chap ters. Three chap ters in sec tion 20
are ded i cated to var i ous skin dis eases re lated to
spe cific life pe ri ods: preg nancy, in fancy, child hood,
and ad o les cence. Fur ther chap ters de scribe skin
changes in nu tri tional, met a bolic, and he red i tary
dis eases. Skin al ter ations in the dis or ders as so ci -
ated with amino acid met a bolic er rors, skin amylo -
idoses, porphyrias, Fabry’s dis ease, and skin
changes in fat me tab o lism dis or ders are de scribed
in de tail. De scrip tions of the dis eases and skin le -
sions are ac com pa nied by nu mer ous ta bles, sche -
matic pre sen ta tions, and pho to graphs. Skin chang -
es in he red i tary dis eases of the con nec tive tis sue
are briefly and clearly pre sented in the re spec tive
chap ters. A de tailed ac count of xeroderma pigmen -
to sum is given in the chapter on heritable diseases
with increased sensitivity to cellular injury.
Skin changes in hematologic dis eases are con -
cisely and sys tem at i cally pre sented in a spe cial
chap ter. The con ve nient and pre cise de scrip tion is
sub stan ti ated by a ta ble of skin symp toms in par tic -
u lar hematologic dis eases, given on five pages. Pri -
mary and sec ond ary skin lym pho mas are de scribed 
in spe cial chap ters, with spe cial ref er ence to the di -
ag no sis and ther a peu tic op tions. The clas si fi ca tion
of lym pho mas ac cord ing to the World Health Or ga -
ni za tion is pro vided in ad di tion to the EORTC clas -
si fi ca tion of pri mary skin lym pho mas. The de scrip -
tion of Langerhans histiocytoses (pre vi ously called
histiocytosis X) is ac com pa nied by very impressive
photographs of these rare and severe diseases.
Skin changes as so ci ated with dis eases of the
gas tro in tes ti nal tract and hepatobiliary tract, re nal
dis eases, pe riph eral vas cu lar dis eases, di a be tes
mellitus and other en do crine dis eases are pre -
sented in the respective chapters.
Sec tion 26 deals with the group of rheu matic,
multisystem dis eases. A very de tailed ac count is
given of lupus erythematosus, dermatomyositis,
scleroderma, sys temic necrotizing arteritis, cu ta ne -
ous necrotizing venulitis, and pig mented purpuric
dermatosis.
Sec tion 27 deals with cu ta ne ous man i fes ta tions
of other or gan sys tem dis eases, i.e. sarcoidoses,
ma lig nant dis eases (cu ta ne ous paraneoplastic
syn dromes), neurocutaneous dis eases, tu ber ous
sclerosis com plex, neurofibromatoses, and Behçet’s 
dis ease. The de scrip tion of skin le sions is very clear
and con cise, thus def i nitely highly use ful to many
phy si cians of var i ous spe cial ties.
The fifth part of Fitzpatrick’s DIGM de scribes
dis eases due to mi cro bial agents, in fes ta tions,
bites, and stings. This part of the book is abun dant
in var i ous use ful data from gen eral mi cro bi ol ogy. A
spe cial ac count is given of the staph y lo coc cal
scalded skin syn drome, en riched with ex cel lent
pho to graphs and microphotographs.
Sec tion 29 cov ers fun gal dis eases with cu ta ne -
ous in volve ment. Su per fi cial fun gal in fec tions, ony -
ch omycoses, tinea nigra, piedra, candidiasis, pityri -
asis versicolor, and deep fun gal in fec tions are de -
scribed, with spe cial ref er ence to sys temic myco -
ses. These are fol lowed by vi ral dis eases of the
skin, with due at ten tion paid to the clas si fi ca tion,
rep li ca tion, and cel lu lar events dur ing var i ous vi ral
in fec tions. Skin le sions in dis eases caused by hu -
man im mu no de fi ciency vi rus (HIV) are pre sented in 
spe cial chap ters. De scrip tion of skin al ter ations
caused by prions and rickettsiae points to the com -
pre hen sive ness and richness of the data offered in
the Fitzpatrick’s DIGM.
Sec tion 31 pro vides a de tailed ac count of sex u -
ally trans mit ted dis eases, de scrib ing syph i lis, en -
demic (nonvenereal) treponematoses, chancroid,
lymphogranuloma venereum, granuloma inguinale, 
and gon or rhea. Sec tion 32 is ded i cated to leishma -
niasis, cu ta ne ous toxoplasmosis, cysticercosis,
and other helminthic in fec tions. Sev eral chap ters
re fer to dermatologic is sues re lated to out door ac -
tiv i ties, such as snake bites and jel ly fish burns. The
is sues are pre sented con cisely and il lus trated with
ex cel lent pho to graphs, use ful not only to a der ma -
tol o gist but also to every other specialist.
A nov elty in a dermatologic text book is the in clu -
sion of ev i dence-based der ma tol ogy. Prac ti cal ev i -
dence-based med i cine (EBM) is pred i cated on find -
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ing and us ing the best ev i dence. Po ten tial sources
of ev i dence in clude un der stand ing the eti ol ogy and
pathophysiology of dis ease and logic, per sonal ex -
pe ri ence, col leagues or ex perts, text books, ar ti cles
published in journals, and reviews.
Spe cial sec tion deals with top i cal ther apy and its 
prin ci ples. Abun dant data are pro vided on top i cal
agents in der ma tol ogy, i.e. corticosteroids, retino -
ids, an ti bi ot ics, antimycotics, sunscreens, kerato -
lytics, immunomodulators, and other top i cal agents, 
as well as on cos me tics and skin care in derma -
tologic prac tice. In the seg ment on sys temic ther -
apy, an ac count is given of sys temic corticosteroids, 
sul fones, antimalarials, retinoids, cytostatics, anti -
his ta minics, an ti bi ot ics, an ti vi ral agents, sys temic
antimycotics, immunosuppressants, and novel bi o -
logic drugs used in the management of psoriasis.
The last chap ters of Fitzpatrick’s DIGM deal with 
phototherapy, photodynamic ther apy, use of la ser in 
der ma tol ogy, and sur gi cal tech niques used in cos -
metic der ma tol ogy, and tu mor sur gery. A chap ter on 
skin re sur fac ing by use of la ser is a novel topic in
dermatologic lit er a ture, and so are the chap ters on
the use of bot u li num toxin in cos metic med i cine,
hair trans plan ta tion and al o pe cia reduction, and on
nail surgery.
The sub ject in dex pro vided at the end of the
book is very com pre hen sive, writ ten on 139 pages.
The re view of Fitzpatrick’s DIGM, a text book
writ ten by more than 400 au thors, def i nitely de -
serves by its con tents, sys tem atic pre sen ta tion,
and rel e vance to be dis tin guished from all other
dermatologic text books. In Fitzpatrick’s DIGM, the
ba sic and clin i cal dermatologic sci ence have been
best and most con ve niently in te grated, mak ing it a
piv otal dermatologic book in the world med i cal lit er -
a ture, con vinc ingly point ing to the role of der ma tol -
ogy in the med i cine in gen eral. In deed, it is a great
plea sure and true for tune to have this valuable book 
in one’s own library.
Aida Pašiæ, MD, PhD
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AN NOUNCE MENTS
4th World Con gress of the In ter na tional Acad emy of Cos metic Der ma tol ogy, Cairo, Egypt, April 12-18, 2004.
Contact Larry Millikan, MD, Tulane Uni ver sity Med i cal School of Der ma tol ogy. TB-36, 1430 Tulane Av e nue, New Or -
leans, LA 70112. Fax +1 504 587 73382
Up date on Atopic Ec zema/Der ma ti tis Syn drome, Cavtat, Croatia, April 25-28, 2004. Con tact: Prof. Jasna
Lipozenèiæ, De part ment of Der ma tol ogy and Venerology, Zagreb Uni ver sity Hos pi tal Cen ter, Šalata 4, 10000 Zagreb;
jasna.lipozencic@zg.tel.hr; www.cybermed.hr/4dermkh
Sec ond EADV In ter na tional Spring Sym po sium, Bu da pest, Hun gary, April 29-May 1, 2004. Con tact:
info@eadvbudapest2004.com; www.eadvbudapest2004.com
66th An nual Meet ing of the So ci ety for In ves ti ga tive Der ma tol ogy, St. Louis, Mis souri, May 4-7, 2004. Con tact:
Kate Rader, Meet ings Man ager, 820 W. Su pe rior Av e nue, 7th Floor, Cleve land, OH 44113; phone: 216/579-9300; fax:
216/579-9333; e-mail: Krader@sidnet.org
31st An nual Joint Meet ing of So ci ety for Cu ta ne ous Ultrastructure Re search and Eu ro pean So ci ety for
Dermatopathology, Rome, It aly, May 6-8, 2004. Con tact: www.prex.it/congressi/scur/in dex.html
9th In ter na tional Con gress of Der ma tol ogy, Beijing, China, May 19-22, 2004. Con tact: ICD2004 Sec re tar iat, In ter -
na tional De part ment, Chi nese Med i cal As so ci a tion, 42 Dongsi Xidajie, Beijing 100710, China; ICD2004@chinamed.
com.cn; www.chinamed.com.cn/der ma tol ogy
  In ter na tional Sym po sium “Fron tiers in Al lergy and Autoimmunity”, Mainz, Ger many, May 21-22, 2004. Con -
tact: Anja.Oberlaender@uni-mainz.de
15th Ljudevit Jurak In ter na tional Sym po sium on Com par a tive Pa thol ogy; Main Topic: Head & Neck Pa thol ogy,
Zagreb, Croatia, June 4-5, 2004. Con tact: www.kbsm.hr/jurak/sym po sium.htm
7th Con gress of the Eu ro pean So ci ety of Con tact Der ma ti tis, Co pen ha gen, Den mark, June 6-8, 2004. Con tact:
Or ga niz ing Sec re tar iat PREXY S.r.l. – Vialle Monza 20125 Milano, Liss@ics.dk; congressi@prex.it,  www.iscd2004.info
23rd Con gress of the Eu ro pean Acad emy of Allergology and Clin i cal Im mu nol ogy, Am ster dam, Neth er lands,
June 12-16, 2004. Con tact: Dept. Allergology, Uni ver sity Hos pi tal Rot ter dam, dr. Molewaterplein 40, NL-3015 GD Rot ter -
dam, The Neth er lands; degroot@algo.azr.nl; www.congrex.com/eaaci2004
28th An nual Meet ing of the Is rael So ci ety of Der ma tol ogy and Venereology, Eilat, Is rael, June 16-17, 2004. Con -
tact: Prof. Sa rah Brenner, The Tel Aviv Sourasky Med i cal Cen ter, Weizman Street, Tel Aviv 64239, Is rael; tel: 972 3
6974287; fax: 972 3 6974810
65
Acta Dermatovenerol Croat 2004;12(1):65-67 ANNOUNCEMENTS
10th Con gress of the Eu ro pean Con fed er a tion of Med i cal My col ogy, June 17-20, 2004, Wroclaw, Po land. Con -
tact: Con gress Care, Muntelbolwerk 1, P.O. Box 440, 5201 AK’s-Hertogenbosch, The Neth er lands; info@congresscare.
com, www.congresscare.com
4th Eu ro pean Con gress of Aestetic Med i cine and 6th Con gress of the Swiss So ci ety of Aestetic Med i cine,
Zuerich, Swit zer land, June 25-26, 2004. Con tact: Pro Ser vices Con sult ing - Pa tri cia Lafitte, Chemin des Baules 14, CH -
1268 Begnins - Swit zer land; Phone +41 (022) 366 08 10; Fax: +41 (022) 366 08 15; patricialafitte@deckpoint.ch;
www.ssme.ch
X World Con gress of Pe di at ric Der ma tol ogy, Rome, It aly, July 7-10, 2004. Con tact: Tri umph Congressi, Via
Lucilio, 60, 00136 Rome, It aly; der mo@gruppotriumph.it
19th Con tin u ing Med i cal Ed u ca tion Course for Prac ti cal Der ma tol ogy and Venerology, Mu nich, Ger many, July
25-30, 2004. Con tact: www.fortbildungswoche.de
Amer i can Acad emy of Der ma tol ogy, Acad emy ’04, New York, USA, July 28-Au gust 1, 2004. Con tact: Amer i can
Acad emy of Der ma tol ogy, De part ment of Meet ings & Con ven tions, 930 E Wood field Road, Schaumburg, IL 60173; fax:
847 330 1090
7th Dresden Sym po sium on Autoantibodies, Dresden, Ger many, Sep tem ber 1-4, 2004. Con tact: k_conrad@
rcs.urz.tu-dresden.de
3rd Con gress of the Dermatovenerologists, Struga, Mac e do nia, Sep tem ber 15-18, 2004.; Con tact: Con gress Sec -
re tar iat, Clinic of Dermatovenerology, Vodnjanska 17, 91000 Skopje, Mac e do nia; Phone: +389 2 3147-205; Phone-Fax:
+389 2 3134-042; makderm@unet.com.mk
Allergie Kongress 2004, Aachen, Ger many, Sep tem ber 15-19, 2004. Con tact: Gerhard.Schultze-Werninghaus@
ruhr-uni-bochum.de; www.allergie-kongress-2004.de
1st Cro atian Con gress of Psychodermatology, Cavtat, Croatia, Sep tem ber 23-26, 2004. Con tact: Prof. Mirna
Šitum, De part ment of Der ma tol ogy and Venerology, Clin i cal Hos pi tal “Sestre milosrdnice”, Vinogradska 29, 10000
Zagreb, Croatia; msitum@kbsm.hr
7th In ter na tional Con gress of Der ma tol ogy, Te he ran, Iran, Sep tem ber 29-Oc to ber 2, 2004. Con tact:
info@iranderm.org; www.iranderm.org
25th An nual Meet ing of the In ter na tional So ci ety of Dermatologic Sur gery, Bar ce lona, Spain, Oc to ber 6-9, 2004. 
Con tact: isds2004@mccann.es; www.isds2004.com
6th Der ma tol ogy and Dermatopathology Meet ing of the Turk ish So ci ety of Dermatopathology, Is tan bul, Tur key 
Oc to ber 7, 2004. Con tact: Rana Yavuzer Anadolu, M.D., An kara Uni Koza sok. 114-86, 00670 An kara Tur key; phone:
90-312-3245724: ranaadolu@hotmail.com
Up date on Pso ri a sis, Con tin u ing Med i cal Ed u ca tion Course or ga nized by Chair of Dermatovenerology of the Uni -
ver sity School of Med i cine Zagreb, Šalata 4, 10000 Zagreb, Croatia, Oc to ber 15-16, 2004. Con tact: Prof. Jasna
Lipozenèiæ, Šalata 4, 10000 Zagreb, Croatia. Phone./Fax: +385-1-4920-014; e-mail: jasna.lipozencic@zg.tel.hr
Ther a peu tic In no va tion in Der ma tol ogy and Dermatocosmetology, Bang kok, Thai land, Oc to ber 23-25, 2004.
Con tact: thadapiaru.@thaicosderm.org
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4th In ter na tional Con gress on Autoimmunity, Bu da pest, Hun gary, No vem ber 3-7, 2004. Con tact: fax:0041 22 732
2850; phone 0041 22 908 0488
13th Con gress of the Eu ro pean Acad emy of Der ma tol ogy and Venerology, Flor ence, It aly, No vem ber 17-21,
2004. Con tact: pres i dent@eadv2004.org; reg is tra tion@eadv2004.org; www.eadv2004.org
10th World Con gress on Can cers of the Skin, Vi enna, Aus tria, March 19-23, 2005. Con tact: Elfriede Pomp, De -
part ment of Der ma tol ogy, Uni ver sity of Vi enna, Vi enna Gen eral Hos pi tal, Waehringer Guertel 18-20, A-1090 Vi enna,
e-mail: info@wccs.at; www.wccs.at
Spring Sym po sium of the Eu ro pean Acad emy of Der ma tol ogy and Venerology, So fia, Bul garia, 2005. Con tact:
Bul gar ian Dermatological So ci ety; dermven@bg.com
8th Con gress of the Eu ro pean So ci ety for Pe di at ric Der ma tol ogy, Bu da pest, Hun gary, May 5-7, 2005. Con tact:
www.con ven tion.hu; www.espd2005.com
World Al lergy Con gress – 19th In ter na tional Con gress of Allergology and Clin i cal Im mu nol ogy and 24th
Con gress of the Eu ro pean Acad emy of Allergology and Clin i cal Im mu nol ogy, Mu nich, Ger many, June 26-July 1,
2005. Con tact: wac2005@congrex.se www.congrex.com/wac2005
14th IACD (In ter na tional Acad emy of Cos metic Der ma tol ogy) World Con gress, Paris, France, July 3-5, 2005.
Con tact: iacd2005@mci-group.com; www.iacd-paris2005.com
16th Biennal Meet ing of the In ter na tional So ci ety for Sex u ally Trans mit ted Dis eases Re search (ISSTDR), Am -
ster dam, Neth er lands, July 10-13, 2005. Con tact: isstdr@aidsfonds.nl; www.isstdr.org 
6th World Con gress on Mel a noma, Van cou ver, B.C., Can ada, Sep tem ber 2-9, 2005. Con tact: Venue West Con fer -
ence Ser vices Ltd., Van cou ver, B.C., Can ada; con gress@venuewest.com
15th World Con gress of the In ter na tional Un ion of Phlebology, Rio de Ja neiro, Oc to ber 2-7, 2005; Con tact: RIO
UIP 2005 - Sec re tary, Rua Santa Clara, 494 - Sorocaba - 108030-421 SP - Brasil; Phone: 55 (15) 231-6619; Fax: 55 (15)
221-4074/232-9241; inspemoc@dglnet.com.br; angelo.scuderi@flebologiabrasil.com.br;  www.flebologiabrasil.com.be
14th Con gress of the Eu ro pean Acad emy of Der ma tol ogy & Venerology, Lon don, Oc to ber 12-15, 2004. Con tact: 
Con gress Pres i dent; tel: 34 93 200 7083; fax: 34 93 209 3152; e-mail: pres i dent@eadv2005.org; website: www.eadv.org
21st World Con gress of Der ma tol ogy, Bue nos Ai res, Ar gen tina, Oc to ber 1-5, 2007. Con tact: info@dermato
2007.org
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IN STRUC TIONS TO AU THORS
ACTA DERMATOVENEROLOGICA CROATICA (ADC)
is a quar terly peer-re viewed jour nal, in dexed in In dex Medi -
cus/MEDLINE and Excerpta Medica/EMBASE. It pub -
lishes orig i nal sci en tific ar ti cles, short sci en tific com mu ni -
ca tions, clin i cal ar ti cles, case re ports, re views, re ports,
news and comments, and an nounce ments in the fields of
der ma tol ogy and venerology.
Gen eral Guide lines
Type the com plete manu script dou ble-spaced, on one 
side of A4 bond pa per, with a left side mar gin of at least 4
cm.
The manu scripts should not ex ceed 12-15 typed
pages in case of orig i nal sci en tific pa pers, and 6-8 pages
in case of short com mu ni ca tions, clin i cal ar ti cles, case re -
ports, and re views.
The manu scripts should be writ ten in Eng lish. The au -
thors are re spon si ble for en sur ing that the Eng lish used is 
suit able for pub li ca tion. All ma te rial is as sumed to be sub -
mit ted ex clu sively to this jour nal.
All manu scripts are sub ject to peer re view.
Prep a ra tion of Manu scripts for Sub mis sion
Ti tle Page
The ti tle page should carry (a) the ti tle of the pa per,
which should be con cise but in for ma tive; (b) full name of
each au thor, with in sti tu tional af fil i a tion; (c) name(s) of de -
part ment(s) and in sti tu tion(s) to which the work should be
at trib uted; (d) name and ad dress (with tele phone and fax
num bers as well as the e-mail adress) of the au thor to
whom re quests for re prints should be ad dressed; (f)
source(s) of sup port in the form of grants, equip ment,
drugs, or all of these; and (g) a short run ning head of not
more than 40 char ac ters (count let ters and spaces) at the
foot of the ti tle page.
Sec ond Page
The sec ond page should carry a sum mary of not more 
than 250 words, fol lowed by three to six key words from
the Med i cal Sub ject Head ings (MeSH) list of In dex
Medicus.
Manu script
The text of ob ser va tional and ex per i men tal is usu ally,
but not nec es sar ily, di vided into sec tions with the head -
ings In tro duc tion, Ma te rial (Pa tients) and Methods, Re -
sults, and Dis cus sion. Long ar ti cles may need sub head -
ings within some sec tions to clar ify their con tents, es pe -
cially Re sults and Dis cus sion sec tions. Other types of ar -
ti cles, such as case re ports, re views, and ed i to ri als, are
likely to need other for mat.
Ab bre vi ated terms should be writ ten in full the first
time they are used in the text, with ab bre vi a tion in pa ren -
the ses.
Un der line the words that must be printed in italic.
Ref er ences should be iden ti fied in the text by arabic
nu mer als in pa ren the ses, and be num bered and listed
con sec u tively at the end of the manu script in the or der in
which they are first cited in the text.
In di cate in the text where the il lus tra tions (fig ures and
ta bles) should be in serted. 
Ta bles and fig ures should be pro vided each on a sep -
a rate sheet of pa per af ter the ref er ences. De scrip tive leg -
ends to fig ures should be typed dou ble-spaced on a sep -
a rate sheet of pa per, whereas fig ures should be sub mit -
ted in an en ve lope, with the num ber, the name of the (first) 
au thor, and ti tle of the manu script on the back: each ta ble
should be typed on a sep a rate sheet of pa per, num bered
in the or der in which they are first cited in the text, with a ti -
tle and de scrip tive leg end. Terms used in ta bles should
not be ab bre vi ated.
Eth ics
When re port ing ex per i ments on hu man sub jects, in di -
cate whether the pro ce dures were in ac cor dance with the
eth i cal stan dards of the re spon si ble com mit tee on hu man 
ex per i men ta tion (in sti tu tional or re gional) or with the Hel -
sinki Dec la ra tion from 1975 as re vised in 1983. Do not
use pa tients, names, ini tials or hos pi tal num bers, es pe -
cially any il lus tra tive ma te rial.
Sta tis tics
De scribe sta tis ti cal meth ods and pro vide enough data 
to en able a knowl edge able reader to as sess the re ported
re sults him or her self. Please state the sta tis ti cal pack age 
(ver sion, man u fac turer) used for sta tis ti cal anal y sis.
Ac knowl edge ments
Please spec ify: (a) con tri bu tions that need ac knowl -
edg ing but do not jus tify au thor ship, such as gen eral sup -
port by a de part men tal chair man; (b) ac knowl edge ments
of tech ni cal help; (c) ac knowl edge ments of fi nan cial and
ma te rial sup port, spec i fy ing the na ture of sup port; (d) fi -
nan cial re la tion ship that may be a source of con flict of in -
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ter est. Tech ni cal help should be ac knowl edged in a sep a -
rate para graph as well as other con tri bu tions.
Ref er ences
Ref er ences should be typed dou ble-spaced on a sep -
a rate sheet of pa per. The Van cou ver style, pro posed by
the In ter na tional Com mit tee of Med i cal Jour nal Ed i tors, is
used (Engl J Med 1991,324:421-8, BMJ 1991,302:338-41, 
or www.icmje.org) . Ex am ples of cor rect forms of ref er -
ences are given be low:
Jour nal ar ti cle
Stan dard jour nal ar ti cle (list all au thors, but if their
num ber ex ceeds six, give six fol lowed by et al.)
You CH, Lee KY, Chey RY, Menguy R. Electrogastro -
graphic study of pa tients with un ex plained nau sea, bloat -
ing and vom it ing. Gastroenterology 1989;79:311-4.
Chap ter in a book
Weinstein L, Swartz MN. Patho logic prop er ties of in -
vad ing mi cro or gan isms. In: Sodeman WA Jr, Sodeman
WA, ed i tors. Patho logic phys i ol ogy: mech a nisms of dis -
ease. Phil a del phia: Saunders; 1974. p. 457-72.
Ar ti cle not in Eng lish
Massone L, Borghi S, Pestarino A, Piccini R, Gambini
C. Lo cal isa tions palmaires purpuriques de la dermatite
herpetiforme. Ann Dermatol Venerol 1987;114:1545-7.
Con fer ence pa per
Harley NH. Com paring ra don daugh ter dosimetric
and risk mod els. In: Gammage RB, Kaye SV, ed i tors. In -
door air and hu man health. Pro ceed ings of the Sev enth
Life Sci ences Sym po sium; 1984 Oct 29-31; Knox ville
(TN). Chelsea (MI):Lewis, 1985:69-78.
Disertation
Youssef NM. School ad just ment of chil dren with con -
gen i tal heart dis eases (dis ser ta tion). Pitts burgh (PA):
Uni ver sity of Pitts burgh; 1988.
Sub mis sion of Manu scripts
Manu scripts should be printed on pa per and sub mit -
ted in trip li cate, with one copy on a floppy disk, and sent
to:
Ed i to rial Of fice
De part ment of Der ma tol ogy and Venerology
Zagreb Uni ver sity Hos pi tal Cen ter
Šalata 4, 10000 Zagreb, Croatia
e-mail: jasna.lipozencic@zg.tel.hr
Manu scripts on Disks
Floppy disks should be 3.5-inch (1.44 MB) IBM for -
mat ted and la beled with the name of the au thor.
The file, the word-pro cess ing pro gram, and ver sion
used should be in di cated by pen. MS-Word for Win dows
is pre ferred, al though manu scripts pre pared us ing any
other IBM-com pat i ble word-pro ces sor are ac cept able.
Avoid com plex for mat ting; the text will be styled ac -
cord ing to the ADC de sign spec i fi ca tions. Do not use
bold, cap i tal ized text, or a run ning head. Do not use foot -
notes or endnotes. Sub mit the text, ta bles, and il lus tra -
tions as sep a rate files. For ta bles, al ways use ta ble ed i tor
func tion; en sure that each data point is con tained within a
unique cell, i.e. do not use car riage re turns within cells.
For il lus tra tions, the pre ferred for mats are TIFF of 300 dpi 
res o lu tion, al though any for mat in gen eral use is ac cept -
able pro vided it is not ap pli ca tion-spe cific. If MS Excell is
used for charts make sure to en close orig i nal Excell file.





